<!DOCTYPE html>
<html>

  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, user-scalable=no, initial-scale=0.95, maximum-scale=0.95, minimum-scale=0.95"/>
    <meta http-equiv="x-ua-compatible" content="IE=edge">
    <title>Liverpool HIV Interactions</title>
    <link rel="stylesheet" media="all" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv_site-0a478b945d0a5a038ce1c2c7353d4cdcc80f95b7d764296440f4a7790aac6305.css" />
    <!--[if IE 8]>
        <script src="//cdnjs.cloudflare.com/ajax/libs/es5-shim/4.0.5/es5-shim.min.js"></script>
        <style>
            .ng-hide {
                display: none !important;
            }
        </style>
    <![endif]-->
    <script src="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/application-558b3c2a3e06dc8db0be037ca1d2b0a8b417b18dfe38e0d45ee242ed38ca7613.js"></script>
    
    <meta name="csrf-param" content="authenticity_token" />
<meta name="csrf-token" content="E1Y/H0VwcReIKbHEkJywoAa6+bTBFqOW4az7AjlMn2WkEnc2IQBCyEbUUXmEaT8zZu0v9N8r5JdwcYhmJfrQfw==" />
    
    <link rel="icon" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-6af0467185368caf8c843f5fbf2095eb85d3057e8a2dbfadc5ffbb7bda4d8f59.ico" sizes="32x32">
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-152px-8970667e12c076f671daad84dcacda13b40c6f22672b38c55ad61f72e857b460.png">
    <link rel="apple-touch-icon-precomposed" sizes="144x144" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-144px-24f03e597ce22e8446280458d4f244e00620008785ccc07c52ae61f18f50911a.png">
    <link rel="apple-touch-icon-precomposed" sizes="120x120" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-120px-e5b3af06dec7a9a0f9965209b7ffba504447096d086d79b26dbb8f1962b6251f.png">
    <link rel="apple-touch-icon-precomposed" sizes="114x114" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-114px-106d37d88ee6e9a4275d2de639a68b139ae7d66416b4bb64b317a37e8b2673e6.png">
    <link rel="apple-touch-icon-precomposed" sizes="72x72" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-72px-b24efd122931fef6f36ce176141fd6d47a46fa7e0770b5f98e8e2eec849d57ac.png">
    <link rel="apple-touch-icon-precomposed" sizes="57x57" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-57px-154d723ded7ac95257566911bfbe8b158829cf0ada223a9f737d453dbd3e293b.png">
    <link href='http://fonts.googleapis.com/css?family=Varela+Round' rel='stylesheet' type='text/css'>
    <!-- start Mixpanel --><script type="text/javascript">(function(e,b){if(!b.__SV){var a,f,i,g;window.mixpanel=b;b._i=[];b.init=function(a,e,d){function f(b,h){var a=h.split(".");2==a.length&&(b=b[a[0]],h=a[1]);b[h]=function(){b.push([h].concat(Array.prototype.slice.call(arguments,0)))}}var c=b;"undefined"!==typeof d?c=b[d]=[]:d="mixpanel";c.people=c.people||[];c.toString=function(b){var a="mixpanel";"mixpanel"!==d&&(a+="."+d);b||(a+=" (stub)");return a};c.people.toString=function(){return c.toString(1)+".people (stub)"};i="disable time_event track track_pageview track_links track_forms register register_once alias unregister identify name_tag set_config people.set people.set_once people.increment people.append people.union people.track_charge people.clear_charges people.delete_user".split(" ");
for(g=0;g<i.length;g++)f(c,i[g]);b._i.push([a,e,d])};b.__SV=1.2;a=e.createElement("script");a.type="text/javascript";a.async=!0;a.src="undefined"!==typeof MIXPANEL_CUSTOM_LIB_URL?MIXPANEL_CUSTOM_LIB_URL:"file:"===e.location.protocol&&"//cdn.mxpnl.com/libs/mixpanel-2-latest.min.js".match(/^\/\//)?"https://cdn.mxpnl.com/libs/mixpanel-2-latest.min.js":"//cdn.mxpnl.com/libs/mixpanel-2-latest.min.js";f=e.getElementsByTagName("script")[0];f.parentNode.insertBefore(a,f)}})(document,window.mixpanel||[]);
mixpanel.init("cac4e9c0b9aef2c3bc30326ca7d1683f");</script><!-- end Mixpanel -->
    <!--[if lt IE 8]>
  <p class="browserupgrade">You are using an <strong>outdated</strong> browser. Please <a href="http://browsehappy.com/">upgrade your browser</a> to improve your experience.</p>
<![endif]-->

<!--[if lte IE 9]>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv.min.js"></script>
<![endif]-->

    <script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-75467942-1', 'auto');
  ga('send', 'pageview');
</script>

  </head>

  <body>
    <div class="header">
  <div class="inner-wrapper">
    <a class="logo" href="/">
      <p class="logo-icon"></p><p>HIV Drug Interactions</p>
</a>    <div class="header-right-column">
      <a href="https://www.liverpool.ac.uk/" target="_blank" class="uol-header-logo"></a>
          <div class="header-button-stack">
            <a href="https://alumni.liv.ac.uk/give-back/donate/drug-interactions-donation-page" target="_blank" class="header-right-column-button">
              <p>Donate Now</p>
              <p class="header-button-icon"></p>
            </a>

            <div class="apps-dropdown-nav-wrapper">
              <a href="#" class="header-right-column-button apps-dropdown-button">
                <p>Apps</p>
                <p class="header-button-icon"></p>
              </a>
                <div class="apps-dropdown-nav">
                  <a href="https://itunes.apple.com/gb/app/liverpool-hiv-ichart/id979962744?mt=8" target="_blank" class="appstore-link">
                    <p class="icon"></p>
                    <p>Download from the AppStore</p>
                  </a>
                  <a href="https://play.google.com/store/apps/details?id=com.liverpooluni.icharthiv&hl=en_GB" target="_blank" class="google-play-link">
                    <p class="icon"></p>
                    <p>Download from Google Play</p>
                  </a>
                </div>
            </div>
          </div>


    </div>


    <a href="javascript:;" class="mobile-nav-icon">
      <p></p>
      <p></p>
      <p></p>
    </a>
    <a href="https://www.liverpool.ac.uk/" target="_blank" class="uol-header-logo mobile-uol"></a>

  </div>
</div>
<a class="mobile-interaction-link" href="/checker">
  <p>Interaction Checker</p>
  <p class="header-button-icon"></p>
</a><a href="https://alumni.liv.ac.uk/give-back/donate/drug-interactions-donation-page" target="_blank" class="mobile-interaction-link donate-mobile-link">
  <p>Donate Now</p>
  <p class="header-button-icon"></p>
</a>

<div class="navigation">
  <div class="inner-wrapper">


    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Interaction Charts</a>

      <div class="drop-down-nav interaction-charts">
        <a href="/checker">Interaction Checker</a>
        <a href="/drug_queries/new">Interaction Checker Lite</a>
        <a href="/view_all_interactions/new">View All Checker</a>
        <a href="/printable_charts">Printable Charts</a>
        <a href="/treatment_selectors">Treatment Selectors</a>
      </div>
    </div>

    <a href="/site_updates">Site Updates</a>
    <!--
    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Site News/Updates</a>
      <div class="drop-down-nav site-news">
        <a href="/articles">Latest Articles</a>
        <a href="/site_updates">Site Updates</a>
      </div>
    </div>
    -->




    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">About Us</a>
      <div class="drop-down-nav about-drop-down">
        <a href="/mission">Mission Statement</a>
        <a href="/board">Editorial Board</a>
      </div>
    </div>

    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Pharmacology Resources</a>
      <div class="drop-down-nav resources-drop-down">
        <a href="/fact_sheets">Fact Sheets</a>
      </div>
    </div>

    <a href="/feedback">Contact Us</a>

    <a href="/support-us">Support Us</a>

  </div>
</div>

    <div class="row">
  <div class="col-lg-12">


  </div>
</div>

    <div class="inner-body-wrapper">
  <div class="inner-wrapper">

    <div class="interaction-block-single-page-wrapper">


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Abacavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Acarbose</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. After ingestion of acarbose, the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolised by intestinal enzymes and by the microbial flora.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Acenocoumarol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as acenocoumarol is mainly metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Acetazolamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Acetazolamide is predominantly excreted unchanged via active renal tubular secretion. In vitro studies have shown that acetazolamide may competitively inhibit the renal transporters hOAT1, hOAT3 and hOAT4. However, a clinically relevant interaction is unlikely in the range of observed clinical concentrations.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Aciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Aciclovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. A clinically relevant interaction is unlikely in the range of observed clinical concentrations.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Acitretin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as acitretin undergoes isomerisation and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Adefovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration with didanosine enteric coated tablets (Videx EC) has no effect on the pharmacokinetics of didanosine or adefovir. However, as adefovir is nephrotoxic, renal function should be monitored and didanosine dosage adjusted accordingly.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The pharmacokinetics of adefovir have been evaluated in healthy adult volunteers (n=21) following multiple dose administration of adefovir (10 mg once daily) in combination with enteric coated didanosine (400 mg). Adefovir did not alter the pharmacokinetics of enteric coated didanosine (didanosine EC) and the pharmacokinetics of adefovir were unchanged. <br /><em>Hepsera Prescribing Information, Gilead Sciences Inc, May 2008.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Adrenaline (Epinephrine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Adrenaline is rapidly inactivated, mostly in the liver by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). There is therefore little potential for interaction with didanosine via modulation of, or competition for metabolic or elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Adrenaline is a naturally occurring catecholamine secreted by the adrenal medulla in response to exertion or stress. Adrenaline is rapidly inactivated in the body, mostly in the liver by the enzymes catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Much of a dose of adrenaline is excreted as metabolites in urine. The plasma half-life is about 2-3 minutes. However, when given by subcutaneous or intramuscular injection, local vasoconstriction may delay absorption so that the effects may last longer than the half-life suggests.<br /><em>Adrenaline (Epinephrine) Injection BP 1 in 1000 UK Summary of Product Characteristics, Hameln pharmaceuticals ltd, updated August 2010</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>African Potato</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on the metabolic data there is little potential for pharmacokinetic interactions.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Agomelatine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as agomelatine is metabolised predominantly by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Albendazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Albendazole rapidly undergoes extensive first-pass metabolism in the liver, and is generally not detected in plasma. Albendazole sulphoxide is the primary metabolite, which is thought to be the active moiety in effectiveness against systemic tissue infections. Albendazole sulphoxide and its metabolites appear to be principally eliminated in bile, with only a small proportion appearing in the urine.<br /><em>Zentel&#174; Australian Product Information, GlaxoSmithKline Updated January 2009<br />Eskazole&#174; Australian Product Information, GlaxoSmithKline Updated September 2010</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Alcohol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Alcuronium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Alcuronium is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>An intravenous (IV) single-bolus injection of alcuronium (0.25 mg/kg = ED95) was administered to 10 patients undergoing maxillofacial surgery during nitrous-oxide opioid anesthesia. Alcuronium neuromuscular block, plasma concentration, and renal elimination (HPLC assay) were measured during the 12-h after its administration. Two hours after the injection of alcuronium, partial recovery from the neuromuscular block had occurred from 100% to 26% +/- 24% depression of twitch tension, although less than 25% of the injected dose was recovered from the urine. The 12-h plasma concentration and urinary recovery were 0.1 +/- 0.08 mg/L and 61% +/- 20%, respectively. Recovery from neuromuscular block was dominated by intercompartmental distribution rather than by renal elimination. Alcuronium does not undergo biodegradation; apart from negligible biliary excretion, the kidney represented the only excretory pathway.<br /><em>Diefenbach C, K&#252;nzer T, Buzello W, Theisohn M. Alcuronium: a pharmacodynamic and pharmacokinetic update. Anesth Analg. 1995 Feb;80(2):373-7</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Alendronic Acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary) </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Alfentanil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alfentanil undergoes extensive CYP3A4 metabolism. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Alfuzosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alfuzosin is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Aliskiren</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolized and is mainly excreted unchanged in faeces. P-glycoprotein is a major determinant of aliskiren bioavailability.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Allopurinol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is not recommended as didanosine exposure is increased. If concomitant use is unavoidable, a dose reduction of didanosine may be required and patients should be closely monitored. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Co-administration of didanosine and allopurinol results in increased systemic exposure to didanosine, which can result in didanosine-associated toxicity. When didanosine and allopurinol were co-administered (14 healthy volunteers), the AUC and the Cmax for didanosine significantly increased 105% and 71%, respectively. Therefore, co-administration of allopurinol (a xanthine oxidase inhibitor) with didanosine is not recommended. Patients treated with didanosine who require allopurinol administration should be switched to an alternative treatment regimen or should be closely monitored for didanosine related undesirable effects.<br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Coadministration is contraindicated because systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity. The effect of allopurinol (300 mg/day for 7 days) on the pharmacokinetics of didanosine (400 mg single dose) was investigated in healthy volunteers (n=14). Didanosine AUC increased 1.13-fold and Cmax increased by 69%. When allopurinol (300 mg/day for 7 days) and a 200 mg single dose of didanosine was studied in 2 subjects with renal impairment, didanosine AUC increased by 312% and Cmax increased by 232%. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Co, November 2011.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Almotriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Almotriptan is partly eliminated unchanged in the urine and partly metabolized (mainly via monoamine oxidase-A and to a lesser extent by CYP3A4, CYP2D6 and flavin monooxygenase).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Aloe vera</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Aloe vera is only a weak inhibitor of CYPs in vitro and therefore is unlikely to cause clinically significant interactions. It does not inhibit P-gp and there is no evidence to suggest it impacts UGTs.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Alosetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. In vitro data indicate that alosetron is metabolized by CYPs 2C9, 3A4 and 1A2, with in vivo data suggesting that CYP1A2 plays a more prominent role.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Alprazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on  metabolism and clearance a clinically significant interaction is unlikely as alprazolam is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Aluminium hydroxide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Aluminium hydroxide is slowly but perhaps incompletely converted to aluminium chloride in the stomach. Some absorption of soluble aluminium salts occurs from the gastro-intestinal tract with some excretion in the urine. Some unabsorbed aluminium hydroxide combines with phosphates and some form carbonates and salts of fatty acids, all these salts are excreted in the faeces.<br /><em>Alu-Cap&#174; (Aluminium hydroxide) Capsules UK Summary of Product Characteristics, Meda Pharmaceuticals, updated June 2012</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amantadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amantadine is mainly eliminated renally by glomerular filtration and active secretion. A bicarbonate dependent organic cation transporter has been identified as the major uptake transporter of amantadine in the renal proximal tubule.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amikacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as amikacin is eliminated renally by glomerular filtration. However as amikacin is nephrotoxic, renal function should be monitored and didanosine dosage adjusted accordingly.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amiloride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amiloride is eliminated unchanged by the kidney. In vitro data indicate that amiloride is a substrate of OCT2 and an interaction is unlikely as didanosine is eliminated by other renal transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amiodarone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amiodarone is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amisulpride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolized and is primarily eliminated renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amitriptyline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amitriptyline is metabolized predominantly by CYP2D6 and CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amlodipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amlodipine is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amodiaquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amodiaquine is mainly metabolized by CYP2C8 to N-desethylamodiaquine, an active metabolite but less potent than the parent compound.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amoxicillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly eliminated unchanged in the kidney and in vitro data indicate that it is a substrate of OAT3 whereas didanosine is eliminated by other renal transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amphetamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amphetamine is metabolized by CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amphotericin B</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but amphotericin B is nephrotoxic and therefore renal function should be monitored and didanosine dosage adjusted accordingly.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ampicillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion. After oral administration, approximately 20-40% is excreted unchanged in the urine, whereas about 60-80% is excreted unchanged in the urine after parenteral administration. As didanosine is eliminated by renal tubular secretion, there is potential for competition with ampicillin for renal transporters, which could lead to increased levels of either drug when ampicillin is administered intravenously. When administered orally, there is little potential for significant interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Amyl nitrate (Poppers)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Amyl nitrate is metabolized rapidly by hydrolytic denitration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Anastrozole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anastrozole is mainly oxidized to hydroxyanastrozole by CYP3A4 (major) and glucuronidated by UGT1A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Anidulafungin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anidulafungin is not metabolised hepatically but undergoes chemical degradation at physiological temperature.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Antacids</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as antacids are unlikely to alter didanosine absorption.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Apixaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apixaban is metabolized by CYP3A4 and to a lesser extent by CYP1A2, CYP2C8, CYP2C9 and CYP2C19.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Apomorphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as apomorphine is metabolized by several pathways including glucuronidation, sulfation and to a lesser extent N-demethylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Aprepitant</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Aripiprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as aripiprazole is metabolized by CYP3A4 and CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Artemisinin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Artemisinins undergo rapid metabolism via several CYP450 (CYPs 3A4, 2A6, 2B6) and the active metabolite (dihydroartemisinin, which has greater potency than the parent drug) is further metabolized via UGTs 1A9 and 2B7. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ascorbic Acid (Vitamin C)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ascorbic acid is oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate - 2 - sulphate. Large doses are rapidly excreted in the urine when in excess of the requirements of the body. There is therefore little potential for interaction with didanosine via modulation of, or competition for metabolic pathways. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Ascorbic acid is readily oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate - 2 - sulphate. Metabolic turnover appears to be greater in females than males. Large doses are rapidly excreted in the urine when in excess of the requirements of the body and after an intravenous dose, about 40% is excreted in 8 hours, which is increased to about 70% after tissue saturation. The amount of unchanged drug is dose dependent; in women the excretion of ascorbic acid appears to vary with the stage of the menstrual cycle and it is decreased when taking oral contraceptives. Oxalic acid and ascorbate - 2 - sulphate are excreted in the urine.<br /><em>Ascorbic Acid Injection 500mg/5ml UK Summary of Product Characteristics, UCB Pharma Limited, updated March 2009</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Asenapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (mainly CYP1A2, with minor contributions from CYP3A4 and CYP2D6).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Asparaginase</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for pharmacokinetic interaction. Acute pancreatitis is a relatively common adverse event in patients taking asparaginase, and has also been associated with didanosine therapy (<1% of patients), which has been fatal in some cases. Didanosine should be used only with extreme caution in patients with a history of pancreatitis, when treatment with other medicinal products known to cause pancreatic toxicity is unavoidable, close observation is warranted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Limited data suggest that asparaginase is likely to be eliminated by the reticuloendothelial system. Less than 0.1% of a total injected dose is recovered in urine.&nbsp; Uptake by receptor-mediated endocytosis has also been suggested as a mechanism of asparaginase elimination<br /><em>Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Narta UK, Kanwar SS, Azmi W. Crit Rev Oncol Hematol. 2007 Mar;61(3):208-21.<br />Comparative pharmacokinetic studies of three asparaginase preparations. Asselin BL, Whitin JC, Coppola DJ et al. J Clin Oncol. 1993 Sep;11(9):1780-6.<br />Elimination of l-asparaginase in children treated for acute lymphoblastic leukemia. Brueck M, Koerholz D, Nuernberger W et al. Dev Pharmacol Ther. 1989;12(4):200-4.</em></p>
<p>Acute pancreatitis occurs in &lt;10% of cases. There have been isolated reports of pseudocyst formation up to four months after last treatment, so appropriate testing (e.g. ultrasound) may need to be considered beyond last treatment. In very rare cases, haemorrhagic or necrotising pancreatitis occurs, with fatal consequences. <br /><em>Erwinase&#174; 10,000 Unit/vial, Lyophilisate for solution for injection (Asparaginase from Erwinia chrysanthemi) UK Summary of Product Characteristics, EUSA Pharma (Europe) Limited, updated March 2011 Erwinaze&#174; (asparaginase Erwinia chrysanthemi) for injection US Prescribing Information, EUSA Pharma (USA), Inc, updated November 2011</em></p>
<p>Pancreatitis is a known serious complication among HIV infected patients. It has also been associated with didanosine therapy (&lt;1% of patients) and has been fatal in some cases. Didanosine should be used only with extreme caution in patients with a history of pancreatitis. Positive relationships have been found between the risk of pancreatitis and daily dose of didanosine. Whenever warranted by clinical conditions, didanosine should be suspended until the diagnosis of pancreatitis is excluded by appropriate laboratory and imaging techniques. Similarly, when treatment with other medicinal products known to cause pancreatic toxicity is required, didanosine should be suspended whenever possible. If concomitant therapy is unavoidable, close observation is warranted. Dose interruption should be considered when biochemical markers of pancreatitis have significantly increased, even in the absence of symptoms. Significant elevations of triglycerides are a known cause of pancreatitis and warrant close observation. <br /><em>Videx EC&#174; (didanosine) gastroresistant capsules, UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated February 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Aspirin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to salicylic acid and then further metabolized mainly by glucuronidation (by several UGT, major UGT1A6). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Astemizole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as astemizole is metabolized by CYPs 2D6, 2J2 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Atazanavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>It is recommended that didanosine be administered on an empty stomach. When coadministered with didanosine buffered or enteric coated formulations, atazanavir (with or without ritonavir) should be given with food 2 h before or 1 h after didanosine. The buffered formulation of didanosine, but not the enteric coated formulation, decreased atazanavir concentrations. Didanosine concentrations were decreased in the presence of food. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>No significant effect on atazanavir concentrations was observed when administered with enteric-coated didanosine, but administration with food decreased didanosine concentrations. Coadministration of atazanavir/ritonavir (300/100 mg once daily) and didanosine (400 mg single dose with food) decreased didanosine AUC and Cmax by 34% and 38%, and increased Cmin by 25%. Atazanavir concentrations were greatly decreased when co-administered with didanosine (buffered tablets) and stavudine. The mechanism of interaction is a reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets. Coadministration of atazanavir (400 mg single dose), simultaneously with ddI/d4T (200/40 mg single dose, fasted) decreased atazanavir AUC, Cmax and Cmin by 87%, 89% and 84%, respectively. When atazanavir was dosed 1 h after ddI/d4T, atazanavir AUC and Cmin increased by 3% and Cmax increased by 12%. No significant effect on didanosine concentrations was observed. Didanosine should be taken at the fasted state 2 hours after atazanavir/ritonavir taken with food. <br />
<em>Reyataz Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, <em>April 2014</em>.</em></p>
<p>
</p><div>
<div>Coadministration of atazanavir with didanosine buffered tablets resulted in a marked decrease in atazanavir exposure. It is recommended that atazanavir be given (with food) 2 h before or 1 h after didanosine buffered formulations. Simultaneous administration of didanosine EC and atazanavir with food results in a decrease in didanosine exposure but has no significant effect on atazanavir exposures. Thus, atazanavir and didanosine EC should be administered at different times. Coadministration of atazanavir (400 mg single dose) with didanosine buffered tablets (200 mg single dose) did not alter exposure to didanosine (8% and 2% reduction in Cmax and AUC respectively, n=31); however, exposure to atazanavir was markedly decreased (Cmax, AUC and Cmin decreased by 89%, 87% and 84% respectively, n =31. Administration of atazanavir (400 mg single dose) 1 h after ddI buffered tablets (200 mg single dose), resulted in no significant change in atazanavir Cmax, AUC or Cmin (12%, 3%, and 3% increase respectively, n=31). <br />
</div>
<em>Reyataz Prescribing Information, Bristol-Myers Squibb Co, September 2015.</em><br />
</div>
<em></em><p>&nbsp;</p>
<div>The interaction between the enteric coated formulation of didanosine (ddI-EC, 400 mg once daily) and atazanavir (400 mg alone or 300 mg plus 100 mg ritonavir once daily) was investigated in 35 healthy volunteers. ddI had no effect on atazanavir or atazanavir/ritonavir exposure. Reduced plasma didanosine exposure was observed when didanosine was administered with atazanavir (or atazanavir/ritonavir) and food consistent with the effect of food previously observed on didanosine. Both drugs should therefore be administered as per their current dosing recommendations but at different times: didanosine in the fasted state and atazanavir with food.</div>
<div><em>Pharmacokinetics of didanosine enteric-coated capsules co-administered with atazanavir or atazanavir/ritonavir. Kaul S, Olszyk C, Ji P, et al 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 2005, abstract 648.</em>
</div>
<p>The pharmacokinetics of atazanavir (400 mg once daily) with ddI-EC and/or tenofovir (300 mg once daily) were investigated in 36 healthy subjects. Addition of ddI (500 mg with food) decreased atazanavir Cmax, AUC and Cmin (14%, 11% and 18% respectively); ddI Cmax, AUC and Cmin were increased by 1.08-, 1.26- and 2.18-fold respectively compared to ddI 400 mg alone without food. In the presence of ddI-EC (250 mg once daily with food) and tenofovir (300 mg once daily), atazanavir Cmax, AUC and Cmin decreased by 24%, 26% and 39% respectively (compared to atazanavir alone); ddI Cmax, AUC and Cmin changed 0.95-, 1.15- and 1.89-fold respectively (compared to ddI 400 mg alone without food). <br />
<em>Pharmacokinetic evaluation of the combination of atazanavir, enteric coated didanosine and tenofovir disoproxil fumarate for a once daily antiretroviral regimen. Kaul S, Bassi K, Damle B, et al. 43rd ICAAC, Chicago, September 2003, abstract A-1616.</em></p>
<p>Coadministration of atazanavir (400 mg single dose) with didanosine buffered tablets (200 mg single dose) did not alter exposure to didanosine (8% and 2% reduction in Cmax and AUC respectively, n=31); however, exposure to atazanavir was markedly decreased (Cmax, AUC and Cmin decreased by 89, 87 and 84% respectively, n =31. Administration of atazanavir (400 mg single dose) 1 h after ddI buffered tablets (200 mg single dose), resulted in no significant change in atazanavir Cmax. AUC or Cmin (1.12-, 1.03- and 1.03-fold increase respectively, n=31).<br />
<em>BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interactions studies in healthy subjects. O&#8217;Mara E, Mummaneni V, Randal D, et al,. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2000, abstract 504. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Atenolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atenolol is mainly eliminated unchanged by the kidney, predominantly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Atorvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atorvastatin is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Atovaquone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atovaquone is mainly eliminated unchanged in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Atropine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction when atropine is used either systemically or as eye drops. Although metabolism of atropine is not fully elucidated, up to 50% is excreted unchanged via the kidneys. There is therefore little potential for clinically significant interactions with didanosine via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><strong>Systemic use:</strong> Atropine is metabolised in the liver by oxidation and conjugation to give inactive metabolites. About 50% of the dose is excreted within 4 hours and 90% in 24 hours in the urine, about 30 to 50% as unchanged drug.<br /><em>Atropine Injection BP Minijet UK Summary of Product Characteristics, International Medication Systems (UK) Ltd, updated October 2005</em></p>
<p><strong>Ocular use:</strong> Atropine is also absorbed by mucous membranes but less readily from the eye and skin, although significant toxicity can sometimes occur through absorption of excessive eye drops. Atropine is metabolised by hepatic oxidation and conjugation to inactive metabolites, with about 2% undergoing hydrolysis to tropine and tropic acid. About 30% of the dose is excreted unchanged in the urine. Only trace amounts of the dose are eliminated in the faeces.<br /><em>Minims Atropine Sulphate 1%, Eye drops solution UK Summary of Product Characteristics, Bausch &amp; Lomb U.K Limited, updated July 2012</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Azathioprine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Azathioprine is partly inactivated via the enzyme xanthine oxidase. As didanosine is also metabolised by this enzyme, competition could possibly increase the risk of toxicity and monitoring of haematological parameters is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Azithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction expected with didanosine gastro-resistant capsules (Videx EC). No significant effect with azithromycin and didanosine buffered tablets when administered 4 h apart. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><em><strong>LHPG Comment:</strong> Note dose separation in the study.</em></p>
<p>The interaction between azithromycin (1200 mg/day) and didanosine (200 mg twice daily, buffered tablets) was studied in 12 HIV-infected subjects. Azithromycin was administered 4 h prior to the didanosine dose and had no significant effect on any didanosine pharmacokinetic parameter. <br /><em>Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients. Amsden G, et al. J Clin Pharmacol, 2001, 41: 210-216. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Baclofen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as baclofen is primarily eliminated by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Beclometasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclometasone is a pro-drug which is not metabolised by CYP450 but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone-17-monopropionate.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bedaquiline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bedaquiline is metabolised by CYP3A4 and mainly eliminated in faeces. There are no clinical data on the safety and efficacy of bedaquiline when coadministered with antiretroviral agents.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bendroflumethiazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on  metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is eliminated by hepatic metabolism (70%) and excreted unchanged in the urine (30%) via OAT1 and OAT3. In vitro data indicate that bendroflumethiazide inhibits these renal transporters but a clinically relevant drug interaction is unlikely in the range of observed clinical concentrations.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Benserazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as benserazide is hydrolysed to trihydroxybenzylhydrazine. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Benznidazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning the metabolism/elimination of benznidazole, there is little potential for significant interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Benznidazole is absorbed from the gastrointestinal tract after oral doses (&gt; 90% bioavailability) and is widely distributed throughout the body. More than 40% of the drug is bound to plasma protein. The peak plasma concentration occurs after 3 to 4 hours and the half-life is about 12 hours. It is metabolised in the liver and more than 70% of the metabolites are excreted by the kidneys; about 30% of a dose is excreted in the faeces.<br /><em>Raaflaub J, Ziegler WH. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 1979; 29: 1611&#8211;14.</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bepridil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bepridil is mainly metabolized by CYP2D6 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Betamethasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Betamethasone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bexarotene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Bexarotene is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bezafibrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug-drug interaction is unlikely. In vitro data suggest that bezafibrate inhibits the renal transporter OAT1 but a clinically relevant drug interaction with didanosine is unlikely in the observed range of clinical concentrations.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Biperiden</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as biperiden undergoes hydroxylation in the liver.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bisacodyl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisacodyl is converted to an active metabolite by intestinal and bacterial enzymes. Absorption from the gastrointestinal tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bisoprolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolized by CYP3A4 and CYP2D6 and partly eliminated unchanged in the urine. There is no evidence that bisoprolol and didanosine are eliminated by the same renal transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bleomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bleomycin is inactivated by a cytosolic enzyme, bleomycin hydrolase, and two thirds of the administered drug is excreted unchanged in urine, probably by glomerular filtration. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Boceprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as boceprevir is metabolized by aldoketoreductase and CYP3A.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bortezomib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Bortezomib is mainly metabolized by CYP3A4 and 2C19 and to a lesser extent by CYPs 1A2, 2D6 and 2C9. A pharmacokinetic interaction is unlikely, however, the risk of neurotoxicity may be potentially increased as both drugs can cause neuropathy.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bosentan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bosentan is metabolized by CYP3A4 and CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bromazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bromazepam undergoes oxidative biotransformation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Budesonide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as budesonide is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bupivacaine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Bupivacaine is predominantly metabolized via CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Bupivacaine is extensively metabolised in the liver, predominately by aromatic hydroxylation to 4-hydroxy-bupivacaine and N-dealkylation to PPX, both mediated by cytochrome P4503A4. About 1% of bupivacaine is excreted in the urine as unchanged drug in 24 h and approximately 5% as PPX. The plasma concentrations of PPX and 4-hydroxy-bupivacaine during and after continuous administration of bupivacaine are low as compared to the parent drug. <br /><em>Marcain&#174; Polyamp Steripack 0.25% and 0.5% UK Summary of Product Characteristics, AstraZeneca UK Limited, updated May 2012</em></p>
<p>Bupivacaine is extensively metabolized in the liver predominantly by aromatic hydroxylation to 4-hydroxy-bupivacaine and N-dealkylation to 2,6-pipecoloxylidine (PPX), both mediated by cytochrome P450 3A4. The terminal half-life of bupivacaine in adults is 2.7 hours, and in neonates it is prolonged up to eight hours. The kidney is the main excretory organ for most local anaesthetics and their metabolites. About 1% of bupivacaine is excreted in the urine as unchanged drug in 24 h and approximately 5% as PPX. The plasma concentrations of PPX and 4-hydroxy-bupivacaine during and after continuous administration of bupivacaine are low as compared to the parent drug.<br /><em>Sensorcaine&#174; Bupivacaine Hydrochloride Injection USP Canadian Product Monograph, AstraZeneca Canada Inc, Last revised: February 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Buprenorphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>The interaction between buprenorphine and didanosine, lamivudine and tenofovir was investigated in 27 HIV-, buprenorphine/naloxone maintained subjects. When compared to values obtained from 20 control subjects not receiving buprenorphine, no significant changes in buprenorphine pharmacokinetics were observed. When compared to controls, buprenorphine had no statistically significant effect on NRTI concentrations. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The interaction between buprenorphine and didanosine, lamivudine and tenofovir was investigated in 27 HIV-, buprenorphine/naloxone maintained subjects. Data for didanosine and tenofovir were compared to values obtained from 20 control subjects not receiving buprenorphine; lamivudine was compared to control data. No significant changes in buprenorphine pharmacokinetics were observed when coadministered with didanosine, lamivudine and tenofovir. When compared to controls, buprenorphine had no statistically significant effect on NRTI concentrations. <br /><em>Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine and tenofovir. Baker K, Gruber VA, Moody DE, et al. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 2009, abstract A1-1306.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Bupropion</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bupropion is primarily metabolized by CYP2B6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Buspirone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as buspirone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Caffeine citrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as caffeine is mainly metabolized by CYP1A2. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Calcium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcium is eliminated through faeces, urine and sweat.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Candesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as candesartan is mainly eliminated unchanged via urine and bile.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cannabis</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. THC, the principal psychoactive constituent of cannabis, is metabolized mainly by CYP2C9 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Capecitabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Capecitabine is activated by sequential enzyme reactions to fluorouracil. Dihydropyrimidine dehydrogenase plays a role in fluorouracil metabolism. Nucleoside analogues such as didanosine may compete for or inhibit this metabolism pathway, leading to increased fluorouracil toxicity. The clinical relevance of this interaction is unknown and clinical monitoring is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Capreomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Capreomycin is predominantly excreted in the urine as unchanged drug and may potentially compete with didanosine for renal elimination transport mechanisms, which could result in increased concentrations of either or both drugs. Monitoring of renal function may be warranted, particularly as there have been reports of renal toxicity with capreomycin use.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)<br /><em></em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Captopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Captopril is largely excreted in the urine by OAT1 but didanosine does not inhibit this renal transporter.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Carbamazepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on  metabolism and clearance a clinically significant interaction is unlikely. Carbamazepine is almost completely metabolized in the liver to carbamazepine 10,11 epoxide.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Carbidopa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbidopa is partly metabolized and partly eliminated unchanged (30% of the total urinary excretion). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Carbimazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Carbimazole is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole (also known as methimazole).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Carboplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Carboplatin is excreted primarily by renal glomerular filtration. However, coadministration can increase the risk of peripheral neuropathy due to additive toxicity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Carboplatin is excreted primarily by glomerular filtration in urine, with recovery of 65% of a dose within 24 hours. Most of the drug is excreted within the first 6 hours. Approximately 32% of a given dose of carboplatin is excreted unchanged.<br /><em>Carboplatin Summary of Product Characteristics, Hospira UK Ltd,&nbsp;June 2009.<br />Carboplatin Prescribing Information, Hospira Inc,&nbsp;August 2007</em> .</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Carvedilol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, with additional metabolism via CYP2D6 and to a lesser extent 2C9 and 1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Caspofungin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cat&#39;s Claw (Uncaria tomentosa)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cats claw was demonstrated to strongly inhibit CYP3A4 in vitro, but didanosine does not undergo CYP3A4 metabolism.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cefalexin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Cefalexin is predominantly eliminated unchanged renally by glomerular filtration and tubular secretion via OAT1 and MATE1. Thus, there is potential for competition with cefalexin for renal transporters, which could lead to increased concentrations of either drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cefazolin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cefazolin is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Cefazolin is excreted unchanged in the urine. In the first 6 hours approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours. <br /><em>Cefazolin for Injection, US Prescribing Information, Pfizer Labs, Issued April 2009</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cefixime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cefixime is predominantly eliminated unchanged via renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Cefixime is predominantly eliminated as unchanged drug in the urine. Glomerular filtration is considered the predominant mechanism. Metabolites of cefixime have not been isolated from human serum or urine.<br /><em>Suprax&#174; tablets (Cefixime) Summary of Product Characteristics, Sanofi-Aventis, updated November 2010</em></p>
<p>Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours. In animal studies, it was noted that cefixime is also excreted in the bile in excess of 10% of the administered dose. There is no evidence of metabolism of cefixime in vivo. <br /><em>Suprax&#174; (cefixime) US Prescribing Information, Lupin Pharmaceuticals INC, updated November 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cefotaxime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cefotaxime is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite. The desacetyl metabolite has been shown to contribute to the bactericidal activity. Two other urinary metabolites (M2 and M3) account for about 20-25%. They lack bactericidal activity.<br /><em>Cefotaxime for injection US Prescribing Information, Pfizer Labs, updated December 2009</em></p>
<p>Cefotaxime is partially metabolised prior to excretion. The principal metabolite is the microbiologically active product, desacetyl-cefotaxime. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime. Plasma clearance is reported to be between 260 and 390ml/minute and renal clearance 145 to 217 ml/minute.<br />Probenecid interferes with renal tubular transfer of cefotaxime delaying its excretion and increasing the plasma concentration.<br /><em>Cefotaxime for injection Summary of Product Characteristics, Wockhardt UK Ltd, updated August 2008</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ceftazidime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ceftazidime is predominantly eliminated unchanged via renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Ceftazidime is not metabolised in the body and is excreted unchanged in the active form into the urine by glomerular filtration. Approximately 80 to 90% of the dose is recovered in the urine within 24 hours. Less than 1% is excreted via the bile, significantly limiting the amount entering the bowel.<br /><em>Fortum&#174; 500 injection (ceftazidime) Summary of Product Characteristics, GlaxoSmithKline UK, updated August 2009</em></p>
<p>Approximately 80% to 90% of an IM or IV dose of ceftazidime is excreted unchanged by the kidneys over a 24-hour period. After the IV administration of single 500-mg or 1-g doses, approximately 50% of the dose appeared in the urine in the first 2 hours. An additional 20% was excreted between 2 and 4 hours after dosing, and approximately another 12% of the dose appeared in the urine between 4 and 8 hours later. The calculated plasma clearance of approximately 115 mL/min indicated nearly complete elimination of ceftazidime by the renal route. Administration of probenecid before dosing had no effect on the elimination kinetics of ceftazidime, suggesting that ceftazidime is eliminated by glomerular filtration and is not actively secreted by renal tubular mechanisms.<br /><em>Fortaz&#174; (ceftazidime for injection) US Prescribing Information, GlaxoSmithKline, updated August 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ceftriaxone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ceftriaxone is eliminated mainly as unchanged drug; approximately 60% of the dose being excreted in the urine, almost exclusively by glomerular filtration, and the remainder via the biliary and intestinal tracts. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Ceftriaxone is eliminated mainly as unchanged drug; approximately 60% of the dose being excreted in the urine (almost exclusively by glomerular filtration) and the remainder via the biliary and intestinal tracts. The elimination of ceftriaxone is not altered by probenecid<br /><em>Rocephin&#174; (ceftriaxone) 250mg, 1g and 2g vials Summary of Product Characteristics, Roche Products Limited, updated May 2011</em></p>
<p>Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds. The elimination of ceftriaxone is not altered by co-administration with probenecid.<br /><em>Rocephin&#174; (ceftriaxone sodium) for injection, US Prescribing Information, Genentech USA, Inc, updated November 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Celecoxib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as celecoxib is metabolised mainly by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cetirizine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. In vitro data indicate that cetirizine inhibits OCT2 but this is not involved in the renal elimination of didanosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Chlorambucil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorambucil is almost completely metabolized (little is known about chlorambucil metabolism in humans, most probably non CYP mediated) and has extremely low urinary excretion. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Chloramphenicol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Chloramphenicol is predominantly metabolised via UDP-glucuronyltransferases, in particular UGT2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The primary UGT enzymes responsible for chloramphenicol O-glucuronidation were evaluated in vitro. Reaction phenotyping for the glucuronidation of chloramphenicol with 12 expressed human liver UGT isoforms has identified UGT2B7 as having the highest activity for 3-O- and 1-O-chloramphenicol glucuronidation with minor contributions from UGT1A6 and UGT1A9. The formation of 1-O-chloramphenicol glucuronide by pooled HLM and expressed UGT2B7 exhibited substrate inhibition kinetics with apparent K(m) values of 408.2 and 115.0 microM, respectively. Azidothymidine (AZT) and hyodeoxycholic acid (substrates of UGT2B7) inhibited 3-O- and 1-O-chloramphenicol glucuronidation in pooled HLMs. In 10 donor HLM preparations, both chloramphenicol 3-O- and chloramphenicol 1-O-glucuronidation showed a significant correlation with AZT glucuronidation (UGT2B7) at 30 microM chloramphenicol. These results suggest that UGT2B7 is the primary human hepatic UDP-glucuronosyltransferase isoform catalyzing 3-O- and 1-O-chloramphenicol glucuronidation with minor contributions from UGT1A6 and UGT1A9.<br /><em>Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol. Chen M, LeDuc B, Kerr S, Howe D, Williams DA. Drug Metab Dispos. 2010 Mar;38(3):368-75.</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Chlordiazepoxide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlordiazepoxide is extensively metabolized by hepatic microsomal enzymes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Chloroquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Chloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney (50%). Due to the multiple elimination pathways, a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Chlorphenamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Chlorphenamine is predominantly metabolized in the liver via CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Chlorphenamine is metabolised to the monodesmethyl and didesmethyl derivatives. About 22% of an oral dose is excreted unchanged in the urine.<br /><em>Piriton&#174; (Chlorphenamine) Tablets&nbsp; UK Summary of Product Characteristics, GlaxoSmithKline Consumer Healthcare, updated May 2010</em></p>
<p>Eight healthy volunteers received a single 8mg oral dose of rac-chlorphenamine either given alone or following administration of quinidine 50mg every 6 h for 2 days prior to the study day and every 6 h thereafter until the end of the study. For (S)-(+)-chlorphenamine, administration of quinidine, an inhibitor of CYP2D6, resulted in an increase in Cmax to 13.94 (P&lt;0.01), a reduction in CLoral to 0.22 l h-1 kg-1 (P&lt;0.01), and a prolongation of elimination half-life from 18.0 h to 29.3 h (P&lt;0.001). Administration of quinidine decreased CLoral for (R)-(-)-chlorphenamine to 0.60+/-0.10 l h-1 kg-1 (P&lt;0.005). In CYP2D6 poor metabolizers, systemic exposure was greater after chlorphenamine alone than in extensive metabolizers, and administration of quinidine resulted in a slight increase in CLoral. Stereoselective elimination of chlorphenamine occurs in humans, with the most pharmacologically active (S)-(+)-enantiomer cleared more slowly than the (R)-(-)-enantiomer. CYP2D6 plays a role in the metabolism of chlorphenamine in humans.<br /><em>The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorphenamine. Yasuda SU, Zannikos P, Young AE et al. Br J Clin Pharmacol. 2002 May;53(5):519-25.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Chlorpromazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction is expected with Videx-EC (didanosine gastro-resistant capsules).  However, didanosine chewable/dispersible tablets and powder for oral solution contain an antacid which reduces chlorpromazine absorption. Chlorpromazine should not be taken within 2 hours of antacid administration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Chlortalidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as chlortalidone is mainly excreted unchanged in the urine and faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ciclosporin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ciclosporin is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cidofovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of cidofovir/probenecid increased didanosine AUC by 1.6-fold. There was no effect on cidofovir pharmacokinetics. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Coadministration of cidofovir (3 mg/kg IV over 1 h) with probenecid and didanosine (200 mg twice daily or, if &lt;60 kg, 100 mg twice daily) was studied in 18 HIV+ subjects. Coadministration had no effect on cidofovir pharmacokinetics, but the AUC of didanosine increased by 1.6-fold. <br /><em>Drug-drug interaction study with intravenous cidofovir and either trimethoprim/sulfamethoxazole, didanosine, or fluconazole in HIV-infected individuals. Luber A, Lalezari J, Rooney J, et al. 42nd ICAAC, San Diego, September 2002, abstract A-1828.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cilazapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cilazapril is mainly eliminated unchanged by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cimetidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as in vitro data indicate that cimetidine inhibits OAT1 at concentrations much higher than the observed clinical concentrations. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ciprofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction with didanosine gastro-resistant capsules (Videx EC). Coadministration with other formulations has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged by the kidneys by glomerular filtration and tubular secretion via OAT3. It is also metabolized and partially cleared through the bile and intestine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Unlike the didanosine chewable/dispersible tablets, didanosine gastro-resistant capsules do not contain antacids and therefore drug interactions mediated by altered gastric pH are not anticipated when didanosine gastro-resistant capsules are co-administered with medicinal products where absorption is influenced by gastric acidity. Specific interaction studies with ciprofloxacin showed no evidence of significant interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Coadministration of didanosine EC (400 mg single dose) and ciprofloxacin (750 mg single dose) to 16 HIV-negative subjects resulted in no change in the AUC and Cmax of ciprofloxacin. When the buffered formulation of ddI (200 mg twice daily for 3 days) was coadministered with ciprofloxacin (750 mg twice daily for 3 days, 2 h before ddI) to 8 HIV-infected subjects, ddI AUC and Cmax decreased by 16% and 28%, respectively. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>The effect of the didanosine encapsulated enteric coated beadlet formulation (400 mg) on ciprofloxacin (750 mg) was evaluated in 16 healthy volunteers. The geometric mean Cmax and AUC values were 8.1% and 9.1% lower, respectively, when given in combination. However, 90% CI of the ratios of the geometric means fell within the criteria defined for a lack of interaction (0.75 to 1.33). Didanosine as this formulation did not affect the pharmacokinetics of ciprofloxacin and the drugs may be administered simultaneously. <br /><em>Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole and ciprofloxacin. Damle BD, et al. Antimicrob Agent Chemother, 2002, 46:385-391. </em></p>
<p>The pharmacokinetics of didanosine and ciprofloxacin were evaluated following administration of didanosine (200 mg twice daily, buffered tablets) and ciprofloxacin (750 mg twice daily) to 16 HIV-infected subjects as single agents or in combination (ciprofloxacin 2 h prior to didanosine). When coadministered, there were statistically significant decreases in ciprofloxacin AUC (26%) and urinary recovery (29%), though these were not considered to be clinically significant. Other than a decrease in didanosine AUC (16%), ciprofloxacin did not alter the pharmacokinetics of didanosine. <br /><em>A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (CIPRO) in male subjects seropositive for HIV but asymptomatic. Knupp CA, et al. Biopharmac Drug Dis, 1997, 18: 65-77. </em></p>
<p>The pharmacokinetics of ciprofloxacin (500 mg) were determined in a HIV-negative subject on four occasions following administration of ciprofloxacin alone, 2 h before didanosine-placebo buffered tablets, 2 h after didanosine-placebo buffered tablets and concomitantly with didanosine-placebo buffered tablets. Administration of ciprofloxacin concurrently or 2 h after the antacids in the placebo tablet reduced ciprofloxacin concentrations to below the minimum inhibitory concentration for moderately sensitive microorganisms. Administration of ciprofloxacin 2 h before the antacids resulted in normal concentrations. The results from this single subject suggest that ciprofloxacin should be given either 2 h before or at least 6 h after administration of didanosine buffered tablets. <br /><em>Avoiding the ciprofloxacin-didanosine interaction. Sahai J. Ann Intern Med, 1995, 123: 394-395. The pharmacokinetics of ciprofloxacin (750 mg) administered alone and immediately after didanosine-placebo buffered tablets were determined in 12 HIV-negative subjects. Significant decreases in ciprofloxacin Cmax (from 3.38&#177;0.63 to 0.25&#177;0.21 &#181;g/ml) and AUC (from 15.5&#177;2.69 to 0.26&#177;0.21 &#181;g.h/ml) were seen when coadministered with the buffered tablets. The simultaneous administration of ciprofloxacin and didanosine should be avoided.Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Sahai J, et al. Clin Pharmacol Ther, 1993, 53: 292-297. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cisapride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cisapride is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cisatracurium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisatracurium undergoes mainly (80% of overall elimination) spontaneous degradation in plasma and tissues at physiological pH and temperature (Hofmann elimination).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cisplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Cisplatin is eliminated renally via OCT2 and MATE1. A pharmacokinetic interaction is unlikely, however, the risk of neurotoxicity may be potentially increased as both drugs can cause neuropathy.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Citalopram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Citalopram is metabolized by CYP2C19 (38%), 2D6 (31%) and 3A4 (31%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clarithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as clarithromycin is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clavulanic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Clavulanic acid is extensively metabolized (likely by a non CYP mediated pathway) and excreted in the urine by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clindamycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Clindamycin is metabolized by CYP3A4 with some metabolites having antibacterial activity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clobetasol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely with the topical use of clobetasol.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clofazimine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadminisistration has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction with clofazimine and enteric coated formulations of didanosine. Coadministration of the buffered formulations of didanosine may decrease clofazimine exposure. In a crossover study in 16 healthy volunteers, administration with an aluminium-magnesium antacid decreased clofazimine bioavailability by 22%. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><em><strong>Note:</strong> Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction with clofazimine and enteric coated formulations of didanosine.&nbsp;Buffered formulations of didanosine may decrease clofazimine exposure as they contain an antacid. <br /></em></div>
<div>In a crossover study in 16 healthy volunteers, administration with an aluminium-magnesium antacid decreased clofazimine bioavailability by 22%.<br /><em>Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Nix DE, Adam RD, Auclair B, et al. Tuberculosis (Edinb). 2004;84(6):365-73.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clofibrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolyzed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clomifene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. CYP2D6 is thought to have a role in clomifene metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Based on early studies with 14C-labeled clomiphene citrate, the drug was shown to be readily absorbed orally in humans and excreted principally in the feces. Cumulative urinary and fecal excretion of the 14C averaged about 50% of the oral dose and 37% of an intravenous dose after 5 days. Mean urinary excretion was approximately 8% with fecal excretion of about 42%.<br /><em>Clomid&#174; (clomiphene citrate tablets USP) US Prescribing Information, Sanofi-aventis U.S. revised June 2006</em></p>
<p>A study aimed to define the role of CYP2D6 and CYP3A4 in the in vitro metabolism of enclomiphene, the more active isomer of clomiphene. Enclomiphene (25 microM) was incubated with human liver microsomes (from 4 extensive (EM) and 1 poor metaboliser with respect to CYP2D6) and with microsomes from lymphoblastoid cells expressing CYP2D6. Microsomes from all the EM livers and recombinant CYP2D6 metabolised enclomiphene (the disappearance of drug ranged from 40-60%). No metabolism was detected in microsomes from the PM liver. Quinidine (1 microM) completely inhibited the metabolism of enclomiphene by all the EM livers and by recombinant CYP2D6 (p&lt;0.001, one way ANOVA). Ketoconazole (2 microM) had no significant effect on enclomiphene metabolism in 3 out of the 4 EM livers. The extent of enclomiphene metabolism was correlated with the amount of CYP2D6 present (p&lt;0.001, Pearson correlation test). The findings indicate that CYP2D6 is primarily responsible for the metabolism of enclomiphene.<br /><em>CYP2D6 is primarily responsible for the metabolism of clomiphene. Ghobadi C, Gregory A, Crewe HK, Rostami-Hodjegan A, Lennard MS. Drug Metab Pharmacokinet. 2008;23(2):101-5</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clomipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolized by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. In addition, clomipramine and desmethylclomipramine are metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clonazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clonazepam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clonidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in form of the unchanged parent drug (40-60% of the dose). Clonidine is a weak inhibitor of OCT2 but is unlikely to affect didanosine which is eliminated by different renal transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clopidogrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clopidogrel is a prodrug that is converted to its active metabolites via CYPs 3A4, 2B6, 2C19 and 1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clorazepate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolized to oxazepam by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cloxacillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion. About 35% of an oral dose is excreted in the urine and up to 10% in the bile. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete) last reviewed 03/11/11</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Clozapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clozapine is metabolized by CYPs 1A2, 2C19, 3A4, and to a lesser extent by CYPs 2C9 and 2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cobicistat (with ATV or DRV)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cocaine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cocaine is metabolized by several pathways (non CYP and CYP mediated), with metabolism to norcocaine by CYP3A4 being less than 10% of the overall metabolic clearance.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Codeine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Codeine undergoes predominantly direct glucuronidation with CYP3A4 mediated metabolism accounting for only 10-15% of the overall metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Colchicine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as colchicine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Colecalciferol (Vitamin D3)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Metabolism of vitamin D to active metabolites occurs in the liver and kidneys, and is thought to involve CYP3A4 and CYP24A1. There is little potential for interaction with didanosine via modulation of, or competition for, metabolic pathways. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cubeb pepper (Piper cubeba)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cyanocobalamin (Vitamin B12)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cyclophosphamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclophosphamide is activated (major pathway) to 4-hydroxycyclophosphamide by CYPs 2B6 (major), 2C9 and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cycloserine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cycloserine is predominantly excreted renally via glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Cycloserine is excreted into the urine, levels appearing within half an hour of oral ingestion. Approximately 66 per cent of a dose appears unchanged in the urine in 24 hours. A further 10 per cent is excreted over the next 48 hours. It is not significantly excreted in the faeces. Approximately 35 per cent is metabolised, but the metabolites have not yet been identified.<br /><em>Cycloserine UK Summary of Product Characteristics, King Pharmaceuticals Ltd,&nbsp; updated November 2007</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cyproterone acetate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyproterone acetate is metabolized by CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Cytarabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cytarabine is metabolized by cytidine deaminase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dabigatran</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dabigatran is not metabolized by CYP450 isoenzymes and is mainly cleared by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dacarbazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dacarbazine undergoes activation to MTIC primarily via CYP1A2 and to a lesser extent by CYP2E1, with CYP1A1 having a role in extrahepatic metabolism. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Daclatasvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. No dose adjustment of daclatasvir or didanosine is required. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dactinomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Results of a study in patients with malignant melanoma indicate that dactinomycin (3H actinomycin D) is minimally metabolized, is concentrated in nucleated cells, and does not penetrate the blood-brain barrier. Approximately 30% of the dose was recovered in urine and feces in one week. The terminal plasma half-life for radioactivity was approximately 36 hours.<br /><em>Cosmegen&#174; (dactinomycin) for Injection US Prescribing Information, Lundbeck, Updated March 2012</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dalteparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but a clinically significant pharmacokinetic interaction is unlikely. Dalteparin is excreted largely unchanged by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dapsone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of didanosine (buffered)  had no significant effect on dapsone pharmacokinetics. However, coadministration of both drugs may increase the risk of peripheral neuropathy (additive toxicity).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Specific interaction studies have been conducted with dapsone without evidence of interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>When the buffered formulation of ddI (200 mg twice daily for 14 days) was coadministered with dapsone (100 mg single dose) to 6 HIV-infected subjects, there was no change in dapsone AUC or Cmax. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>The effect of didanosine (200 mg twice daily, buffered tablets) on the pharmacokinetics of dapsone (100 mg) was investigated in 6 HIV-infected subjects. There were no significant differences in dapsone pharmacokinetics when administered alone or with didanosine. Mean values for didanosine Cmax and AUC were 1.72&#177;0.40 vs. 1.73&#177;0.27 &#181;g/ml and 36.3&#177;15.9 vs. 38.1&#177;15.1 &#181;g.h/ml (alone vs. combination), respectively. <br /><em>Effects of the antacids in didanosine tablets on dapsone pharmacokinetics. Sahai J et al. Ann Intern Med, 1995, 123: 584-587. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Darifenacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Darifenacin is metabolized by CYP3A4 and CYP2D6.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Darunavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interactions were observed when didanosine and darunavir/ritonavir were administered 2 h apart (didanosine on an empty stomach, 2 h prior to darunavir/ritonavir with food). No dose adjustments are required; however, as didanosine should be administered on an empty stomach it should be administered 1 h before or 2 h after darunavir/ritonavir (which are administered with food). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Coadministration of didanosine (400 mg once daily) and darunavir/ritonavir decreased didanosine AUC by 9% and decreased Cmax by 16%. There was no significant effect on darunavir AUC, Cmax and Cmin. Darunavir coadministered with low dose ritonavir and didanosine can be used without dose adjustments. Didanosine is to be administered on an empty stomach, thus it should be administered 1 hour before or 2 hours after darunavir/ritonavir given with food. <br /><em>Prezista Summary of Product Characteristics, Janssen-Cilag Ltd, <em>June 2012</em>.</em></p>
<p>Coadministration of didanosine (400 mg once daily) and darunavir/ritonavir (600/100 mg twice daily) was studied in 17 subjects. Darunavir Cmax decreased by 7%, with AUC and Cmin increased by 1% and 7%, respectively. Didanosine Cmax and AUC decreased by 16% and 9% respectively. Didanosine should be administered one hour before or two hours after darunavir/ritonavir (which are administered with food). <br /><em>Prezista Prescribing Information, Tibotec Inc, June 2012.</em></p>
<p>Coadministration of darunavir/ritonavir (600/100 mg twice daily) and didanosine (400 mg once daily) was studied in 17 HIV- subjects. During the combination phase, didanosine was administered on an empty stomach and darunavir/ritonavir were given 2 h later with food. Didanosine had no significant affect on darunavir AUC (no change), Cmax (7% decrease) or Cmin (7% increase). Didanosine AUC and Cmax decreased by 9% and 16%, respectively in the presence of darunavir/ritonavir. Ritonavir AUC and Cmax decreased by 14% and 21% in the presence of didanosine, whereas Cmin increased by 5%. Coadministration was generally safe and well tolerated and no dose adjustment for didanosine or darunavir/ritonavir is recommended.<br /><em>Pharmacokinetic interaction trial between darunavir in combination with low-dose ritonavir and didanosine. Sekar VJ, et al. 4th IAS Conference on HIV Pathogenesis, Treatment &amp; Prevention, Sydney, July 2007, abstract WEPEB012.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dasatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.  Dasatinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Daunorubicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. A clinical study reported that antiretroviral regimens containing didanosine had no effect on the pharmacokinetics of liposomal daunorubicin.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Daunorubicin hydrochloride is mainly metabolized in the liver; each accompanying medication influencing liver function may also influence the metabolism or pharmacokinetics of daunorubicin hydrochloride and as a consequence influence efficacy and/or toxicity. Daunorubicin is rapidly taken up by tissues, especially by the kidneys, spleen, liver and heart. It does not cross the blood-brain barrier, subsequent release of drug and its metabolites from the tissues is slow (t&#189; = 55 hours). Daunorubicin is rapidly metabolised in the liver. The major metabolite daunorubicinol is also active. Daunorubicin is excreted slowly in the urine, mainly as metabolites with 25% excreted in the first 5 days. Biliary excretion also makes a significant (40%) contribution to elimination. <br /><em>Daunorubicin 20mg Powder for Injection UK Summary of Product Characteristics, Zentiva, updated March 2012</em></p>
<div>The plasma pharmacokinetics of DaunoXome(daunorubicin citrate liposome injection) differ significantly from the results reported for conventional daunorubicin hydrochloride. DaunoXome has a small steady-state volume of distribution of 6.4 L, (probably because it is confined to vascular fluid volume), and clearance of 17 mL/min. These differences in the volume of distribution and clearance result in a higher daunorubicin exposure (in terms of plasma AUC) from DaunoXome than with conventional daunorubicin hydrochloride. The apparent elimination half-life of DaunoXome is 4.4 hours, far shorter than that of daunorubicin, and probably represents a distribution half-life. Daunorubicinol, the major active metabolite of daunorubicin, was detected at low levels in the plasma following intravenous administration of DaunoXome.<br /><em>DaunoXome&#174; (daunorubicin citrate liposome injection) US Prescribing Information, Galen Limited, updated December 2011</em> 
<div>&nbsp;</div>
<div>A study investigated the pharmacokinetics of liposomal daunorubicin (DaunoXome) administered alone or in combination with antiviral therapy including protease inhibitors (PI) to HIV-positive patients affected by Kaposi's sarcoma (KS). Patients with extensive or rapidly progressing AIDS-related KS (n=18) received DaunoXome at a dose of 40mg/m2 alone or with triple combination therapy consisting of one PI plus two nucleoside reverse transcriptase inhibitors (stavudine, didanosine, lamivudine, or zidovudine). Daunorubicin pharmacokinetics were determined in a total of 23 cycles, 6 with DaunoXome alone, 9 in combination with indinavir, 6 with ritonavir and 2 with saquinavir. Plasma samples were obtained at different times during the 72 h after DaunoXome administration. Daunorubicin and daunorubicinol plasma levels were determined by high-performance liquid chromatography. There were no significant differences in the pharmacokinetic parameters of daunorubicin in patients receiving DaunoXome in combination with indinavir and ritonavir compared with those in patients not receiving PIs. Therefore in patients affected by AIDS-related KS treated with Highly Active AntiRetroviral Therapy (HAART) there is no pharmacokinetic justification for reducing the doses of DaunoXome<br /><em>The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Fumagalli L, Zucchetti M, Parisi I et al. Cancer Chemother Pharmacol. 2000;45(6):495-501.</em></div></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Delavirdine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction expected with the enteric coated formulation of didanosine (Videx-EC). Concurrent administration of other formulations reduces exposure of both drugs though the clinical significance of this reduction is unknown. Simultaneous coadministration of ddI buffered tablets (125 or 250 mg twice daily) and delavirdine (400 mg three times daily) decreased ddI Cmax (20%) and AUC (21%) when compared to dosing 1 h apart. There were decreases in delavirdine Cmax (32%) and AUC (19%), but no change in Cmin. Separating doses by 1 h overcomes this reduction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration of ddI buffered tablets (125 or 250 mg twice daily for 28 days) and delavirdine (400 mg three times daily for 28 days) to 9 individuals resulted decreases in ddI Cmax and AUC of 20% and 21% when compared to data obtained when delavirdine and didanosine were dosed 1 h apart. There was in a 32% decrease in delavirdine Cmax, a 19% decrease in AUC and no change in Cmin. Administration of ddI buffered tablets and delavirdine should be separated by at least 1 h. <br /><em>Rescriptor Prescribing Information, ViiV Healthcare, April 2012.</em>
<div>&nbsp;</div>A study in 12 HIV+ individuals who received delavirdine (400 mg) and didanosine (125-250 mg every 12 h) found that didanosine AUC (0-infinity) was reduced by concurrent delavirdine (7.93 &#177; 3.9 vs. 6.54 &#177; 2.3 &#181;M.h; alone vs. concurrent). Separating the doses by 1 h overcame this reduction (AUC 1 h apart = 7.94 &#177; 4.8 &#181;M.h). Didanosine Cmax was reduced by concurrent delavirdine (4.65 &#177; 2.0 vs. 3.22 &#177; 0.59 &#181;M; alone vs. concurrent) and again separating the doses by 1 h overcame this reduction (Cmax 1 h apart = 4.63 &#177; 1.3 &#181;M). Coadministration reduced delavirdine exposure; AUC decreased from 22.5 &#177; 14.0 to 14.0 &#177; 5.7 &#181;M.h and Cmax decreased from 7.22 &#177; 4.0 to 3.51 &#177; 1.9 &#181;M. Concurrent administration reduces exposure of both drugs though the clinical significance of this reduction is unknown. These findings require further evaluation at steady-state. <br /><em>Single dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Morse GD, et al. Antimicrob Agents Chemother, 1997, 41: 169-174. </em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Denosumab</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Denosumab is not eliminated via hepatic metabolism but follows the immunoglobulin clearance pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Desflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desflurane is almost exclusively eliminated unchanged by the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Desipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as desipramine is metabolized by CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Desogestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug which is activated to etonogestrel by CYP2C9 (and possible CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dexamethasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction is expected with Videx-EC (didanosine gastro-resistant capsules).  However, didanosine chewable/dispersible tablets and powder for oral solution contain an antacid which may decrease the absorption of dexamethasone. Dexamethasone should be taken at least two hours apart from antacids.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dexmedetomidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexmedetomidine undergoes extensive hepatic metabolism through direct glucuronidation (mainly via UGT1A4, 2B10) and cytochrome P450 (mainly CYP2A6). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dextropropoxyphene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dextropropoxyphene is mainly metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Diamorphine (diacetylmorphine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Diazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolized to nordiazepam (by CYP3A4 and 2C19) and to temazepam (mainly by CYP3A4). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Diclofenac</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidized by CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Diethylcarbamazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning the metabolism/elimination and toxicity profile of diethylcarbamazine, there is little potential for interaction with didanosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Diethylcarbamazine is readily absorbed from the gastrointestinal tract and also through the skin and conjunctiva. It is widely distributed in tissues and is mainly excreted in the urine unchanged and as the N-oxide metabolite. Urinary excretion and hence plasma half-life is dependent on urinary pH. About 5% of a dose is eliminated in the faeces. Results in patients with chronic renal impairment and in healthy subjects, given a single 50-mg oral dose of diethylcarbamazine citrate, indicated that the plasma half-life of diethylcarbamazine is prolonged and its 24-hour urinary excretion considerably reduced in those with moderate and severe degrees of renal impairment<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011 </em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Digoxin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Digoxin is eliminated unchanged in the kidney via the renal transporters OATP4C1 and P-gp, whereas didanosine is excreted by different renal transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dihydrocodeine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 5-10% of the overall metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dihydroergotamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as dihydroergotamine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Diloxanide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Diloxanide furoate is largely hydrolysed under the combined action of bacterial and gut esterases and consequently glucuronidated. No clinically-significant drug interactions are known, and significant interactions with antiretrovirals are unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>In the gut, diloxanide furoate is largely, if not wholly, hydrolysed into diloxanide and furoic acid under the combined action of bacterial and gut esterases. After absorption, diloxanide is very rapidly conjugated to form a glucuronide. In circulating blood, it is present to about 99% as a glucuronide and 1% as free diloxanide. Diloxanide is predominantly excreted in the urine. It is believed that the unabsorbed diloxanide is the active anti-amoebic substance, up to 10% remaining in the gut which is subsequently excreted as diloxanide in the faeces. No clinically-significant drug interactions are known<br /><em>Diloxanide Tablets 500mg UK Summary of Product Characteristics, Sovereign Medical, updated September 2007</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Diltiazem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as diltiazem is metabolized by CYP3A4 and CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Diphenhydramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dipyridamole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Disopyramide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Disopyramide is metabolized by CYP3A4 (25%) and 50% of the drug is eliminated unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Disulfiram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Disulfiram is reduced to diethyldithiocarbamic acid, is conjugated with glucuronic acid, oxidised to sulphate, methylated and decomposed to diethylamine and carbon disulphide.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Docetaxel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a pharmacokinetic interaction is unlikely. However, coadministration of both drugs may increase the risk of peripheral neurotoxicity due to additive toxicity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dolasetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dolutegravir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Domperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as domperidone is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dopamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. There is little potential for dopamine to affect disposition of antiretrovirals, or to be affected if co-administered with antiretrovirals.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Orally administered dopamine is rapidly metabolised in the G.I. tract. Following IV administration, the onset of action of dopamine occurs within 5 minutes, and the drug has a duration of action of less than 10 minutes. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-0-methyltransferase to the inactive compounds homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. Dopamine is excreted in urine principally as HVA and its sulphate and glucuroide conjugates and as 3,4-dihydroxyphenylacetic acid. A very small fraction of a dose is excreted unchanged. <br /><em>Dopamine 40 mg/ml Sterile Concentrate UK Summary of Product Characteristics, Hospira UK Ltd, updated August 2010</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Doxazosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as doxazosin is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Doxepin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolized mainly by CYP2C19 to nordoxepin, an active metabolite. In addition, doxepin and nordoxepin are metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Doxorubicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Doxycycline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Antacids may impair absorption of doxycycline and administration of antacids should be maximally separated from doses of doxycycline. This interaction relates only to buffered tablet formulations of didanosine, which contain antacids. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction between doxycycline and enteric coated formulations of didanosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Absorption of doxycycline may be impaired by concurrently administered antacids containing aluminium, calcium, magnesium or other drugs containing these cations; oral zinc, iron salts or bismuth preparations. Dosages should be maximally separated.<br /><em>Doxycycline Capsules BP 100mg, UK Summary of Product Characteristics, Actavis UK Ltd, updated June 2011<br /><br /></em></div>
<div>The absorption of doxycycline from the gastro-intestinal tract may be inhibited by bi- or tri-valent ions such as aluminium, zinc, calcium (found for example in milk, dairy products and calcium-containing fruit juices), by magnesium (found for example in antacids) or by iron preparations, activated charcoal, cholestyramine, bismuth chelates and sucralfate. Therefore such medicinal products or foodstuffs should be taken after a period of 2 to 3 hours following ingestion of doxycycline. <br />Medicinal products which increase gastric pH may reduce the absorption of doxycycline, and should be taken at least 2 hours after doxycycline.<br /><em>Efracea&#174; 40mg Modified Release Hard Capsules, Summary of Product Characteristics, Galderma (U.K) Ltd, updated November 2011</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Droloxifene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as droloxifene is mainly glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dronabinol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolized by CYP2C9 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Drospirenone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Duloxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dutasteride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dutasteride is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Dydrogesterone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Echinacea</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Edoxaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is minimally metabolised by hydrolysis (mediated by carboxylesterase 1), conjugation, or oxidation by CYP3A4/5 (&lt;10%). Edoxaban is eliminated primarily as unchanged drug in urine.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Efavirenz</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Specific interaction studies have not been performed with efavirenz and didanosine. Clinically significant interactions would not be expected with didanosine since the NRTIs are metabolised via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways. The coadministration of emtricitabine, didanosine and efavirenz was studied in 9 treatment naive, HIV+ patients. When compared to historical data for each drug alone, the pharmacokinetics of emtricitabine were not affected, didanosine AUC and Cmax were higher than expected and efavirenz Cmax, Cmin and AUC were lower than expected. However, efavirenz concentrations may have been underestimated as dosing was delayed by 12 hours for ease of sampling. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><em><strong>LHPG Comment: </strong>Unlike the Videx chewable/dispersible tablets, the new formulation of ddI (Videx EC) does not contain antacids. Interactions with the old formulation that were due to the presence of antacid should not apply to the new formulation. Timing of administration of Videx EC with other medications will still be dependent on food requirements, but no longer on gastric pH requirements. </em></p>
<div>Specific interaction studies have not been performed with efavirenz and NRTIs other than lamivudine, zidovudine, and tenofovir disoproxil fumarate. Clinically significant interactions are not expected since the NRTIs are metabolised via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways. No dosage adjustment is necessary for either medicinal product. <br /><em>Sustiva Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, April 2015.<br />Sustiva Prescribing Information, Bristol-Myers Squibb Company, March 2015.</em>
<div>&nbsp;</div><strong>Didanosine + Emtricitabine</strong> <br />The coadministration of emtricitabine (200 mg once daily), didanosine (400 mg once daily for patients 60 kg and above; 250 mg once a daily for patients &lt;60 kg) and efavirenz (600 mg once daily) was studied in 9 treatment naive, HIV+ patients. When compared to historical data for each drug alone, the pharmacokinetics of emtricitabine were not affected, didanosine AUC and Cmax were higher than expected and efavirenz Cmax, Cmin and AUC were lower than expected. The authors suggest the efavirenz concentrations may have been underestimated as they delayed dosing by 12 hours for ease of sampling. <br /><em>Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS trial). Molina J-M, Peytavin G, Perusat S et al. HIV Medicine, 2004, 5: 99-104.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Eflornithine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Eflornithine is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>After intravenous doses about 80% is excreted unchanged in the urine in 24 hours. The terminal elimination half-life is about 3 hours. It is distributed to the CSF. <br />Less than 1% of a dose is absorbed after topical application. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 23-Sep-2011</em></p>
<p>Eflornithine was administered to six healthy men in single intravenous doses of 5 and 10 mg/kg and oral doses of 10 and 20 mg/kg. Peak plasma concentrations were reached within 6 hr after oral doses. The decay of the plasma concentrations followed first-order kinetics with a mean half-life (t 1/2) for all four doses studied of 199 +/- 6 min (+/- SD). Mean renal clearance was determined as 0.99 +/- 0.03 ml . min-1 . kg-1, accounting for 83% of drug elimination. Mean apparent volume of distribution (aVD) was 0.337 +/- 0.031 l/kg-1, corresponding to 24 l for 70 kg of body weight. The amount of unchanged drug in 24-hr urine samples was 47 +/- 7% and 40 +/- 11% after 10 and 20 mg/kg orally, and 78% and 81 +/- 8% after 5 and 10 mg/kg intravenously. Twenty-four-hour urinary recovery of unchanged drug was 46.9% of the 10mg/kg and 40.3% of the 20 mg/kg oral doses. &gt;86% of the oral doses were cleared from the body by renal filtration. In the case of intravenous dosing, 81% of the drug was eliminated by the kidneys. <br /><em>Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Haegele KD, Alken RG, Grove J et al. Clin Pharmacol Ther. 1981 Aug;30(2):210-7.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Elbasvir/Grazoprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Didanosine is phosphorylated to its active triphosphate form and is not a substrate of any CYP isoenzyme. It is renally excreted. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Eltrombopag </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Eltrombopag is metabolised by cleavage conjugation (UGTs 1A1 and 1A3) and oxidation (CYPs 1A2 and 2C8).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Elvitegravir/Cobi/FTC/TAF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div><div><div>Genvoya should not be co-administered with other antiretroviral medicinal products. <br /><em>Genvoya Summary of Product Characteristics, Gilead Sciences International Ltd, November 2015.</em></div><br /></div><div>Genvoya  is a complete regimen for the treatment of HIV-1 infection;  therefore,  coadministration of Genvoya with other antiretroviral  medications for  treatment of HIV-1 infection should be avoided.</div><div><em>Genvoya US Prescribing Information, Gilead Sciences Inc, November 2015.</em></div></div><em></em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Elvitegravir/Cobi/FTC/TDF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Stribild is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div> <div>Stribild is indicated for use as a complete regimen for the  treatment of HIV 1 infection and must not be administered with other  antiretroviral products.<br /><em>Stribild Summary of Product Characteristics, Gilead Sciences International Ltd, May 2015.</em><br /><br /></div><div>Stribild  is a complete regimen for the treatment of HIV-1 infection; therefore,  Stribild should not be administered with other antiretroviral  medications for treatment of HIV-1 infection.</div><div><em>Stribild Prescribing Information, Gilead Sciences Inc, July 2015.</em></div><div>&nbsp;</div><div>Healthy  volunteers (n=31) were administered a single dose of didanosine (40 mg)  and elvitegravir/ritonavir (200/100 mg once daily) alone and in  combination. Didanosine AUC decreased by 14% and Cmax decreased by 16%  in the presence of elvitegravir/ritonavir. Elvitegravir AUC and Cmax  decreased by 3% and 5%, with Cmin increasing by 6%.</div><div><em>Pharmacokinetics  of coadministered ritonavir-boosted elvitegravir and zidovudine,  didanosine, stavudine, or abacavir. Ramanathan S, Shen G, Hinkle J, et  al. J Acquir Immune Defic Syndr, 2007, 46(2):160-6.</em></div> </div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Empagliflozin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is mainly glucuronidated by UGTs 1A3, 1A8, 1A9 and 2B7. It is a substrate of P-gp and BCRP, and also a substrate of the renal transporter OAT3 and the hepatic transporters OATP1B1 and OATP1B3.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Emtricitabine (FTC)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Emtricitabine/TAF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. However, increased didanosine concentrations and toxicity were observed when combined with tenofovir-DF. If this combination is judged strictly necessary, patients should be carefully monitored for efficacy and didanosine related adverse events. The US Prescribing Information for didanosine and tenofovir-DF recommend a reduced dose of didanosine (250 mg once daily for adults weighing 60 kg or greater with creatinine clearance 60 mL/min or greater; 200 mg once daily for adults weighing less than 60 kg with creatinine clearance 60 mL/min or greater). A decreased dosage of 250 mg didanosine with tenofovir-DF has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection. A high rate of virological failure and emergence of resistance have been reported with once daily regimens of didanosine with lamivudine and tenofovir-DF; the same problems may be seen if Descovy is administered with a third nucleoside analogue.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when tenofovir disoproxil fumarate was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen. Therefore, the same problems may be seen if Descovy is administered with a third nucleoside analogue.<br><em>Descovy Summary of Product Characteristics, Gilead Sciences Ltd, April 2016.</em></p>

</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Enalapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.  Enalapril is hydrolysed to enalaprilat which is eliminated renally, possibly via OATs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Enflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as enflurane is predominantly metabolized by CYP2E1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Enfuvirtide (T20)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Enoxaparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enoxaparin does not undergo cytochrome metabolism but is desulphated and depolymerised in the liver, and is excreted predominantly renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Entecavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Entecavir is eliminated renally via glomerular filtration and active renal secretion by both organic anion and cation transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ephedrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ephedrine is predominantly eliminated unchanged via the kidneys. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Ephedrine is rapidly and completely absorbed after oral administration and extensively distributed throughout the body with accumulation in the liver, lungs, kidneys, spleen and brain. The plasma half-life is reported to be between 3-11 hours, with up to 95% being excreted in the urine.<br /><em>Ephedrine Hydrochloride Tablets UK Summary of Product Characteristics, Wockhardt UK Ltd, updated November 2008</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Epirubicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as epirubicin is glucuronidated by UGT2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Eprosartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as eprosartan is largely excreted in bile and urine as unchanged drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ergometrine (Ergonovine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Ergometrine is extensively metabolized, most likely by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ergotamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Ergotamine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Erlotinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Erlotinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ertapenem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied significant drug interaction is unlikely. Ertapenem is mainly eliminated through the kidneys by glomerular filtration with tubular secretion playing a minor role.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Erythromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Erythromycin is extensively metabolized in the liver.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Escitalopram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Esomeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as esomeprazole is mainly metabolized by CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Estazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Estazolam is metabolized to its major metabolite 4-hydroxyestazolam via CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Estradiol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as estradiol is metabolized by CYP1A2 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Estramustine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Estramustine phosphate undergoes rapid dephosphorylation to estramustine which is then oxidized by 17beta-hydroxysteroid dehydrogenases to estromustine. Estramustine and estromustine are subsequently hydrolyzed to estradiol and estrone, respectively. Estradiol is then hydroxylated by CYPs 1A1, 1A2 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ethambutol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolized by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and in the urine (50%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ethinylestradiol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethinylestradiol is mainly metabolized by hydroxylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ethionamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ethionamide is extensively metabolized in the liver, animal studies suggest involvement of flavin-containing monooxygenases.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Ethionamide is extensively metabolized to active and inactive metabolites. Metabolism is presumed to occur in the liver and 6 metabolites have been isolated: 2-ethylisonicotinamide, carbonyl-dihydropyridine, thiocarbonyl-dihydropyridine, S-oxocarbamoyl dihydropyridine, 2-ethylthioiso-nicotinamide, and ethionamide sulphoxide. The sulphoxide metabolite has been demonstrated to have antimicrobial activity against Mycobacterium tuberculosis. Less than 1% of the oral dose is excreted as ethionamide in urine.<br /><em>Trecator&#174; US Prescribing Information, Wyeth Pharmaceuticals Inc. (now Pfizer) revised November 2007</em></p>
<p>An in vitro study examined the inhibitory effects of pyrazinamide and ethionamide, both of which are chemically related to isoniazid, on the CYP-mediated activities in human liver microsomes and compared them to that of isoniazid. No remarkable effects on any CYP activities were observed by pyrazinamide and ethionamide.<br /><em>Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. Nishimura Y, Kurata N, Sakurai E, Yasuhara H. J Pharmacol Sci. 2004 Nov;96(3):293-300.</em></p>
<p>Flavin-containing monooxygenases (FMOs) are a superfamily of flavoprotein monooxygenases active towards a wide range of xenobiotics. ethionamide (ETA) is a pro-drug requiring bioactivation to exert toxicity. M. tuberculosis possesses a flavin monooxygenase (EtaA) that oxygenates ETA first to the sulfoxide and then to 2-ethyl-4-amidopyridine, presumably through a second oxygenation involving sulfinic acid. ETA is also a substrate for mammalian flavincontaining monooxygenases (FMOs). A study examined activity of expressed human and mouse FMOs toward ETA, as well as liver and lung microsomes. All FMOs converted ETA to the S-oxide (ETASO), the first step in bioactivation. Co-incubations with the general CYP and FMO inhibitors SKF-525A and thiourea, suggest that ETA S-oxygenation in mouse liver and lung microsomes is predominantly, FMO-mediated.<br /><em>Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes. Henderson MC, Siddens LK, Morr&#233; JT, et al. Toxicol Appl Pharmacol. 2008 Dec 15;233(3):420-7</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ethosuximide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ethosuximide is mainly oxidized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Etonogestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel undergoes hepatic metabolism by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Etoposide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etoposide is partly glucuronidated by UGT1A1 and partly metabolized by CYP3A4 to reactive catechol metabolites. Conversion to reactive metabolites can also be mediated by prostaglandin synthase or myeloperoxidase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Etravirine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No dose adjustment is needed for either drug. Coadministration increased etravirine Cmax (16%, AUC (11%) and Cmin (5%). Didanosine Cmax decreased by 9% and there was no change in AUC. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>No significant effect on didanosine and etravirine PK parameters is seen. Coadministration with didanosine (400 mg once daily) had no effect on didanosine AUC and decreased Cmax by 9%. Etravirine AUC increased by 11%, Cmax increased by 5% and Cmin increased by 16%. Etravirine and didanosine can be used without dose adjustments. <br /><em>Intelence Summary of Product Characteristics, Janssen-Cilag Ltd, March 2012.</em></p>
<p>The interaction between etravirine and didanosine was evaluated in clinical studies and no dose adjustment is needed for either drug. Coadministration of didanosine (400 mg once daily) and etravirine was studied in 15 subjects. Etravirine Cmax, AUC and Cmin increased by 16%, 11% and 5%, respectively. Data from 14 subjects showed that didanosine Cmax and AUC decreased by 9% and 1%.<br /><em>Intelence Prescribing Information, Tibotec Pharmaceuticals Ltd, March 2012.</em></p>
<p>The steady state pharmacokinetic interaction between etravirine (800 mg twice daily, phase II formulation) and ddI (400 mg once daily) was studied in healthy volunteers (n=14). Etravirine was administered with food 2 h after administration of ddI. In the presence of ddI, etravirine AUC, Cmax and Cmin increased 11%, 16% and 4% respectively. ddI AUC and Cmax decreased 1% and 9% respectively in the presence of etravirine. The combination was generally safe and well tolerated. The lack of clinically relevant interactions means that no dosage adjustments are necessary when etravirine is combined with ddI. <br /><em>No significant interaction between TMC125 and didanosine in healthy volunteers. Scholler M, Hoetelmans R, Bollen S, et al. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, April 2005, abstract 29.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Eucalpytus globulus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. There is no evidence to suggest that eucalyptus impacts UGTs or P-gp.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Everolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.  Everolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Exemestane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exemestane is metabolized by CYP3A4 and aldoketoreductase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Exenatide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as exenatide is primarily eliminated by glomerular filtration. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ezetimibe</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Famciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famciclovir is converted to penciclovir by aldehyde oxidase. Penciclovir is secreted in the urine possibly by OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Famotidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famotidine is eliminated by renal excretion via OAT3 (65-70%) and by metabolic routes (30-35%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Felodipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as felodipine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fenofibrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is metabolised to an active metabolite, fenofibric acid: in vitro data suggest that fenofibric acid inhibits OAT3. A clinically relevant drug interaction is unlikely as didanosine is excreted via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fentanyl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fesoterodine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fesoterodine is rapidly hydrolysed to its active metabolite which is subsequently metabolized by CYP2D6 and CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fexofenadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine undergoes negligible metabolism and is mainly eliminated unchanged in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Finasteride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Finasteride is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fish oils</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Flecainide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flecainide is metabolized mainly via CYP2D6, with a proportion (approximately 30%) of the parent drug also eliminated unchanged renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Flibanserin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flibanserin is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Flucloxacillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucloxacillin is mainly eliminated renally partly by glomerular filtration and partly by active secretion via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fluconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction with didanosine gastro-resistant capsules (Videx EC). Other formulations may require dose separation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Unlike the didanosine chewable/dispersible tablets, didanosine gastro-resistant capsules do not contain antacids and therefore drug interactions mediated by altered gastric pH are not anticipated when didanosine gastro-resistant capsules are co-administered with medicinal products where absorption is influenced by gastric acidity. Specific interaction studies with fluconazole showed no evidence of significant interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Coadministration of single doses of enteric coated didanosine (400 mg) and fluconazole (200 mg) was studied in 14 HIV-negative subjects. The Cmax and AUC of fluconazole given as a single agent or in combination were similar. Statistical analysis indicated that both parameters satisfied the criteria for a lack of drug interaction (90% CI equivalence interval 0.80-1.25); 90% CI on geometric mean point estimates were 0.99-1.03 for AUC and 0.93-1.03 for Cmax. Enteric coated didanosine can be concomitantly administered with fluconazole, whose bioavailability may be influenced by an interaction with antacids.<br /><em>Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated enteric-coated bead formulation with either itraconazole or fluconazole. Damle B, et al. Biopharm Drug Dispos, 2002, 23: 59-66. </em></p>
<p>Coadministration of didanosine (buffered tablets) and fluconazole (200 mg once daily) were investigated in 12 HIV-infected subjects. No significant differences were found in didanosine AUC when given alone (1528&#177;908 ng.h/ml) or with fluconazole (1486&#177;649 ng.h/ml). Cmax values were similar when given alone (971&#177;509 ng/ml) or with fluconazole (942&#177;442 ng/ml).<br /><em>Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus. Bruzzese VL, et al Antimicrob Agents Chemother, 1995, 39:1050-1053. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Flucytosine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Flucytosine is metabolised to 5-flurouracil which is further metabolised by dihydropyrimidine dehydrogenase. This enzyme is also involved in the catabolic pathway of pyrimidine analogs and competition could potentially increase haematological toxicity. Monitor haematological parameters and consider dose reduction if required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fludarabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Fludarabine phosphate is rapidly hydrolyzed (non-CYP mediated) to 2F-ara-A, the principal metabolite, which is then eliminated renally. However, use with caution due to the risk of peripheral neuropathy associated with both drugs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fludrocortisone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolized in the liver to inactive metabolites, possibly via CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Flunitrazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolized mainly via CYP3A4 and CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fluocinolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely with the topical use of fluocinolone.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fluorouracil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Dihydropyrimidine dehydrogenase plays a role in fluorouracil metabolism. Nucleoside analogues such as didanosine may compete for or inhibit this metabolism pathway, leading to increased fluorouracil toxicity. The clinical relevance of this interaction is unknown, however clinical monitoring is necessary.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>A clinically significant interaction between the antiviral sorivudine and fluorouracil prodrugs, resulting from inhibition of dihydropyrimidine dehydrogenase by sorivudine or chemically related analogues. Caution should be taken when using fluorouracil in conjunction with medications which may affect dihydropyrimidine dehydrogenase activity.<br /><em>Fluorouracil 50 mg/ml Injection UK Summary of Product Characteristics, Hospira UK Ltd, updated August 2011</em></p>
<p>The disposition and metabolic fate of 3'-deoxy-2',3'-didehydrothymidine (D4T) were evaluated both in isolated hepatocytes and in nonhuman primates. Rapid formation of thymine and beta-aminoisobutyric acid (BAIBA) occurred following incubation of hepatocytes with 10 microM [5(-3)H]D4T. Substantial levels of tritiated water were also detected. Exposure of cells to D4T in the presence of either 1 mM thymine or 10 microM benzyloxybenzyluracil, an inhibitor of dihydropyrimidine dehydrogenase, decreased intracellular BAIBA levels by approximately 89 and 63%, respectively. Concurrently, [3H]thymine levels increased two- to fivefold. These results are consistent with D4T being cleaved to thymine, which is then degraded to BAIBA. A similar metabolic disposition was observed in monkeys following administration of 25 mg of [5(-3)H]D4T per kg of body weight. Approximately 50% of the administered dose was recovered in urine within 24 h, with the majority of the radioactivity representing unchanged drug. <br /><em>Cretton EM, Zhou Z, Kidd LB, In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine. Antimicrob Agents Chemother. 1993 Sep;37(9):1816-25</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fluoxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolized by CYPs 2D6 and 2C9 and to a lesser extent by 2C19 and 3A4 to form norfluoxetine. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fluphenazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Fluphenazine is predominantly metabolised via CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Fluphenazine is metabolised by P450 2D6 and is itself an inhibitor of this drug metabolising enzyme. The plasma concentrations and the effects of fluphenazine may therefore be increased and prolonged by drugs that are either the substrates or inhibitors of this P450 isoform, possibly resulting in severe hypotension, cardiac arrhythmias or CNS side effects.<br /><em>Modecate&#174; (fluphenazine) Concentrate Injection 100mg/ml UK Summary of product Characteristics, sanofi-aventis, updated December 2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Flurazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as the metabolism of flurazepam is most likely CYP-mediated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fluticasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as fluticasone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fluvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as fluvastatin is metabolised mainly by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fluvoxamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Folic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fondaparinux</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fondaparinux does not undergo cytochrome metabolism but is eliminated predominantly renally.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Formestane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Formoterol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation being another pathway. As multiple CYP450 and UGT enzymes catalyze the transformation the potential for a pharmacokinetic interaction is low.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Fosamprenavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interactions are expected with either formulation of didanosine (chewable tablets or gastro-resistant capsules). No dose separation or dosage adjustments are necessary.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><em><strong></strong></em></p>
<div>No&nbsp;drug interactions&nbsp;studies have been performed with fosamprenavir&nbsp;and didanosine chewable tablets or gastro-resistant capsules. No clinically significant interactions are expected. No dose separation or dosage adjustments are necessary.<br /><em>Telzir Summary of Product Characteristics, ViiV Healthcare UK Ltd, May 2011.</em></div>
<p>The effect of the buffered tablet (400 mg, concurrent and 1 h apart) and enteric capsule (400 mg, concurrent) formulations of didanosine on the pharmacokinetics of amprenavir (600 mg bd) were investigated in 16 healthy volunteers. Minor pharmacokinetic changes were seen with concurrent dosing in Cmax and AUC, but not in Cmin , and are likely to clinically insignificant. Amprenavir may be dosed concurrently in the fasting state with either formulation of didanosine.<br /><em>The effects of didanosine formulations on the pharmacokinetics of amprenavir. Shelton M, Giovanniello AG, Cloen D, et al. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 2002, abstract A-1826.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Foscarnet</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Specific interaction studies have been conducted with foscarnet without evidence of interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Furosemide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also eliminated unchanged renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Gabapentin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction is expected with Videx-EC (didanosine gastro-resistant capsules).  However, didanosine chewable/dispersible tablets and powder for oral solution contain an antacid. Coadministration of gabapentin and an antacid decreased gabapentin bioavailability by ~20%. Gabapentin should be taken at least 2 hours following antacid administration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The antacid Maalox reduced the bioavailability of gabapentin (n=16) by about 20%. This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox. It is recommended that gabapentin be taken at least 2 hours following antacid administration.<br /><em>Neurontin (gabapentin) Prescribing Information, Pfizer Inc, March 2011.<br />Busch JA, Radulovic LL, Bockbrader HN, et al. Effect of Maalox TC on single-dose pharmacokinetics of gabapentin capsules in healthy subjects [abstract]. Pharmacol Res, 1992, 9(suppl): S315.</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Gamma-hydroxybutyrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant interaction is unlikely. Gamma-hydroxybutyrate undergoes first pass metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ganciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ganciclovir increased plasma exposure of didanosine when given 2 h apart (~2-fold increase). This effect was slightly reduced if the drugs were administered together. Ganciclovir concentrations decreased if given 2h apart, but not if administered simultaneously. It is not known whether these changes are associated with alterations in either the safety of didanosine or the efficacy of ganciclovir. Use with caution and monitor for didanosine-associated toxicity. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Coadministration of didanosine with ganciclovir may result in didanosine-associated toxicities. Patients should be closely monitored. Administration of didanosine 2 hours prior to, or concurrent with, ganciclovir was associated with a mean increase of 111% in the steady state AUC for didanosine. A minor decrease (21%) in the steady state AUC of ganciclovir was seen when didanosine was given 2 hours prior to ganciclovir, but not when both medicines were given simultaneously. There were no changes in renal clearance for either drug. It is not known whether these changes are associated with alterations in either the safety of didanosine or the efficacy of ganciclovir. There is no evidence that didanosine potentiates the myelosuppressive effects of ganciclovir. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Coadministration increases didanosine concentrations. If there is no suitable alternative to ganciclovir, then use in combination with Videx-EC with caution. Monitor for didanosine-associated toxicity. When the buffered formulation of ddI (200 mg twice daily) was coadministered with ganciclovir (1000 mg three times daily, 2 h after ddI) to 12 HIV-negative subjects, ddI AUC increased by 111% and ganciclovir AUC decreased by 21%. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>Coadministration of didanosine (200 mg twice daily) simultaneously with or 2 h before ganciclovir (1000 mg three times daily) was studied in 12 HIV-infected subjects. There were statistically significant decreases in the ganciclovir AUC (23%), Cmax (22%) and Cmin (21%) when given 2 h after didanosine. No significant differences were observed when the two drugs were given simultaneously. There was no significant difference in half life or renal clearance of ganciclovir when the two drugs were administered simultaneously or sequentially. Ganciclovir (simultaneous, sequential) significantly increased didanosine AUC (107%, 115%) and Cmax (108%, 116%). There were statistically significant increases in percentage ddI excreted unchanged in the urine, but no change in renal clearance. When all pharmacokinetic parameters were compared during sequential or simultaneous administration, there were no significant differences. The increased didanosine exposure may result in increased didanosine concentration-related toxicities; similarly, decreases in ganciclovir concentrations may impair its efficacy. For HIV-infected subjects receiving ganciclovir and didanosine, clinicians should recommend administering the two drug simultaneously and patients should be monitored closely for ddI-associated toxicities. <br /><em>Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine and probenecid in HIV-infected subjects. Cimoch PJ, et al. J Acquir Immun Def Syndr, 1998, 17: 227-234. </em></p>
<p>This study investigated the interaction between high dose oral ganciclovir (2000 mg three times daily) and didanosine (200 mg twice daily) in HIV-infected subjects. Didanosine data were available on 12 subjects and ganciclovir data on 8 subjects. When ganciclovir was administered either before didanosine, increases in didanosine AUC (87.3%) and Cmax (58.6%) were observed; when administered 2 h after didanosine, increases in didanosine AUC and Cmax of 100% and 124% were observed. There were no significant effects of didanosine on the pharmacokinetics of ganciclovir, irrespective of sequence of administration. Although the combination was well tolerated in this short term study (3 days), there remains a concern that with long term administration increased didanosine exposure may increase the prevalence of didanosine related side effects. <br /><em>Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients. Jung D, et al. J Clin Pharmacol,1998, 1057-1062. </em></p>
<p>When didanosine (200 mg twice daily) and ganciclovir were coadministered to HIV-infected subjects, there was an ~2-fold increase in didanosine concentrations when compared to didanosine given alone.Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons. Griffy KG. AIDS, 1996, 10 (suppl 4) S3-S6. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Garlic</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although garlic has been shown to induce intestinal CYP3A4 and/or P-gp, this is not expected to impact didanosine exposure.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Gefitinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.  Gefitinib is metabolized by CYP3A4 and 2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Gemcitabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemcitabine is metabolized in the liver by cytidine deaminase to an inactive metabolite.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Gemfibrozil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as gemfibrozil is metabolised mainly by UGT2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Gentamicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Gentamicin is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Gentamicin is not metabolized in the body but is excreted unchanged in microbiologically active form predominantly via the kidneys.<br /><em>Gentamicin 40 mg/ml Injection Summary of Product Characteristics, Hospira UK Ltd, updated August 2011</em></p>
<p>Little, if any, metabolic transformation occurs; the drug is excreted principally by glomerular filtration.&nbsp; After several days of treatment, the amount of gentamicin excreted in the urine approaches, but does not equal, the daily dose administered.&nbsp; As with other aminoglycosides, a small amount of the gentamicin dose may be retained in the tissues, especially in the kidneys.&nbsp; Minute quantities of aminoglycosides have been detected in the urine of some patients weeks after drug administration was discontinued.&nbsp; Renal clearance of gentamicin is similar to that of endogenous creatinine. Probenecid does not affect renal tubular transport of gentamicin.<br /><em>Gentamicin Injection USP, US Prescribing Information, APP Pharmaceuticals, revised August 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Gestodene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ginger (Zingiber officinale)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ginkgo biloba</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Glibenclamide (Glyburide)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Gliclazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as gliclazide is metabolised by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Glimepiride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as glimepiride is metabolised by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Glipizide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as glipizide is mainly metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Goldenseal root (Hydrastis canadensis)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Goserelin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Goserelin is mainly hydrolyzed.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Granisetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as granisetron is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Grapefruit juice</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although grapefruit juice inhibits CYP3A4, this is not expected to alter exposure of didanosine as its metabolism is not CYP-mediated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Griseofulvin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied.  Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Griseofulvin undergoes metabolism to inactive metabolites, principally 6-desmethylgriseofulvin or its glucuronide conjugate, the majority of which are excreted in the urine, with less than 1% of the administered dose being excreted as unchanged drug. The remainder of the dose, principally as metabolites, is excreted in bile and faeces. <br /><em>Griseofulvin 500mg Tablets Summary of Product Characteristics, Morningside Healthcare Ltd, May 2010.</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Halofantrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halofantrine is extensively metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Haloperidol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol undergoes glucuronidation (UGT2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4, 2D6).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Halothane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halothane undergoes both oxidative and reductive metabolism by cytochromes. In vitro data have shown that oxidation occurs mainly via CYP2E1 and to a lesser extent CYP2A6 and reduction via CYP2A6 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Heparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Heparin is thought to be eliminated via the reticuloendothelial system.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>After intravenous or subcutaneous injection heparin is extensively bound to plasma proteins. The half-life of heparin depends on its dose and route as well as the method of calculation and is subject to wide inter- and intra-individual variation; a range of 1 to 6 hours with an average of 1.5 hours has been cited. It may be slightly prolonged in renal impairment, decreased in patients with pulmonary embolism, and either increased or decreased in patients with liver disorders. Heparin is taken up by the reticuloendothelial system. It is excreted in the urine, mainly as metabolites, although after large doses up to 50% may be excreted unchanged.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), last reviewed 2011-11-15</em></p>
<p>Heparin is not eliminated enzymatically nor by glomerular filtration or renal tubular secretion. In all likelihood, the anticoagulant is transferred to reticuloendothelial cells, which may also provide the means for its degradation.<br /><em>Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5: 204&#8211;20.</em></p>
<p>After either subcutaneous or intravenous injection heparin is distributed primarily within the intravascular space. A short distribution phase is seen which is thought to correspond to endothelial cell binding and internalisation. The disposition curve for unfractionated heparin has a unique concave-convex shape which is the result of combined saturable and nonsaturable elimination mechanisms. The nonsaturable elimination mechanism is renal and is the primary route of elimination for low molecular weight heparins.<br /><em>Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22: 359&#8211;74.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Heroin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically relevant drug interaction is unlikely. When used illicitly, heroin is mainly injected or inhaled through the nose and goes directly in the bloodstream. Heroin is then rapidly deacetylated to 6-monoacetylmorhine (6-MAM) and subsequently to morphine by plasma and liver esterase, respectively. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Didanosine does not affect these metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Hops (Humulus lupulus)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that extracts of hops activate PXR and thereby induce the expression of CYP3A4, CYP2B6 and MDR1. However, this is not expected to alter exposure of didanosine as its metabolism is not CYP-mediated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Hydralazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Hydralazine is metabolised via primary oxidative metabolism and acetylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Hydralazine is rapidly absorbed from the gastrointestinal tract and peak plasma concentrations have been reported to occur in the plasma after about one hour. It is metabolised by hydroxylation of the ring system and conjugation with glucuronic acid, and by N-acetylation.<br /><em>Hydralazine Tablets BP 50mg UK Summary of Product Characteristics, Actavis UK Ltd, updated April 2011</em></p>
<p>Hydralazine is rapidly absorbed after oral administration, and peak plasma levels are reached at 1 to 2 hours. Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours. Binding to human plasma protein is 87%. Plasma levels of hydralazine vary widely among individuals. Hydralazine is subject to polymorphic acetylation; slow acetylators generally have higher plasma levels of hydralazine and require lower doses to maintain control of blood pressure. Hydralazine undergoes extensive hepatic metabolism; it is excreted mainly in the form of metabolites in the urine.<br /><em>Hydralazine hydrochloride tablets USP US Prescribing Information, TEVA Pharmaceuticals USA, updated March 2012</em></p>
<p>Pharmacokinetic data indicate hydralazine is absorbed well from the gastrointestinal tract, and has an extensive and complex metabolism depending on acetylator status: slow acetylators undergo primary oxidative metabolism, while rapid acetylators are acetylated.<br /><em>Mulrow JP, Crawford MH. Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure. Clin Pharmacokinet. 1989 Feb;16(2):86-9</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Hydrochlorothiazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Hydrochlorothiazide is not metabolised and is cleared by the kidneys via OAT1. In vitro data indicate that hydrochlorothiazide is unlikely to inhibit OAT1 in the range of clinically relevant drug concentrations and therefore is unlikely to affect the renal elimination of didanosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Hydrocodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Hydrocortisone (oral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Hydrocortisone (topical)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but no clinically relevant drug interactions are expected with the topical use of hydrocortisone.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Hydromorphone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Hydroxyurea (Hydroxycarbamide)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration not recommended due to increased risk of hepatotoxicity, peripheral neuropathy and pancreatitis. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Pancreatitis (fatal and nonfatal) and peripheral neuropathy (severe in some cases) have been reported in HIV infected patients receiving didanosine in association with hydroxyurea and stavudine. Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV infected patients treated with antiretroviral agents and hydroxyurea; fatal hepatic events were reported most often in patients treated with stavudine, hydroxyurea and didanosine. Hence, this combination must be avoided. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>When didanosine is used in combination with other agents with similar toxicities, the incidence of these toxicities may be higher than when didanosine is used alone. Thus, patients treated with didanosine in combination with stavudine, with or without hydroxyurea, may be at increased risk for pancreatitis and hepatotoxicity, which may be fatal, and severe peripheral neuropathy. The combination of didanosine and hydroxyurea, with or without stavudine, should be avoided. Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV-infected patients treated with hydroxyurea and other antiretroviral agents. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. This combination should be avoided. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Hydroxyzine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ibandronic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ibandronic acid should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day. Medicinal products and supplements should be similarly avoided prior to taking ibandronic acid. Fasting should be continued for at least 30 minutes after taking ibandronic acid. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary) </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ibuprofen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ifosfamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for pharmacokinetic interaction. Ifosfamide is predominantly metabolized by CYP3A4 and CYP2B6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The pharmacokinetics of ifosfamide exhibit considerable interindividual variation. It is a prodrug that is extensively metabolised, chiefly by cytochrome P450 isoenzymes such as CYP3A4 and CYP2B6 in the liver, to both active and inactive metabolites; there is some evidence that metabolism is saturated at very high doses. Although licensed product information states that a mean terminal elimination half-life is about 15 hours after a single high-dose intravenous bolus, most studies at lower doses recorded elimination half-lives of 4 to 8 hours. After repeated doses there is a decrease in the elimination half-life, apparently due to autoinduction of metabolism. It is excreted largely in urine, as unchanged drug and metabolites. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 20-Aug-2010<br />Wagner T. Clin Pharmacokinet 1994; 26: 439&#8211;56; Boddy AV, Yule SM. Clin Pharmacokinet 2000; 38: 291&#8211;304; Kerbusch T, et al. Clin Pharmacokinet 2001; 40: 41&#8211;62.</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Iloperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Iloperidone is metabolised by CYP3A4 and CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Imatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied.  Imatinib is primarily metabolized by CYP3A4 and to a lesser extent by CYPs 1A2, 2D6, 2C9 and 2C19. In vitro data indicate that imatinib inhibits CYPs 3A4, 2D6, 2C9 and 2C19. A pharmacokinetic interaction is unlikely. However, hepatotoxicity, occasionally severe, may occur with imatinib. Hepatic steatosis, hepatitis and rarely liver failure have been reported with didanosine. Close monitoring of liver function is warranted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Imipenem/Cilastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal clearance of unchanged drug occurs via glomerular filtration and to a lesser extent, active tubular secretion for both imipenem (when administered with cliastatin), and cilastatin.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>When administered alone, imipenem is metabolised in the kidneys by dehydropeptidase-I. Individual urinary recoveries ranged from 5 to 40%, with an average recovery of 15-20% in several studies. Cilastatin is a specific inhibitor of dehydropeptidase-I enzyme and effectively inhibits metabolism of imipenem so that concomitant administration of imipenem and cilastatin allows therapeutic antibacterial levels of imipenem to be attained in both urine and plasma.<br />Approximately 70% of the administered antibiotic was recovered intact in the urine within ten hours, and no further urinary excretion of imipenem was detectable. Urine concentrations of imipenem exceeded 10 &#956;g/ml for up to eight hours after a 500 mg/500 mg dose of imipenem/cilastatin. The remainder of the administered dose was recovered in the urine as antibacterially inactive metabolites, and faecal elimination of imipenem was essentially nil.<br /><em>Primaxin&#174; IV Injection Summary of Product Characteristics, Merck Sharp &amp; Dohme Limited, updated October 2011<br />Primaxin&#174; I.V. (Imipenem and cilastatin for injection) US Prescribing Information, Merck&amp;Co Inc, Issued February 2010</em><br /><br />Approximately 70-80% of the dose of cilastatin was recovered unchanged in the urine as cilastatin within 10 hours of administration of imipenem/cilastatin. No further cilastatin appeared in the urine thereafter. Approximately 10% was found as the N-acetyl metabolite, which has inhibitory activity against dehydropeptidase comparable to that of cilastatin. Activity of dehydropeptidase-I in the kidney returned to normal levels shortly after the elimination of cilastatin from the blood stream.<br /><em>Primaxin&#174; IV Injection Summary of Product Characteristics, Merck Sharp &amp; Dohme Limited, updated October 2011<br />Primaxin&#174; I.V. (Imipenem and cilastatin for injection) US Prescribing Information, Merck&amp;Co Inc, Issued February 2010</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Imipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Indapamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is extensively metabolized by CYP P450. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Indinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Enteric-coated didanosine can be administered without any restrictions with respect to time of administration or food. Other formulations of didanosine should be administered at least one hour apart on an empty stomach. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><em><strong>LHPG Comment:</strong> Unlike the Videx chewable/dispersible tablets, the new formulation of ddI (Videx EC) does not contain antacids. Interactions with the old formulation that were due to the presence of antacid should not apply to the new formulation. Timing of administration of Videx EC with other medications will still be dependent on food requirements, but no longer on gastric pH requirements.</em></p>
<p>Unlike the didanosine chewable/dispersible tablets, didanosine gastro-resistant capsules do not contain antacids and therefore drug interactions mediated by altered gastric pH are not anticipated when didanosine gastro-resistant capsules are co-administered with medicinal products where absorption is influenced by gastric acidity. Specific interaction studies with indinavir showed no evidence of significant interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Coadministration of didanosine EC (400 mg single dose) and indinavir (800 mg single dose) to 23 HIV-negative subjects resulted in no change in the AUC and Cmax of indinavir. When the buffered formulation of ddI (200 mg single dose) was coadministered simultaneously with indinavir (single dose) to 16 HIV-negative subjects, there was no change in ddI AUC or Cmax. When the same doses were administered 1 h apart (indinavir 1 h before didanosine), the AUC and Cmax of ddI decreased by 17% and 13% respectively. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>No formal interaction study has been performed. A normal (acidic) gastric pH may be necessary for optimum absorption of indinavir whereas acid rapidly degrades didanosine which is formulated with buffering agents to increase pH. Antiretroviral activity was unaltered when didanosine was administered 3 hours after treatment with indinavir. Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach. Coadministration of enteric-coated didanosine (400 mg single dose) and indinavir (800 mg single dose) had no effect on indinavir or didanosine concentrations. Enteric-coated didanosine can be administered without any restrictions with respect to time of administration or food. <br /><em>Crixivan Summary of Product Characteristics, Merck Sharp &amp; Dohme Ltd, <em>February 2012</em>.</em></p>
<p>If indinavir and buffer-containing didanosine formulations are administered concomitantly, they should be administered at least one hour apart on an empty stomach. <br /><em>Crixivan Prescribing Information, Merck &amp; Co Inc, <em>April 2012</em>.</em></p>
<p>Coadministration of single doses of enteric-coated ddI (400 mg) and indinavir/ritonavir (1200/400 mg) and the effect of food were investigated in 8 HIV-negative subjects. When given with food, the addition of ddI had no significant effect on indinavir AUC (5% decrease) or Cmax (3% decrease). However, when indinavir/ritonavir and didanosine were given two hours after food, there was no significant effect on indinavir AUC (5% decrease), but a 14% increase in IDV Cmax when compared to indinavir/ritonavir given alone and with food. When given two hours after food, the addition of indinavir/ritonavir significantly reduced ddI exposure (23% decrease in AUC, 42% decrease in Cmax). Coadministration with food resulted in a similar decrease in Cmax (46%), but lessened the effect on ddI AUC (4% decrease). If ddI and indinavir/ritonavir are used in combination, the most favourable pharmaockinetics are obtained if dosed with food. <br /><em>Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers. la Porte C, Verweij-van Wissen C, van Ewijk N, et al. J Clin Pharmacol, 2005, 45(2): 211-218.</em></p>
<p>Coadministration of indinavir (800mg three times daily) and a single dose of didanosine (400 mg given 1 hour before indinavir) was studied in 12 HIV+ individuals. Didanosine had little effect on indinavir exposure when taken 1 h before indinavir. Administration of didanosine and indinavir should be separated by 1 h, although the gastric buffering effects of a 400 mg dose of didanosine appears to persist for ~90 minutes.<br /><em>If taken 1 hour before indinavir, didanosine does not affect indinavir exposure despite persistent buffering effects. Shelton MJ, Mei H, HewittRG, et al. Antimicrob Agents Chemother, 2001, 45:298&#8211;300.</em></p>
<p>The effect of the ddI encapsulated enteric coated beadlet formulation (400 mg) on indinavir (800 mg) was evaluated in 23 healthy volunteers. It was found that ddI as this formulation did not affect the pharmacokinetics of indinavir and the drugs may be administered simultaneously. <br /><em>Lack of effect of simultaneously administerd didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole and ciprofloxacin. Damle BD, Mummaneni V, Kaul S &amp; Knupp CA. Antimicrob Agent Chemother, 2002, 46:385-391.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Insulin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Interferon alpha</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Patients receiving interferon alpha with or without ribavirin should be closely monitored for treatment associated toxicity, especially hepatic decompensation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Interleukin 2 (Aldesleukin)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as interleukin-2 is mainly eliminated by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Inula racemosa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Iodine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Iodine is converted to iodide, which is trapped in the thyroid gland. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Iodine is converted to iodide, which is trapped in the thyroid gland. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva.<br /><em>Aqueous Iodine Oral Solution BP UK Summary of Product Characteristics, Thornton &amp; Ross Ltd, updated November 2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ipratropium bromide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. A small proportion of an inhaled ipratropium dose is systemically absorbed (6.9%). Metabolism is via ester hydrolysis and conjugation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>After intravenous administration approximately 60% of the dose is metabolised, mainly by conjugation (40%), wheras after inhalation about 77% of the systemically available dose is metabolised by ester hydrolysis (41%) and conjugation (36%). After inhalation of ipratropium bromide either with HFA 134a or CFC propellant, cumulative renal excretion over 24 hours was approximately 12% and 10%, respectively.&nbsp; In an excretion balance study cumulative renal excretion (6 days) of drug-related radioactivity (including parent compound and all metabolites) accounted for 72.1% after intravenous administration, 9.3% after oral administration and 3.2% after inhalation. The main urinary metabolites bind poorly to the muscarinic receptor and have to be regarded as ineffective.<br /><em>Atrovent&#174; (Ipratropium bromide) 20 micrograms/actuation Inhaler CFC-Free UK Summary of Product Characteristics, Boehringer Ingelheim Limited, updated August 2011</em></p>
<p>After inhalation, around 10 to 30% of a dose is deposited in the lungs where it exerts its therapeutic effect. Only a small amount of ipratropium reaches the systemic circulation. The majority of a dose is swallowed but is poorly absorbed from the gastrointestinal tract. Following oral administration, the apparent systemic availability was around 2%, and after inhalation it was 6.9%. Ipratropium and its metabolites are eliminated in the urine and faeces.<br /><em>Ensing K, et al. Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. Eur J Clin Pharmacol 1989; 36: 189&#8211;94.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Irbesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as irbesartan is metabolized by via glucuronidation and oxidation (mainly CYP2C9).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Irinotecan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Irinotecan is converted to its active metabolite SN38 via tissue carboxylesterase and to inactive metabolites (APC, NPC) via CYP3A4. SN38 is further inactivated by several UGTs. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Iron supplements</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Isoflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as isoflurane is almost exclusively eliminated unchanged by the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Isoniazid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant effect of the antacid component of didanosine tablets on isoniazid pharmacokinetics. The effect of didanosine on isoniazid was not studied. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The effect of the antacid in didanosine tables on isoniazid pharmacokinetics was investigated in 12 HIV-negative subjects. Isoniazid pharmacokinetics were determined following administration of a single dose of isoniazid (300 mg) alone and in combination with a single dose of didanosine placebo tablets (2 tablets containing antacid component only) and were not significantly different when administered alone or in combination with antacids. <br /><em>Effect of antacids in didanosine tablet on bioavailability of isoniazid. Gallicano K, et al. Antimicrob Agents Chemother, 1994, 38:894-897. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Isosorbide dinitrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Isosorbide dinitrate undergoes extensive first past metabolism, predominantly in the liver.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Isosorbide dinitrate is readiliy absorbed from the oral mucosa and also following oral administration. It undergoes extensive first pass metabolism, mainly in the liver. <br /><em>Isosorbide Dinitrate Tablets BP 20mg UK Summary of Product Characteristics, Actavis UK Ltd, updated October 2011</em></p>
<p>Isosorbide dinitrate (ISDN) is eliminated from plasma with a short half-life (about 0.7h). The metabolic degradation of ISDN occurs via denitration and glucuronidation, like all organic nitrates. The rate of formation of the metabolites has been calculated for isosorbide-5-mononitrate (IS-5-MN) with 0.27 h -1, and isosorbide (IS) with 0.16 h-1. IS-5-MN and IS-2-MN are the primary metabolites which are also pharmacologically active. IS-5-MN is metabolised to isosorbide 5-mononitrate-2-glucuronide (IS-5-MN-2-GLU). The half-life of this metabolite (about 2.5h) is shorter than that of IS-5-MN (about 5.1h). The half-life of ISDN is the shortest of all and that of IS-2-MN (about 3.2h) lies in between. <br /><em>Isoket&#174; (Isosorbide dinitrate) 1mg/ml injection/infusion UK Summary of Product Characteristics, UCB Pharma Limited, updated July 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Isotretinoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Isotretinoin is metabolised mainly by CYP2C8 and CYP3A4 with the participation of CYP2B6 and CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Itraconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction with didanosine gastro-resistant capsules (Videx EC). Other formulations may require dose separation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Unlike the didanosine chewable/dispersible tablets, didanosine gastro-resistant capsules do not contain antacids and therefore drug interactions mediated by altered gastric pH are not anticipated when didanosine gastro-resistant capsules are co-administered with medicinal products where absorption is influenced by gastric acidity. Specific interaction studies with itraconazole showed no evidence of significant interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Coadministration of single doses of enteric coated didanosine (400 mg) and itraconazole (200 mg) was studied in 25 HIV-negative subjects. The Cmax and AUC of itraconazole given as a single agent or in combination were similar. Statistical analysis indicated that Cmax satisfied the criteria for a lack of drug interaction (90% CI equivalence interval 0.75-1.33); 90% CI on geometric mean point estimates for Cmax was 0.79-1.20. The AUC of itraconazole decreased by 12% in the presence of didanosine; 90% CI on geometric mean point estimates for AUC were 0.71-1.09, indicating an indeterminate effect on AUC. The slight decrease in itraconazole AUC is not likely to significantly influence its antifungal activity. <br /><em>Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated enteric-coated bead formulation with either itraconazole or fluconazole. Damle B, et al. Biopharm Drug Dispos, 2002, 23: 59-66. </em></p>
<p>The pharmacokinetics of itraconazole (200 mg single dose) were determined in 6 HIV-negative subjects alone and when given with didanosine (300 mg, buffered tablets dispersed in 240 ml water). When given alone, itraconazole Cmax was 0.9&#177;0.3 &#181;g/ml; however, when given with didanosine, concentrations of itraconazole were undetectable. <br /><em>Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. May DB, et al. Pharmacother, 1994, 14: 509-513. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ivabradine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction as ivabradine is metabolised by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ivermectin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. In vitro studies suggest that ivermectin is predominantly metabolised via CYP3A4, whereas didanosine is excreted via pathways responsible for the elimination of endogenous purines.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Ivermectin is metabolized in the liver, and ivermectin and/or its metabolites are excreted almost exclusively in the feces over an estimated 12 days, with less than 1% of the administered dose excreted in the urine.<br />In vitro studies using human liver microsomes and recombinant CYP450 enzymes have shown that ivermectin is primarily metabolized by CYP3A4. Depending on the in vitro method used, CYP2D6 and CYP2E1 were also shown to be involved in the metabolism of ivermectin but to a significantly lower extent compared to CYP3A4. The findings of in vitro studies using human liver microsomes suggest that clinically relevant concentrations of ivermectin do not significantly inhibit the metabolizing activities of CYP3A4, CYP2D6, CYP2C9, CYP1A2, and CYP2E1.<br /><em>Stromectol&#174; US Prescribing Information, Merck Sharp &amp; Dohme BV Issued May 2010</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Kanamycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Kanamycin is predominantly eliminated unchanged via renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Kanamycin is rapidly excreted by glomerular filtration and most of a parenteral dose appears unchanged in the urine within 24 hours.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 20-August-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ketamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Ketamine is mainly metabolized by CYP3A4 and to a lesser extent by CYP2B6 and CYP2C9 in the range of concentrations used in anaesthesia.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ketoconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction with didanosine gastro-resistant capsules (Videx EC). Other formulations may require dose separation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Unlike the didanosine chewable/dispersible tablets, didanosine gastro-resistant capsules do not contain antacids and therefore drug interactions mediated by altered gastric pH are not anticipated when didanosine gastro-resistant capsules are co-administered with medicinal products where absorption is influenced by gastric acidity. Specific interaction studies with ketoconazole showed no evidence of significant interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Coadministration of didanosine EC (400 mg single dose) and ketoconazole (200 mg single dose) to 21 HIV-negative subjects resulted in no change in the AUC and Cmax of ketoconazole. When the buffered formulation of ddI (375 mg twice daily for 4 days) was coadministered with ketoconazole (200 mg once daily for 4 days, 2 h before ddI) to 12 HIV-infected subjects, there was no change in ddI AUC and a 12% decrease in Cmax. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>The effect of the didanosine encapsulated enteric coated beadlet formulation (400 mg) on ketoconazole (200 mg) was evaluated in 21 healthy volunteers. The geometric mean Cmax and AUC values were similar (&lt;3% difference) when given alone or in combination and 90% CI of the ratios of the geometric means fell within the criteria defined for a lack of interaction (0.75 to 1.33). Didanosine as this formulation did not affect the pharmacokinetics of ketoconazole and the drugs may be administered simultaneously. <br /><em>Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole and ciprofloxacin. Damle BD, et al. Antimicrob Agent Chemother, 2002, 46:385-391. </em></p>
<p>The steady state pharmacokinetics of didanosine (375 mg twice daily) and ketoconazole (200 mg daily) were evaluated when given alone or in combination (ketoconazole 2 h prior to didanosine) to 12 HIV-infected subjects. There was a statistically significant reduction (12%) in didanosine Cmax when given with ketoconazole (1836 ng/ml) than alone (2094 ng/ml). Didanosine AUC was reduced by 8% when given in combination (2872 ng.h/ml) than alone (3107 ng.h/ml). There were no significant differences in ketoconazole pharmacokinetics when give alone or with didanosine. Coadministration of didanosine and ketoconazole does not result in a clinically significant interaction and it is not necessary to alter the dosing regimen of either drug as alone as ketoconazole is administered 2 h before ddI. <br /><em>Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. Knupp CA, et al. J Clin Pharmacol, 1993, 33: 912-917. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Labetalol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated by UGTs 1A1 and 2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lacidipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as lacidipine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lacosamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacosamide is metabolized to O-desmethyl-lacosamide mainly by CYP2C19 (~30% of the dose) and is eliminated unchanged through the kidneys (~40% of the dose).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lactulose</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lactulose to lactic acid occurs via gastro-intestinal microbial flora only.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lamivudine (3TC)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Renal elimination interaction unlikely. High rate of virological failure and of emergence of resistance at an early stage have been reported when didanosine was combined with tenofovir and lamivudine as a once daily regimen. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when didanosine was combined with tenofovir disoproxil fumarate and lamivudine as a once daily regimen. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when the main route of elimination is active renal secretion via the organic cationic transport system. Didanosine is not eliminated by this mechanism and are unlikely to interact with lamivudine.<br />Triple NRTI Therapy:<br />There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when lamivudine was combined with tenofovir disoproxil fumarate and abacavir as well as with tenofovir disoproxil fumarate and didanosine as a once daily regimen. <br /><em>Epivir Summary of Product Characteristics, ViiV Healthcare UK Ltd, October 2010.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lamotrigine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamotrigine is mainly glucuronidated by UGT1A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lansoprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lansoprazole is mainly metabolized by CYP2C19 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lapatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Lapatinib is metabolized by CYP3A4 and does not significantly inhibit renal transporters (OAT, OCT).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ledipasvir/Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Didanosine is phosphorylated to its active triphosphate form and the parent drug is renally excreted. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lercanidipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is mainly metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Letrozole </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Letrozole is metabolised by CYP3A4 and CYP2A6 to carbinol, an inactive metabolite.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Leuprorelin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Leuprorelin acetate is a peptide that is primarily degraded by peptidases.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Levamisole (Ergamisol)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Metabolism and elimination of levamisole has not been well characterized. Based on limited information, and single dose use of levamisole, clinically significant  interactions are not considered likely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Levamisole is rapidly absorbed from the gastrointestinal tract and peak plasma concentrations occur within 1.5 to 2 hours. It is extensively metabolised in the liver. The plasma half-life for levamisole is 3 to 4 hours and for the metabolites is 16 hours. It is excreted mainly in the urine as metabolites and a small proportion in the faeces. About 70% of a dose is excreted in the urine over 3 days, with about 5% as unchanged levamisole.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Levetiracetam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Levetiracetam undergoes enzymatic hydrolysis (non CYP) and is eliminated unchanged in the urine by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Levocetirizine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as less than 14% of a dose of levocetirizine is metabolised. Levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Levodopa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. In the presence of a peripheral dopa-decarboxylase inhibitor (carbidopa or benserazide) levodopa is metabolised mainly to 3-O-methyldopa by catechol-O-methyltransferase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Levofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as levofloxacin is metabolised to a very small extent.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Levomepromazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as levomepromazine is metabolised by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Levonorgestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is hydroxylated in the liver and the metabolites are excreted as glucuronide conjugates.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Levonorgestrel (Emergency Contraception)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Levothyroxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lidocaine (Lignocaine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Linagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as linagliptin is mainly eliminated as parent compound in faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Linezolid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Linezolid undergoes non-CYP mediated metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div> (See Summary) <br /></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Liquorice (Glycyrrhiza glabra)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Liraglutide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as liraglutide is degraded by endogenous endopeptidases. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lisinopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lithium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Lithium is mainly eliminated unchanged through the kidneys. Lithium is freely filtered at a rate that is dependent upon the glomerular filtration rate therefore no pharmacokinetic interaction is expected. However, since lithium is nephrotoxic, renal function should be monitored periodically and didanosine dosage adjusted accordingly.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Loperamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant effect of loperamide on didanosine pharmacokinetics. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Specific interaction studies have been conducted with loperamide without evidence of interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>When the buffered formulation of ddI (300 mg single dose) was coadministered with loperamide (4 mg four times daily for 1 day) to 12 HIV-infected subjects, there was no change in ddI AUC and a 23% decrease in Cmax. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>The pharmacokinetics of single doses of didanosine (300 mg) when given alone or 1 h after the final of 4 doses of loperamide (4 mg each) were determined in 12 HIV-infected subjects. Mean Cmax was significantly higher when given alone (2.04 &#181;g/ml) than with loperamide (1.57 &#181;g/ml). No significant treatment effect was observed for AUC (3.48 vs. 3.22 &#181;g.h/ml, alone vs. combination). The dose or frequency of didanosine administration do not need to be altered when given concomitantly with loperamide. <br /><em>Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV-seropositive asymptomatic male and female patients. Knupp CA, et al. Eur J Clin Pharmacol, 1993, 45: 409-413. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lopinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>It is recommended that didanosine be administered on an empty stomach. Therefore, didanosine should be given one hour before or two hours after Kaletra ORAL SOLUTION (which is taken with food), but can be administered simultaneously with Kaletra TABLETS (which can be taken without food). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><em><strong>LHPG Comment: </strong>Unlike the Videx chewable/dispersible tablets,the new formulation of ddI (Videx EC) does not contain antacids. Interactions with the old formulation that were due to the presence of antacid should not apply to the new formulation. Timing of administration of Videx EC with other medications will still be dependent on food requirements, but no longer on gastric pH requirements.</em></p>
<p>Kaletra TABLETS can be administered simultaneously with didanosine without food. For Kaletra ORAL SOLUTION, it is recommended that didanosine be administered on an empty stomach. Therefore, didanosine should be given one hour before or two hours after Kaltera oral solution(which is taken with food). <br /><em>Kaletra Prescribing Information, Abbott Laboratories, May 2012.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Loratadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lorazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as lorazepam is mainly glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lormetazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as lormetazepam is mainly glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Losartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lovastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as lovastatin is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lumefantrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as lumefantrine is metabolized predominantly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Lysergic acid diethylamide (LSD)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. LSD (lysergic acid diethylamide) is metabolized to O-H-LSD and N-desmethyl-LSD partly by CYP (unknown isoenzyme).</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Macitentan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Macitentan is metabolized mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Magnesium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Magnesium is eliminated in kidney, mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Malabar nut tree (Justicia adhatoda, Adhatoda vasica)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on the limited data available on the effect of malabar nut tree leaf extracts on drug metabolism, a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mannitol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Mannitol is metabolised only very slightly, if at all, to glycogen in the liver; it is predominantly eliminated unchanged via glomerular filtration. There is little potential for mannitol to affect the disposition of antiretrovirals, or to be altered if co-administered with antiretrovirals.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Mannitol is metabolized only very slightly, if at all, to glycogen in the liver. The drug is freely filtered by the glomeruli, with less than 10% tubular reabsorption; it is not secreted by tubular cells. The elimination half-life in adults is about 100 minutes. Approximately 80% of a 100-g dose is excreted unchanged in urine within 3 hours. When large dose are given as in forced diuresis, retention of the drug may occur. In the presence of renal disease in which glomerular function is impaired or in conditions that impair small vessel circulation, such as congestive heart failure, cirrhosis with ascitic accumulation, shock, or dehydration, mannitol clearance is lower than normal.<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, December 2008</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Maprotiline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Maraviroc</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction expected. Maraviroc and NRTIs can be co-administered without dose adjustment. The US Prescribing Information recommends maraviroc should be reduced to 150 mg twice daily in patients with creatinine clearance less than 30 ml/min or on haemodialysis if there are any symptoms of postural hypotension. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>No significant interaction expected. Maraviroc 300 mg twice daily and NRTIs can be co-administered without dose adjustment. <br /><em>Celsentri Summary of Product Characteristics,&nbsp;</em><em>ViiV Healthcare, October 2013</em><em>.</em></p>
<p>The recommended dose of maraviroc when coadministered with NRTIs is 300 mg twice daily. Maraviroc should be reduced to 150 mg twice daily in patients with creatinine clearance &lt;30 ml/min or on haemodialysis if there are any symptoms of postural hypotension.<br /><em>Selzentry Prescribing Information,&nbsp;</em><em>ViiV Healthcare, September 2013</em><em>.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>MDMA (Ecstasy)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. MDMA is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mebendazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Orally administered mebendazole is extensively metabolized primarily by the liver. Plasma concentrations of its major metabolites (amino and hydroxylated amino forms of mebendazole) are substantially higher than those of mebendazole. Impaired hepatic function, impaired metabolism, or impaired biliary elimination may lead to higher plasma levels of mebendazole. <br />Mebendazole, the conjugated forms of mebendazole, and its metabolites likely undergo some degree of enterohepatic recirculation and are excreted in the urine and bile. The apparent elimination half-life after an oral dose ranges from 3 to 6 hours in most patients.<br /><em>Ovex&#174; Summary of Product Characteristics, McNeil Products Ltd. Updated April 2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Medroxyprogesterone (IM depot injection)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Medroxyprogesterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Medroxyprogesterone (oral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction as medroxyprogesterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mefenamic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolized by CYP2C9 and glucuronidated by UGT2B7 and UGT1A9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mefloquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefloquine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Megestrol acetate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as megestrol acetate is mainly eliminated in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Meglumine antimoniate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profile of both drugs, there is little potential for pharmacokinetic interaction. Pancreatitis has been described as a relatively common serious adverse effect of meglumine antimoniate therapy, and has also been associated with didanosine (<1% of patients), which has been fatal in some cases. When treatment with other medicinal products known to cause pancreatic toxicity is required, didanosine should be suspended whenever possible. If concomitant therapy is unavoidable, close observation is warranted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>A study analysed 25 visceral leishmaniasis (VL) episodes in human immunodeficiency virus (HIV)-infected patients who were treated with meglumine antimoniate (MA) at the Centers for Disease Control and Prevention (CDC, Atlanta, GA)-recommended dose. Adverse effects were observed in 14 (56%) VL episodes. In 7 (28%), treatment with MA was permanently discontinued due to serious adverse effects that included acute pancreatitis, acute renal failure, and leukopenia. Three (12%) patients died during therapy due to severe acute pancreatitis attributable to MA. MA used at the doses studied was associated with a high rate of serious side effects in HIV-1-infected patients.<br /><em>High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Delgado J, Mac&#237;as J, Pineda JA et al. Am J Trop Med Hyg. 1999 Nov;61(5):766-9</em></p>
<p>The medical charts of 54 Ethiopian visceral leishmaniasis patients treated with meglumine antimoniate were reviewed to assess the effectiveness and safety profile in a routine healthcare setting. None of the patients from south Ethiopia (n=24) and 46.4% of the patients from north Ethiopia (n=30) were HIV co-infected. 33 non-serious and 6 serious adverse events (two pancreatitis, one renal failure and three deaths) were observed in 26 patients. One-third of the non-serious adverse events were due to biochemical pancreatitis. During treatment, a case-fatality rate of 10.0% in north Ethiopia and 0.0% in south Ethiopia was noted. These data point to clinical pancreatitis as a safety concern, especially in patients with HIV co-infection.<br /><em>Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Hailu W, Weldegebreal T, Hurissa Z et al. Trans R Soc Trop Med Hyg. 2010 Nov;104(11):706-12</em></p>
<p>Pancreatitis is a known serious complication among HIV infected patients. It has also been associated with didanosine therapy (&lt;1% of patients) and has been fatal in some cases. Didanosine should be used only with extreme caution in patients with a history of pancreatitis. Positive relationships have been found between the risk of pancreatitis and daily dose of didanosine. Whenever warranted by clinical conditions, didanosine should be suspended until the diagnosis of pancreatitis is excluded by appropriate laboratory and imaging techniques. Similarly, when treatment with other medicinal products known to cause pancreatic toxicity is required, didanosine should be suspended whenever possible. If concomitant therapy is unavoidable, close observation is warranted. Dose interruption should be considered when biochemical markers of pancreatitis have significantly increased, even in the absence of symptoms. <br /><em>Videx EC&#174; (didanosine) gastroresistant capsules, UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated February 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Melarsoprol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning metabolism, elimination and toxicity of melarsoprol, there is little potential  for interaction, although due to the lack of available data, vigilance is required if administering melarsoprol with antiretrovirals.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Melarsoprol is a prodrug and is rapidly metabolised to the active form, melarsen oxide. Melarsoprol itself has a plasma half-life of 30 minutes and is excreted in the faeces and urine.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), last reviewed 2011-03-03</em></p>
<p>The pharmacokinetics of melarsoprol have not been fully evaluated. Using biological assay and atomic absorption spectrometry, the terminal half-life of melarsoprol was originally calculated to be 35 hours and low trypanocidal activity was detected in the CSF. When the terminal half-life was calculated by high-performance liquid chromatography (HPLC), melarsoprol was found to be eliminated from the plasma within 1 hour. Based on these findings it is thought that melarsoprol is rapidly eliminated from the plasma and transformed into metabolites with trypanocidal activity. Melarsen oxide has been identified by HPLC as a metabolite; the peak plasma concentration was reached 15 minutes after a dose and the half-life of free melarsen oxide was 3.9 hours.<br /><em>Bronner U, et al. Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized. Trop Med Int Health 1998; 3: 913&#8211;7.</em></p>
<p>The half-life of melarsoprol determined by HPLC was &lt;1 hour compared with 35 hours determined by bioassay and atomic absorption spectroscopy, indicating the existence of active metabolites. One metabolite, melarsen oxide, was identified by ultraviolet HPLC after incubation of melarsoprol with microsomes. Melarsen oxide could also be detected at the same concentration range in the control run without NaDPH. This indicates that melarsen oxide might not be formed only in a microsomal reaction but also by hydrolysis. The maximum plasma concentration of melarsen oxide was reached 15 minutes after administration; the clearance was 21.5 mL/min/kg and the half-life of free melarsen oxide was 3.9 hours. Either melarsen oxide or a yet-undiscovered active metabolite is irreversibly bound to proteins, as shown by ultrafiltration, precipitation experiments, and atomic absorption spectroscopy. <br /><em>Investigations of the metabolites of the trypanocidal drug melarsoprol. Keiser J, Ericsson O, Burri C. Clin Pharmacol Ther. 2000 May;67(5):478-88.</em></p>
<p>Patients with advanced leukemia (n=8) received escalating intravenous doses of melarsoprol daily for 3 days, repeated weekly for 3 weeks. Doses were 1 mg/kg on day 1, 2 mg/ kg on day 2, and 3.6 mg/kg on day 3 and on all days thereafter, up to a maximum daily dose of 200 mg. Peak plasma concentrations of the parent drug were obtained immediately after injection, which ranged from 1.2 &#181;g/ml on day 1 to 2.4 &#181;g/ml on day 3. Plasma areas under the concentration-times-time curves (AUCs) were proportional to the administered dose, ranging from 0.48 &#181;g.h/ml on day 1 to 1.48 &#181;g.h/ml on day 3. Peak plasma levels were dose-proportional and decayed with a t1/2 of 15 min. Levels of the parent compound were undetectable in plasma at 24 h. There was no detectable level of parent drug in urine at any time. Blood and urine samples were also analyzed for elemental arsenic content. The mean plasma AUC of arsenic on day 1 was 6038 &#181;g.h/ml (range 4497&#177; 9095 &#181;g.h/ml), T1/2a was 38 min and T1/2b was 19.5 h. There was a gradual increase in trough plasma levels of elemental arsenic over the 3-week treatment course.<br /><em>Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Soignet SL, Tong WP, Hirschfeld S, Warrell RP Jr. Cancer Chemother Pharmacol. 1999;44(5):417-21<br /></em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Menthol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. There is no evidence to suggest that menthol impacts UGTs or P-gp.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mephedrone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction as mephedrone is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mercaptopurine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Mercaptopurine is predominantly metabolised by xanthine oxidase, which also plays a role in didanosine metabolism. Competition for metabolism via this enzyme may therefore increase exposure to either drug. Clinical monitoring for adverse events is warranted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>An in vitro study investigated the role of aldehyde oxidase and xanthine oxidase in the oxidation of 6- mercaptopurine. 6-mercaptopurine was incubated with bovine milk xanthine oxidase or partially purified guinea pig liver molybdenum hydroxylase fractions in the absence and presence of xanthine oxidase and aldehyde oxidase inhibitor/substrates, and the reactions were monitored by spectrophotometric and HPLC methods. According to the results obtained from the inhibition studies, it is more likely that 6- mercaptopurine is oxidized to 6-thiouric acid via 6-thioxanthine rather than 8-oxo-6-mercaptopurine. The first step which is the rate limiting step is catalyzed solely by xanthine oxidase, whereas both xanthine oxidase and aldehyde oxidase are involved in the oxidation of 6-thioxanthine to 6-thiouric acid<br /><em>In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase. Rashidi MR, Beedham C, Smith JS, Davaran S. Drug Metab Pharmacokinet. 2007 Aug;22(4):299-306</em></p>
<p>2',3'-Dideoxyinosine (ddI) has potent activity against human immunodeficiency virus (HIV). It is converted within target cells to its active form dideoxyadenosine triphosphate(ddA-TP). 2. In addition to the intracellular formation of ddA-TP, ddI can be broken down to hypoxanthine, by purine nucleoside phosphorylase (PNP) and to uric acid, by xanthine oxidase. Since PNP is present in red blood cells we have examined the metabolism of [14C]-ddI by human blood. 3. When incubated with whole blood at 37 degrees C, ddI was extensively metabolised, principally to hypoxanthine (50.4 +/- 12.5% formed at 6 h; mean +/- s.d.; n = 16). Small amounts of uric acid were formed (3.8 +/- 2.4%). 4. ddI breakdown was temperature dependent, being virtually negligible at 4 degrees C. Metabolism to hypoxanthine occurred within red blood cells. 5. The short half-life of ddI in patients is probably the result of both hepatic and erythrocytic metabolism.<br /><em>Back DJ, Ormesher S, Tjia JF, Macleod R. Metabolism of 2',3'-dideoxyinosine (ddI) in human blood. Br J Clin Pharmacol. 1992 Mar;33(3):319-22.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Meropenem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Meropenem is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporters OAT3/OAT1. A clinically relevant drug interaction is unlikely as meropenem has a higher affinity for OAT3 whereas OAT1 is involved in the elimination of didanosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mesalazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolized to N-acetyl-mesalazine by N-acetyltransferase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mesna</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolic/toxicity profiles of both drugs, there is little potential for interaction. Mesna is rapidly oxidised to its only metabolite, mesna disulphide via the physiological cysteine system. Approximately 32% and 33% of an administered dose is eliminated in the urine in 24 hours as mesna and mesna disulphide respectively.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Analagous to the physiological cysteine system, following intravenous administration, mesna is rapidly oxidised to its only metabolite, mesna disulphide. Mesna disulphide remains in the intravascular compartment and is rapidly eliminated by the kidneys. In the kidney, mesna disulphide is reduced to the free thiol compound, mesna, which acts to detoxify ifosfamide metabolites. Approximately 32% and 33% of the administered dose was eliminated in the urine in 24 hours as mesna and mesna disulphide respectively.<br /><em>Mesna Tablets/Injection US Prescribing Information, Baxter Healthcare Corporation, updated February 2009</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Metformin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is mainly eliminated unchanged in the urine via the renal transporter OCT2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Methadone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration decreases didanosine concentrations. If coadministration of methadone and didanosine is necessary, the recommended formulation of didanosine is Videx-EC: do not coadminister methadone with Videx pediatric powder. Patients should be closely monitored for adequate clinical response including monitoring for changes in HIV RNA viral load. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>When didanosine gastro-resistant capsules were administered to opiate-dependent patients chronically treated with methadone, didanosine exposures were decreased compared to historical non-methadone treated controls. This decrease was more pronounced with the didanosine tablets. Therefore, if didanosine is used in combination with methadone, patients should be closely monitored for adequate clinical response. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Coadministration decreases didanosine concentrations. If coadministration of methadone and didanosine is necessary, the recommended formulation of didanosine is Videx-EC. Do not coadminister methadone with Videx pediatric powder due to significant decreases in didanosine concentrations. Patients should be closely monitored for adequate clinical response when Videx-EC is coadministered with methadone, including monitoring for changes in HIV RNA viral load. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>Pharmacokinetics of didanosine buffered tablets (200 mg twice daily) were determined in 16 subjects stable on methadone maintenance therapy (8 HIV-infected, 8 HIV-negative) and compared those obtained in 10 control subjects not receiving methadone (5 HIV-infected, 5 HIV-negative). Methadone treatment reduced ddI AUC by 57% and Cmax by 66%. This difference in drug exposure is likely to be of clinical significance and may require a dose or formulation modification of didanosine when coadministered with methadone. Trough levels of methadone did not differ significantly from controls. <br /><em>Interaction of methadone with didanosine and stavudine. Rainey PM, et al. J Acquir Immun Def Syndr, 2000, 24:241-248. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Methamphetamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methamphetamine is mainly metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Methotrexate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance there is little potential for a pharmacokinetic interaction. However, due to the potentially toxic effect on the liver, additional hepatotoxic medications should not be given during treatment with methotrexate unless clearly necessary; close monitoring of liver enzymes should be undertaken. Hepatic steatosis, hepatitis and rarely liver failure have been reported with didanosine. Note, some methotrexate product labels contraindicate its use or advise caution in immunodeficiency and some contraindicate its use in HIV infection.</p><br></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Methyldopa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied.  Pancreatitis has been observed as a serious adverse effect of methyldopa therapy, and has also been associated with didanosine therapy (<1% of patients), which has been fatal in some cases. Didanosine should be used only with extreme caution in patients with a history of pancreatitis, when treatment with other medicinal products known to cause pancreatic toxicity is required, didanosine should be suspended whenever possible. If concomitant therapy is unavoidable, close observation is warranted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Increases in serum- and urinary-amylase activity accompanied by fever and suggestive of pancreatitis have been associated with methyldopa in various case reports. Symptoms reappeared on rechallenge in 3 patients. In contrast to the acute form, chronic pancreatitis is not generally attributable to drug use. However, a case of florid chronic pancreatitis, with exocrine and endocrine insufficiency and heavy calcification over 30 months, associated with 2 periods of methyldopa treatment, has been reported. <br /><em>van der Heide H, et al Pancreatitis caused by methyldopa. BMJ 1981; 282: 1930&#8211;1; Anderson JR, et al. Drug-associated recurrent pancreatitis. Dig Surg 1985; 2: 24&#8211;6; Banergee AK, et al. Drug-induced acute pancreatitis. Med Toxicol Adverse Drug Exp 1989; 4: 186&#8211;98; Ramsay LE, et al. Methyldopa-induced chronic pancreatitis. Practitioner 1982; 226: 1166&#8211;9</em></p>
<p>Pancreatitis is a known serious complication among HIV infected patients. It has also been associated with didanosine therapy (&lt;1% of patients) and has been fatal in some cases. Didanosine should be used only with extreme caution in patients with a history of pancreatitis. Positive relationships have been found between the risk of pancreatitis and daily dose of didanosine. Whenever warranted by clinical conditions, didanosine should be suspended until the diagnosis of pancreatitis is excluded by appropriate laboratory and imaging techniques. Similarly, when treatment with other medicinal products known to cause pancreatic toxicity is required, didanosine should be suspended whenever possible. If concomitant therapy is unavoidable, close observation is warranted. Dose interruption should be considered when biochemical markers of pancreatitis have significantly increased, even in the absence of symptoms. Significant elevations of triglycerides are a known cause of pancreatitis and warrant close observation. <br /><em>Videx EC&#174; (didanosine) gastroresistant capsules, UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated February 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Methylphenidate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Methylphenidate is not metabolized by cytochrome P450s to a clinically relevant extent and does not inhibit cytochrome P450s.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Methylprednisolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Methylprednisolone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Metoclopramide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied with enteric coated  capsules or tablets but a clinically significant interaction is unlikely. No significant effect of metoclopramide on didanosine pharmacokinetics was observed with the buffered formulation of didanosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Specific interaction studies have been conducted with metoclopramide without evidence of interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>When the buffered formulation of ddI (300 mg single dose) was coadministered with metoclopramide (10 mg single dose) to 12 HIV-infected subjects, there was no change in ddI AUC and a 13% increase in Cmax. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>The pharmacokinetics of single doses of didanosine (300 mg) when given 5 minutes after a single IV dose of metoclopramide (10 mg) were determined in 12 HIV-infected subjects. No significant treatment effect on Cmax (2.04 vs. 2.30 &#181;g/ml) or AUC (3.48 vs. 3.15 &#181;g/h/ml) was observed (alone vs. combination). The dose or frequency of didanosine administration do not need to be altered when given concomitantly with metoclopramide. <br /><em>Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV-seropositive asymptomatic male and female patients. Knupp CA, et al. Eur J Clin Pharmacol, 1993, 45: 409-413. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Metolazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as metolazone is largely excreted unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Metoprolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Metronidazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mexiletine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mianserin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Miconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Midazolam (oral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Midazolam (parenteral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mifepristone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. CYP3A4 is thought to be the main enzyme involved in mifepristone metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>N-Demethylation and terminal hydroxylation of the 17-propynyl chain are primary metabolic pathways of hepatic oxidative metabolism. Mifepristone is mainly excreted in faeces. After administration of a 600 mg labelled dose, 10% of the total radioactivity is eliminated in the urine and 90% in the faeces. No interaction studies have been performed. CYP3A4 is thought to be the main enzyme involved in metabolism&nbsp; <br /><em>Mifegyne&#174; (Mifepristone) 200mg Tablets UK Summary of Product Characteristics, Nordic Pharma Limited, updated July 2011<br />Mifeprex&#174; (Mifepristone) Tablets 200mg US Prescribing Information, Danco Laboratories LLC, updated April 2009</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Milk thistle</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drug-drug interaction studies suggest that milk thistle has limited clinical impact on substrates of CYP3A, P-gp, UGT and OATP.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Milnacipran</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Milnacipran is mainly eliminated unchanged (50%), and as glucuronides (30%) and oxidative metabolites (20%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Miltefosine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning metabolism, elimination and toxicity of miltefosine, there is little potential for interaction. In vitro studies have shown that interactions between miltefosine and drugs which are metabolised by cytochrome P450, glucuronidated or otherwise conjugated are unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>In vitro studies have shown that interactions between miltefosine and drugs which are metabolised by cytochrome P450, glucuronidated or otherwise conjugated are unlikely, however the possibility of interactions with commonly used drugs can not be totally excluded. No oxidative metabolism of miltefosine was observed in in vitro studies with 15 CYP450 Isozymes. No CYP3A induction was observed in animal studies. A slow metabolic degradation in human hepatocytes was demonstrated, in which a phospholipase D-like cleavage of miltefosine causes the release of choline. Preclinical and clinical studies suggest that only a very small proportion of the administered dose is excreted in the unchanged form. The most likely excreted products are choline and choline-containing products.<br /><em>Impavido&#174; (Miltefosine) Capsules German Product Information, Paladin Labs Ltd, updated September 2009</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mirabegron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirabegron is metabolized by multiple pathways including hydrolysis, glucuronidation and oxidation by CYP2D6 and CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mirtazapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Misoprostol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Magnesium-containing antacids should be avoided during treatment with misoprostol as this may worsen the misoprostol-induced diarrhoea. As the dispersible tablet formulation of didanosine tablets contains magnesium antacid components, doses of misoprostol and didanosine tablets should be maximally separated to avoid side effects. No interaction is expected with didanosine capsules.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Misoprostol is predominantly metabolised via fatty acid oxidising systems and has shown no adverse effect on the hepatic microsomal mixed function oxidase (P450) enzyme system. In specific studies no clinically significant pharmacokinetic interaction has been demonstrated with antipyrine or diazepam. A modest increase in propranolol concentrations (mean approximately 20% in AUC, 30% in Cmax) has been observed with multiple dosing of misoprostol. In extensive clinical studies no drug interactions have been attributed to Misoprostol. <br /><em>Cytotec&#174; (Misoprostol) Tablets UK Summary of Product Characteristics, Pharmacia Limited updated November 2010</em></p>
<p>Magnesium-containing antacids should be avoided during treatment with misoprostol as this may worsen the misoprostol-induced diarrhoea.<br /><em>Cytotec&#174; (Misoprostol) Tablets UK Summary of Product Characteristics, Pharmacia Limited updated November 2010</em></p>
<p>The incidence of diarrhea can be minimized by administering after meals and at bedtime, and by avoiding coadministration of Cytotec with magnesium-containing antacids.<br /><em>Cytotec&#174; (Misoprostol) tablets US Prescribing Information, Pfizer Inc, Revised September 2009</em></p>
<p>Videx tablets contain magnesium antacid components. It is recommended that medicines that may interact with antacids should not be administered within 2 hours of taking Videx tablets.<br /><em>Videx&#174; 25mg Chewable/Dispersible Tablet UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated February 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mitoxantrone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Modafinil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Modafinil is largely metabolized by hydrolysis (esterase mediated) and to a lesser extent by CYP3A4 mediated oxidative metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mometasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Montelukast</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolized by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Morphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically relevant drug interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Didanosine does not affect this metabolic pathway. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Moxifloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Mycophenolate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Mycophenolate is mainly glucuronidated by UGT1A9 and UGT2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Naftidrofuryl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naftidrofuryl is metabolized to 3 major metabolites primarily by plasma pseudo-choline esterases</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Naltrexone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies have shown that neither naltrexone, nor its main metabolite (6-beta-naltrexol), is metabolized by CYP450 enzymes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nandrolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance there is little potential for pharmacokinetic interaction. Nandrolone is metabolized in the liver.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Naproxen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nateglinide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is metabolized mainly by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nebivolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nebivolol metabolism involves CYP2D6</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nefazodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nefazodone is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nelfinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No effect of a single dose of didanosine (200 mg) on nelfinavir pharmacokinetics following a single dose (750 mg). However, since it is recommended that didanosine be administered on an empty stomach, nelfinavir should be administered (with food) one hour after or more than 2 hours before didanosine. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><em><strong>LHPG Comment:</strong> Unlike the Videx chewable/dispersible tablets, the new formulation of ddI (Videx EC) does not contain antacids. Interactions with the old formulation that were due to the presence of antacid should not apply to the new formulation. Timing of administration of Videx EC with other medications will still be dependent on food requirements, but no longer on gastric pH requirements.</em></p>
<p>Clinically significant interactions have not been observed between nelfinavir and nucleoside analogues. Since it is recommended that didanosine be administered on an empty stomach, nelfinavir should be administered (with food) one hour after or more than 2 hours before didanosine. <br /><em>Viracept Summary of Product Characteristics, Roche Products Ltd, September 2011.</em></p>
<p>Coadministration of a single dose of didanosine (200 mg) with a single dose of nelfinavir (750 mg), in 9 subjects, caused no alteration in nelfinavir AUC or Cmax. Cmin determination was not relevant for single-dose. It is recommended that didanosine be administered on an empty stomach; therefore, didanosine should be given one hour before or two hours after nelfinavir (given with food). <br /><em>Viracept Prescribing Information, Agouron Pharmaceuticals Inc, April 2012.</em></p>
<p>Administer nelfinavir 1 hour after Videx-EC. When the buffered formulation of ddI (200 mg single dose) was coadministered with nelfinavir (750 mg single dose, 1 h after ddI) to 10 HIV-infected subjects, nelfinavir AUC increased 12% and there was no change in Cmax. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Neostigmine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Neostigmine is thought to undergo a degree of hepatic metabolism, although the mechanisms are unknown. However, as metabolism also occurs via hydrolysis by cholinesterase and up to 50% of a dose is excreted unchanged via the kidneys, there is little potential for clinically significant interaction with didanosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Neostigmine undergoes hydrolysis by cholinesterase and is also metabolized by microsomal enzymes in the liver. Protein binding to human serum albumin ranges from 15 to 25 percent. Following intramuscular administration, Neostigmine is rapidly absorbed and eliminated. In a study of five patients with myasthenia gravis, peak plasma levels were observed at 30 minutes, and the half-life ranged from 51 to 90 minutes. Approximately 80 percent of the drug was eliminated in urine within 24 hours; approximately 50% as the unchanged drug and 30 percent as metabolites.<br /><em>Neostigmine Methylsulfate Injection USP UA Prescribing Information, American Reagent Inc, updated January 2009</em></p>
<p>Neostigmine kinetics and metabolism were studied after intracellular administration to 8 patients with myasthenia gravis. The plasma neostigmine level declined monoexponentially from 21 +/- 2 to 9 +/- 1 ng/ml between 30 and 120 min. Approximately 80% of the drug was eliminated in urine within 24 hr either as unchanged neostigmine or its metabolites. Approximately 50% of the dose was eliminated as the unchanged drug, 15% as 3-hydroxyphenyltrimethylammonium, and 15% as other unidentified metabolites. The neostigmine t1/2, based on the urinary excretion of the unchanged drug, ranged from 90.2 to 118.7 min. It was concluded that neostigmine was eliminated by renal and extrarenal mechanisms.<br /><em>Somani SM, Chan K, Dehghan A, Calvey TN. Kinetics and metabolism of intramuscular neostigmine in myasthenia gravis. Clin Pharmacol Ther. 1980 Jul;28(1):64-8.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nevirapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No dosage adjustments are required when nevirapine is taken with didanosine as the absorption of nevirapine is not affected by the alkaline buffering agent in some formulations of didanosine. Coadministration of nevirapine (200 mg twice daily) with didanosine (100-150 mg twice daily) caused no alteration in didanosine AUC or Cmax and the effect on nevirapine pharmacokinetics was not significant. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><em><strong>LHPG Comment: </strong>Unlike the Videx chewable/dispersible tablets, the new formulation of ddI (Videx EC) does not contain antacids. Interactions with the old formulation that were due to the presence of antacid should not apply to the new formulation. Timing of administration of Videx EC with other medications will still be dependent on food requirements, but no longer on gastric pH requirements.</em> <br /></p>
<p>Coadministration of nevirapine and didanosine (100-150 mg twice daily) increased didanosine AUC by 8% and decreased Cmax by 2%. Didanosine and nevirapine can be coadministered without dose adjustments. The absorption of nevirapine is not affected by food, antacids or medicinal products which are formulated with an alkaline buffering agent (e.g., didanosine).<br /><em>Viramune Summary of Product Characteristics, Boehringer Ingelheim International GmbH, January 2012.</em></p>
<p>Nevirapine may be administered with or without food, antacid or didanosine. Coadministration of nevirapine (200 mg once daily for 2 weeks then 200 mg twice daily for 2 weeks) with didanosine (100-150 mg twice daily) in 18 HIV+ patients caused no alteration in didanosine AUC or Cmax, Cmin was below the limits of detection for the assay. The effect on nevirapine pharmacokinetics was not significant. In a separate study in HIV-1 infected patients (n=6), nevirapine steady-state systemic exposure (AUC) was not significantly altered by didanosine, which is formulated with an alkaline buffering agent. <br /><em>Viramune Prescribing Information, Boehringer Ingelheim Pharmaceuticals Inc, November 2011.</em></p>
<p>Addition of nevirapine (200 mg twice daily) to a regimen of didanosine (125 or 200 mg twice daily) and zidovudine in 80 HIV+ individuals showed that nevirapine did not interfere with the bioavailability of ddI. Combination of didanosine and nevirapine allows the full impact of their respective pharmacodynamic properties; drugs were taken simultaneously. <br /><em>Population pharmacokinetics of nevirapine, zidovudine and didanosine in human immunodeficiency virus-infected patients. Zhou XJ, Sheiner LB, D'Aquila RT et al. Antimicrob Agents Chemother, 1999, 43:121&#8211;8. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nicardipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nicardipine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Niclosamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. After oral administration, absorption of niclosamide is considered minimal.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>After oral administration, 2-25% of the administered dose is detected in urine. Absorption is considered minimal<br /><em>Yomesan&#174; Summary of Product Characteristics (Germany), Bayer Vital, Updated January 2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nicorandil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of nicorandil takes place mainly via denitration with the denitrated product then merging into the nicotinamide pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nicotinamide (Niacinamide)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Nicotinic acid and nicotinamide are readily absorbed from the gastrointestinal tract after oral doses and widely distributed in the body tissues. The main route of metabolism is their conversion to N-methylnicotinamide and the 2-pyridone and 4-pyridone derivatives; nicotinuric acid is also formed. Small amounts of nicotinic acid and nicotinamide are excreted unchanged in urine after therapeutic doses; however the amount excreted unchanged is increased with larger doses.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via medicines Complete), last modified 2006-01-26</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nifedipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nifurtimox</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning metabolism, elimination and toxicity of nifurtimox, there is little potential  for interaction, although due to the lack of data, vigilance is required if administering nifurtimox with antiretrovirals. Nifurtimox appears to be biotransformed partially at a cytochrome P450 level but mostly by NADPH P450 reductase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Oral nifurtimox is well absorbed and peak serum concentrations occur after 4 hours. It is rapidly and extensively metabolised and relatively low concentrations of nifurtimox appear in the plasma and tissues. It is presumed to cross the blood-brain barrier. Less than 1% of an oral dose is excreted unchanged in the urine. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), last reviewed 2011-03-03</em></p>
<p>Nifurtimox (Nfx) has serious toxic effects including mutagenic, reproductive and carcinogenic actions. Its toxicity has been linked to NADPH dependent nitroreductive metabolic biotransformation with production of oxygen reactive species. Rat liver nuclei exhibit Nfx-nitroreductase activity (Nfx-ase). This activity is null under oxygen and partially inhibited under CO. Results suggest that Nfx is biotransformed partially at a cytochrome P450 level but mostly by NADPH P450 reductase. Formation of reactive metabolites nearby DNA and nuclear proteins might be related to long term deleterious effects of this drug.<br /><em>Rat liver nuclear nifurtimox nitroreductase activity. de Toranzo EG, Herrera DM, Castro JA. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):249-54.</em></p>
<p>Liver microsomal (mic); nuclei (N) and mitochondria (mit) anaerobically nitroreduce Nifurtimox (Nfx) in the presence of NADPH generating system. Simultaneous formation of small amounts of nitrite was observed in microsomes and nuclei but not in mitochondria. The microsomal nitroreductase activity was enhanced by the presence of flavine-adenine-dinucleotide disodium salt (FAD), was not inhibited by CO and was significantly inhibited by diphenyleneiodonium (DPI). In the microsomal NADPH-dependent fraction nitrite formation was null in the presence of FAD, DPI and under air and was partially inhibited by pure CO. Pure human cytochrome P450 reductase in the presence of NADPH significantly nitroreduced Nfx and produced small amounts of nitrite. The nitroreductive process was significantly enhanced by FAD but the nitrite formation became null. FAD itself was able to chemically nitroreduce Nfx without production of nitrite. NADPH generating system enhanced the FAD nitroreductive effect and led to small production of nitrite. Formation of reactive metabolites and nitric oxide during Nfx metabolism might contribute to its toxicity.<br /><em>Nifurtimox biotransformation to reactive metabolites or nitrite in liver subcellular fractions and model systems. Montalto de Mecca M, Diaz EG, Castro JA. Toxicol Lett. 2002 Nov 15;136(1):1-8</em><br /></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nilotinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Nilotinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nimesulide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nimesulide is extensively metabolized in the liver following multiple pathways including CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nisoldipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nisoldipine is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nitrendipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nitrofurantoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for pharmacokinetic interaction. As both nitrofurantoin and didanosine can cause peripheral neuropathy, patients should be monitored for symptoms if nitrofurantoin and didanosine are coadministered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Peripheral neuropathy and susceptibility to peripheral neuropathy which may become severe or irreversible has occurred and may be life threatening. Therefore, treatment should be stopped at the first signs of neural involvement<br /><em>Macrodantin&#174; Capsules 100mg B.P. UK Summary of Product Characteristics, Goldshield Group Limited, updated June 2011</em></p>
<p>Peripheral neuropathy, which may become severe or irreversible, has occurred. Fatalities have been reported.<br /><em>Macrodantin&#174; Capsules US Prescribing Information, Norwich Pharmaceuticals Inc, revised January 2009</em></p>
<p>Patients on didanosine may develop toxic peripheral neuropathy, usually characterised by bilateral symmetrical distal numbness, tingling, and pain in feet and, less frequently, hands. If symptoms of peripheral neuropathy develop, patients should be switched to an alternative treatment regimen.<br /><em>Videx&#174; UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated February 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nitrous oxide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Most inhaled nitrous oxide is rapidly eliminated unchanged through the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Nitrous oxide is rapidly absorbed on inhalation. The blood/gas partition coefficient is low and most of the inhaled nitrous oxide is rapidly eliminated unchanged through the lungs though small amounts diffuse through the skin.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Norelgestromin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as norelgestromin is metabolized to norgestrel (possibly by CYP3A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Norethisterone (Norethindrone)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction as norethisterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Norgestimate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as norgestimate is rapidly deacetylated to the active metabolite which is further metabolized via CYP450.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Norgestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nortriptyline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nortriptyline is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Nystatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Systemic absorption of nystatin from oral or topical dosage forms is not significant, therefore no drug interactions are expected.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Nystatin is formulated in oral and topical dosage forms and is not systemically absorbed from any of these preparations. Interaction with other medicinal products and other forms of interaction: None known<br /><em>Nystan oral suspension&#174; Summary of product Characteristics, E. R. Squibb &amp; Sons Limited, updated February 2010</em></p>
<p>Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.<br /><em>Nystatin oral suspension USP US Prescribing Information, Taro Pharmaceuticals U.S.A., Inc., updated March 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Ofloxacin is primarily eliminated by the kidney. In vitro data suggest that ofloxacin weakly inhibits the renal transporter OAT3 whereas didanosine is partly excreted via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Olanzapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Olanzapine is metabolized mainly by CYP1A2, but also by glucuronidation (UGT1A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Olmesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Olmesartan medoxomil is de-esterified to the active metabolite olmesartan which is eliminated in the faeces and urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ombitasvir/Paritaprevir/r</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Didanosine is phosphorylated to its active triphosphate form, is not a substrate of any CYP isoenzyme, and is renally excreted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ombitasvir/Paritaprevir/r + Dasabuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Didanosine is phosphorylated to its active triphosphate form, is not a substrate of any CYP isoenzyme, and is renally excreted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Omeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Omeprazole is mainly metabolized by CYP2C19 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ondansetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ondansetron is metabolized mainly by CYP1A2 and CYP3A4 and to a lesser extent by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Orlistat</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as orlistat is mainly eliminated unchanged in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Oseltamivir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases which is then excreted in the urine by glomerular filtration and tubular secretion by OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Oxaliplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Oxaliplatin undergoes non-enzymatic biotransformation and is eliminated renally via OCT2 and MATE2-K. A pharmacokinetic interaction is unlikely. However, the risk of neurotoxicity may be potentially increased as both drugs can cause neuropathy.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Oxamniquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Oxamniquine is thought to be predominantly metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Oxamniquine is extensively metabolised to inactive metabolites, mainly the 6-carboxy derivative, which are excreted in the urine. About 70% of a dose of oxamniquine is excreted as the 6-carboxy metabolite within 12 hours of a dose; traces of the 2-carboxy metabolite have also been detected in the urine. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 12-March-2011</em></p>
<p>In vitro studies using human liver microsomes suggest that oxamniquine competitively inhibits CYP2D6 activity. The authors suggest that due to high affinity for the CYP2D6 receptor, oxamniquine may also be a substrate for this metabolic enzyme.<br /><em>Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Masimirembwa CM, Hasler JA, Johansson I. Eur J Clin Pharmacol. 1995;48(1):35-8.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Oxandrolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Oxazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated by UGTs 2B15, 1A9 and 2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Oxcarbazepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Oxcarbazepine is rapidly reduced by cytosolic arylketone reductases to its active metabolite, 10-hydroxycarbazepine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Oxprenolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as oxprenolol is largely metabolised by glucuronidation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Oxybutynin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxybutynin is metabolized by CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Oxycodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Oxytocin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. However, As few data are available, care should be taken when administering oxytocin with antiretrovirals. Elimination of oxytocin occurs  via the liver, kidney, functional mammary gland and oxytocinase. The plasma half-life is approximately five minutes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The plasma half-life of oxytocin is of the order of five minutes, hence the need for continuous iv infusion. Elimination is via the liver, kidney, functional mammary gland and oxytocinase.<br /><em>Syntocinon&#174; (Oxytocin) Ampoules 10 IU/ml UK Summary of Product Characteristics, Alliance Pharmaceuticals, updated March 2007</em></p>
<p>Oxytocin has a plasma half-life of about 1 to 6 minutes which is decreased in late pregnancy and during lactation. Following intravenous administration of oxytocin, uterine response occurs almost immediately and subsides within 1 hour. Following intramuscular injection of the drug, uterine response occurs within 3 to 5 minutes and persists for 2 to 3 hours. Its rapid removal from plasma is accomplished largely by the kidney and the liver. Only small amounts are excreted in urine unchanged.<br /><em>Pitocin&#174; (Oxytocin Injection, USP, synthetic) US Prescribing Information, JHP Pharmaceuticals LLC, updated December 2007</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Paclitaxel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Paliperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily eliminated renally (possibly via OCT) with minimal metabolism occurring via CYP2D6 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pantoprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pantoprazole is mainly metabolized by CYP2C19 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Para-aminosalicylic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Based on the metabolism/elimination and toxicity profiles of both drugs, no pharmacokinetic interaction is expected. However, para-aminosalicylic acid granules have an acid-resistant coating that dissolves promptly at neutral pH such as that found in the small intestine or in neutral foods. The granules should be administered in an acidic food or drink, such as applesauce, yoghurt, or fruit juice. Chewable/dispersible tablet forms of didanosine contain antacids. Patients in whom stomach acid has been neutralized by concurrent administration of antacids do not need to administer para-aminosalicylic acid  granules in an acidic food or drink. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><em><strong>Note:</strong> The food considerations apply to enteric coated formulations of ddI.&nbsp;Food consideration are not applicable with chewable/dispersible tablet forms of didanosine as they contain antacids. <br /></em></div>
<div>Aminosalicylic acid granules (Paser&#174;) have an acid-resistant coating that dissolves promptly (within 1 minute) at neutral pH such as that found in the small intestine or in neutral foods. Therefore, the granules should be administered in an acidic food or drink having a pH less than 5, such as applesauce, yogurt, or fruit juice. Patients in whom stomach acid has been neutralized by concurrent administration of antacids do not need to administer Paser&#174; granules in an acidic food or drink<br /><em>Paser&#174; granules (aminosalicylic acid granules) US prescribing information, Jacobus Pharmaceutical Co.&nbsp; Last updated August 1996</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Paracetamol (Acetaminophen)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Paracetamol is mainly metabolized by glucuronidation (UGT1A9 (major), UGT1A6, UGT1A1, UGT2B15), sulfation and, to a lesser extent, by oxidation. One case report of fulminant hepatitis in patient receiving didanosine and paracetamol. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>A case report describes concomitant fulminant hepatitis and pancreatitis in a 47-year old HIV-infected male being treated with didanosine where the combined use of paracetamol (4 g over a 3 day period) may have had a significant interaction with didanosine. The authors speculate that mitochondrial metabolism may be affected by both paracetamol and didanosine and this may result in hepatotoxicity. <br /><em>Toxic interaction of didanosine and acetaminophen leading to severe hepatitis and pancreatitis: a case report and review of the literature. Lederman JC &amp; Nawaz H. Am J Gastroenterol, 2001, 96: 3474-3475. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Paromomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for pharmacokinetic interaction. Pancreatitis has been described in a patient with HIV infection receiving paromomycin treatment, and has also been associated with didanosine therapy (<1% of patients) and has been fatal in some cases. When treatment with other medicinal products known to cause pancreatic toxicity is required, didanosine should be suspended whenever possible. If concomitant therapy is unavoidable, close observation is warranted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Pancreatitis was associated with use of paromomycin during treatment of cryptosporidiosis in a patient with HIV infection. <br /><em>Paromomycin-associated pancreatitis in HIV-related cryptosporidiosis. Tan WW, et al.&nbsp; Ann Pharmacother 1995; 29: 22&#8211;4.</em> </p>
<p>Pancreatitis is a known serious complication among HIV infected patients. It has also been associated with didanosine therapy (&lt;1% of patients) and has been fatal in some cases. Didanosine should be used only with extreme caution in patients with a history of pancreatitis. Positive relationships have been found between the risk of pancreatitis and daily dose of didanosine. Whenever warranted by clinical conditions, didanosine should be suspended until the diagnosis of pancreatitis is excluded by appropriate laboratory and imaging techniques. Similarly, when treatment with other medicinal products known to cause pancreatic toxicity is required, didanosine should be suspended whenever possible. If concomitant therapy is unavoidable, close observation is warranted. Dose interruption should be considered when biochemical markers of pancreatitis have significantly increased, even in the absence of symptoms. Significant elevations of triglycerides are a known cause of pancreatitis and warrant close observation. <br /><em>Videx EC&#174; (didanosine) gastroresistant capsules, UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated February 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Paroxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is mainly metabolized by CYP2D6 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pazopanib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Pazopanib is metabolized by CYP3A4 and to a lesser extent 1A2 and 2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Peginterferon alfa-2a</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Co-infected patients with advanced cirrhosis receiving HAART may be at increased risk of hepatic decompensation and possibly death if treated with ribavirin and interferons, including Pegasys. Baseline variables in co-infected cirrhotic patients that may be associated with hepatic decompensation include treatment with didanosine. Co-administration of ribavirin and didanosine is not recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Co-infected patients with advanced cirrhosis receiving HAART may also be at increased risk of hepatic decompensation and possibly death if treated with ribavirin in combination with interferons, including Pegasys. Baseline variables in co-infected cirrhotic patients that may be associated with hepatic decompensation include: increased serum bilirubin, decreased haemoglobin, increased alkaline phosphatase or decreased platelet count, and treatment with didanosine. Co-administration of ribavirin and didanosine is not recommended.<br /><em>Pegasys Summary of Product Characteristics, Roche Products Ltd, July 2010.<br />ViraferonPeg Summary of product Characteristics, Schering-Plough Ltd, May 2010.</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Penicillamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for pharmacokinetic interaction. Concomitant oral iron or antacids should not be given within 2 hours of taking penicillamine as oral absorption of penicillamine may be reduced. As the dispersible tablet formulation of didanosine tablets contains antacid components, doses of penicillamine and didanosine tablets should be maximally separated. No interaction is expected with didanosine capsules.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Concomitant oral iron or antacids should not be given within 2 hours of taking penicillamine as oral absorption of penicillamine may be reduced.<br /><em>Penicillamine 250mg Tablets UK Summary of Product Characteristics, Kent Pharmaceuticals Ltd, updated April 2012</em></p>
<p>Videx tablets contain magnesium antacid components. It is recommended that medicines that may interact with antacids should not be administered within 2 hours of taking Videx tablets.<br /><em>Videx&#174; 25mg Chewable/Dispersible Tablet UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated February 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Penicillins</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT) whereas didanosine is partly eliminated renally by OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pentamidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase the risk of pancreatitis. Avoid combination if possible. Due to the prolonged half-life of pentamidine, didanosine should not be started until 1 week after pentamidine therapy is concluded.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pentoxifylline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pentoxifylline has not been well described but some studies indicate oxidation by CYP1A2, reduction by carbonyl reductase, and oxidation by carboxylase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Perazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is demethylated by CYP3A4 and to a lesser extent by CYP2C9, and oxidated by FMO3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pericyazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pericyazine has not been well characterized but is likely to involve CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Perindopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perindopril is hydrolysed to the active metabolite perindoprilat and is metabolized to other inactive metabolites. Elimination occurs predominantly via the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Perphenazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction is expected with Videx-EC (didanosine gastro-resistant capsules).  However, didanosine chewable/dispersible tablets and powder for oral solution contain an antacid which may decrease the absorption of perphenazine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pethidine (Meperidine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolized mainly by CYP2B6 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Phencyclidine (PCP)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Phencyclidine is extensively metabolized to inactive metabolites by a variety of metabolic routes (mainly CYP3A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Phenelzine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenelzine is primarily metabolized by oxidation via monoamine oxidase and to a lesser extent by acetylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Phenobarbital (Phenobarbitone)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenobarbital undergoes CYP-mediated metabolism. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Phenprocoumon</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenprocoumon is metabolized by CYP2C9 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Phenytoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenytoin undergoes CYP-mediated metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Phytomenadione (Vitamin K)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Vitamin K1 is converted to more polar metabolites, such as phytomenadione-2,3-epoxide. The half-life of vitamin K1 in plasma is about 1.5 to 3 hours. Vitamin K1 is excreted in the bile and urine as glucuronide and sulphate conjugates.<br /><em>Konakion MM&#174; (phytomenadione) 2mg/0.2ml paediatric ampoules Product Information, Hoffmann-La Roche Ltd, updated November 2006</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pilocarpine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction when pilocarpine is used either orally or as eye drops. Pilocarpine is primarily metabolized by CYP2A6 and serum esterases, there is therefore little potential for interaction with didanosine via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><strong>Systemic use:</strong> Pilocarpine is primarily metabolized by CYP2A6 and has demonstrated a capacity to inhibit CYP2A6 in vitro. Serum esterases are also involved in the biotransformation of pilocarpine to pilocarpic acid. Approximately 35% of dose is eliminated as 3-hydroxypilocarpine in urine and 20% of dose is excreted unchanged in the urine. Mean elimination half-lives for pilocarpine is 0.76 and 1.35 hours after repeated oral doses of 5 and 10 mg of pilocarpine hydrochloride, respectively.<br /><em>Salagen&#174; (Pilocarpine) 5mg Film Coated Tablets UK Summary of Product Characteristics, Novartis Pharmaceuticals UK Ltd, updated November 2011</em></p>
<p><strong>Ocular use:</strong> Systemic reactions rarely occur when treating chronic simple glaucoma at normal doses. However, in the treatment of acute closed-angle glaucoma the possibility of systemic reactions must be considered because of the higher doses given. Pilocarpine has a low ocular bioavailability when topically applied and this has been attributed to extensive pre-corneal drug loss in conjunction with the resistance to normal corneal penetration. Further, pilocarpine appears to bind to the eye pigments from which it is gradually released to the muscles. Inactivation of pilocarpine in the eye is thought to occur by a hydrolysing enzyme. The amount of this enzyme is not changed by the prolonged use of pilocarpine by glaucoma patients, nor is it changed in patients poorly controlled by glaucoma therapy.<br /><em>Minims Pilocarpine Nitrate 2% w/v Eye drops solution UK Summary of Product Characteristics, Bausch &amp; Lomb U.K Limited, updated July 2012</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pimozide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pimozide is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pindolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolized to hydroxymetabolites (possibly by CYP2D6) and partly eliminated unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pioglitazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolized by mainly CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pipotiazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Piroxicam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as piroxicam is primarily metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pitavastatin </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Posaconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Posaconazole is eliminated mainly unchanged in the faeces and only a minimal amount undergoes biotransformation (mainly glucuronidation by UGT1A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Potassium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as potassium is eliminated renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pramipexole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pramipexole is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OCT2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Prasugrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pravastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Praziquantel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Praziquantel is predominantly metabolised via CYP3A4, whereas didanosine is excreted via the same pathways responsible for elimination of endogenous purines.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Praziquantel is metabolised via various cytochrome P450 isoenzymes, mainly CYP2B1 and CYP3A4, and therefore has the potential to interact with drugs that are inhibitors or inducers of such enzymes. Enzyme-inducing drugs such as carbamazepine, dexamethasone, phenobarbital, and phenytoin may decrease plasma concentrations of praziquantel. Conversely, enzyme inhibitors such as cimetidine, erythromycin, itraconazole, and ketoconazole may increase plasma concentrations of praziquantel. It is excreted in the urine, mainly as metabolites which are thought to be inactive.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Prazosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Prazosin undergoes extensive hepatic metabolism primarily by demethylation and conjugation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Prednisolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisolone undergoes hepatic metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Prednisone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pregabalin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as pregabalin is cleared mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Primaquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Primaquine is metabolised mainly through a non-CYP mediated mechanism and only a small fraction of the drug is believed to be metabolised through CYP450.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Probenecid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. In vitro data suggest that probenecid is a substrate and inhibitor of OAT. Coadministration could increase didanosine concentrations as OAT is involved in the excretion of didanosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Procarbazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Procarbazine is thought to undergo  metabolism via auto-oxidation and hydrolysis.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Procarbazine is metabolised primarily in the liver and kidneys. The drug appears to be auto-oxidised to the azo derivative with the release of hydrogen peroxide. The azo derivative isomerises to the hydrazone, and following hydrolysis splits into a benzaldehyde derivative and methylhydrazine. The methylhydrazine is further degraded to CO2 and CH4 and possibly hydrazine, whereas the aldehyde is oxidised to N-isopropylterephthalamic acid, which is excreted in the urine. <br /><em>Matulane&#174; (procarbazine HCl) Capsules US Prescribing Information, Sigma-tau Pharmaceuticals Inc., updated March 2008</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Prochlorperazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Proguanil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Proguanil is partly excreted unchanged and partly metabolized to its more active metabolite cycloguanil by CYP2C19 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Promethazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Propafenone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Propofol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propofol is glucuronidated via UGT1A9, UGT1A8 and is oxidized mainly via CYP2B6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Propranolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolized by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Propylthiouracil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Propylthiouracil is extensively metabolised, predominantly via glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><br />Propylthiouracil is readily absorbed and is extensively metabolized. Approximately 35% of the drug is excreted in the urine, in intact and conjugated forms, within 24 hours.<br /><em>Propylthiouracil tablets US Prescribing Information, DAVA Pharmaceuticals Inc. updated February 2010</em></p>
<p>Although the exact metabolic fate of propylthiouracil has not been fully established, the drug is extensively metabolized to its glucuronide conjugate and other minor metabolites. The drug and its metabolites are excreted in urine, with about 35% of a dose excreted within 24 hours<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, updated October 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Protamine sulphate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on very limited data concerning the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. The metabolism of protamine has not been fully elucidated, however protamine complexed with heparin is thought to be partially metabolised by fibrinolysin. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Protamine sulphate has a rapid onset of action. Following intravenous administration, neutralisation of heparin occurs within 5 minutes. Although the metabolic fate of the protamine-heparin complex is not known, it appears that the complex is partially degraded, thus freeing heparin. No interactions are known.<br /><em>Protamine Sulphate Injection BP 1% UK Summary of Product Characteristics, Sovereign Medical, updated September 2007<br />Prosulf&#174; (protamine sulphate)10mg/ml Solution for Injection UK Summary of Product Characteristics, Wockhardt UK Ltd updated September 2010</em></p>
<p>Although the metabolic fate of the protamine-heparin complex has not been elucidated, it appears that the protamine in the heparin-protamine complex may be partially metabolized or attacked by fibrinolysin, thus freeing heparin<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, December 2008</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Prucalopride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly eliminated renally, partly by active secretion by renal transporters. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pyrantel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Pyrantel is metabolized by CYP2D6 in vitro, however absorption of an oral dose is minimal, and over 50% of a dose is excreted unchanged in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Only a small proportion of a dose of pyrantel embonate is absorbed from the gastrointestinal tract. Up to about 7% is excreted as unchanged drug and metabolites in the urine but over half of the dose is excreted unchanged in the faeces.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011</em></p>
<p>Pyrantel is predominantly metabolised by CYP2D6 in vitro<br /><em>Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Li XQ, Bj&#246;rkman A, Andersson TB, et al. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pyrazinamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Pyrazinamide is mainly metabolized by xanthine oxidase. As didanosine is also metabolized by this enzyme, competition could increase pyrazinamide exposure and possibly increase the risk of arthralgia (resulting from the inhibition of urate tubular secretion by pyrazinamide). No a priori dosage adjustment is recommended but monitoring for side effects is suggested.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pyridostigmine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Pyridostigmine is predominantly eliminated unchanged via renal tubular secretion, there is therefore little potential for interaction with didanosine via modulation of or competition for metabolism pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Pyridostigmine bromide is poorly absorbed from the gastrointestinal tract. It undergoes hydrolysis by cholinesterases and is also metabolised in the liver. Pyridostigmine is excreted mainly in the urine as unchanged drug and metabolites. It appears that 75% of the plasma clearance of pyridostigmine depends on renal function. 3-Hydroxy-N-methylpyridinium has been identified as one of the 3 metabolites isolated from the urine of patients taking pyridostigmine.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press(via Medicines Complete), last modified 2011-04-15<br /></em>&nbsp;<br />To assess the contribution of tubular secretion to the renal excretion of pyridostigmine, and its modification by other cationic drugs, six volunteers were given single oral doses of 60mg pyridostigmine bromide with and without co-administration of ranitidine or pirenzepine. In patients with myasthenia receiving continuous pyridostigmine therapy, renal clearance values were obtained in the same manner with and without ranitidine (10 patients) or pirenzepine (nine patients) co-medication. Pyridostigmine renal clearance averaged 6.65 ml/min per kg (350% of the creatinine clearance) in all subjects, 74% being due to net tubular secretion. Mean values for pyridostigmine renal clearance and for clearance by secretion were decreased in the presence of pirenzepine, but plasma concentrations were not affected significantly. Ranitidine caused a small non-significant decrease of the pyridostigmine clearance in patients. The renal clearance of creatinine was slightly increased by pyridostigmine in volunteers and slightly decreased by pirenzepine in the total group of subjects.<br /><em>Eiermann B, Sommer N, Winne D, Schumm F, Maier U, Breyer-Pfaff U. Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. Xenobiotica. 1993 Nov;23(11):1263-75.</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pyridoxine (Vitamin B6)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid.<br /><em>Vitamin B Compound Strong Tablets, UK Summary of Product Characteristics, Actavis UK Ltd, updated July 2012</em></p>
<p>Pyridoxine, pyridoxal, and pyridoxamine are readily absorbed from the gastrointestinal tract after oral doses and are converted to the active forms pyridoxal phosphate and pyridoxamine phosphate. They are stored mainly in the liver where there is oxidation to 4-pyridoxic acid and other inactive metabolites which are excreted in the urine. As the dose increases, proportionally greater amounts are excreted unchanged in the urine.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), last modified 2006-07-17</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Pyrimethamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but as pyrimethamine needs an acidic pH for absorption, administer 2 hours before or 1 hour after didanosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Quercetin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Quetiapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is primarily metabolised by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Quinapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Quinidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinidine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Quinine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as quinine is extensively metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rabeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rabeprazole is mainly metabolized by CYP2C19 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Raltegravir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ramipril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolized to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ranitidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant effect on didanosine or ranitidine pharmacokinetics when administered 2 h apart. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Specific interaction studies have been conducted with ranitidine without evidence of interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>When the buffered formulation of ddI (375 mg single dose) was coadministered with ranitidine (150 mg single dose, 2 h before ddI) to 12 HIV-infected subjects, ddI AUC and Cmax increased by 14% and 13% respectively. Ranitidine AUC decreased by 16% and there was no change in Cmax. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>The pharmacokinetic interaction between single doses of didanosine (375 mg, citrate buffered sachet) and ranitidine (150 mg) was studied in 12 HIV-infected subjects. When given in combination (ranitidine 2 h prior to didanosine), there was a statistically significant increase in didanosine AUC (from 2953 to 3359 ng.h/ml), but no effect on Cmax (1617 vs. 1825 ng/ml), half life or renal clearance. The AUC of ranitidine was statistically significantly reduced when given with didanosine (from 1771 to 1483 ng.h/ml), but there was no change in Cmax (325 vs. 333 ng/ml), half life or clearance. Coadministration does not result in a clinically significant interaction and the results suggest that a modification in the dose of didanosine or ranitidine is not necessary if ranitidine is dosed 2 h prior to didanosine. <br /><em>Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus. Knupp CA, et al Antimicrob Agents Chemother, 1992, 2075-2079. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ranolazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranolazine is primarily metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rasagiline </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as rasagiline is metabolised predominantly by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Reboxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as reboxetine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Repaglinide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Repaglinide is metabolized by CYP2C8 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Retinol (Vitamin A)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. Retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Vitamin A substances are readily absorbed from the gastrointestinal tract but absorption may be reduced in the presence of fat malabsorption, low protein intake, or impaired liver or pancreatic function. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. It is released from the liver bound to a specific &#945;1-globulin (retinol-binding protein) in the blood. The retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid; these and other metabolites are excreted in urine and faeces.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ribavirin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Potential interaction that may increase the intracellular triphosphate levels of didanosine, which could cause or worsen clinical toxicities. Increased risk of mitochondrial toxicity. Coadministration is not recommended. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Co-administration of ribavirin and didanosine is not recommended due to an increased risk of adverse events, in particular of mitochondrial toxicity. Based on in vitro data, ribavirin increases the intracellular triphosphate levels of didanosine. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving didanosine and ribavirin with or without stavudine. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Coadministration of didanosine and ribavirin is contraindicated because exposures of the active metabolite of didanosine (dideoxyadenosine 5&#8217;-triphosphate) are increased. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>The pharmacokinetic interaction between didanosine (200 mg twice daily) and ribavirin (600 mg once daily) was studied in 15 HIV-infected subjects. Pharmacokinetic analysis at week 4 (monotherapy) and weeks 6 and 12 (after 2 and 8 weeks of coadministration) revealed no pharmacokinetic interaction and the combination was well tolerated. <br /><em>A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. Japour AJ et al. J Acquir Immune Defic Syndr Hum Retrovirol, 1996, 13: 235-246. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Riboflavin (Vitamin B2)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Riboflavin is absorbed from the GI tract and in the circulation is bound to plasma proteins. Although widely distributed, little is stored in the body, and amounts in excess of requirements are excreted in the urine.<br /><em>Vitamin B Compound Strong Tablets UK Summary of Product Characteristics, Actavis UK Ltd, updated July 2012</em></p>
<p>Riboflavin is readily absorbed from the gastrointestinal tract. Although riboflavin is widely distributed to body tissues little is stored in the body. Riboflavin is converted in the body to the coenzyme flavine mononucleotide (FMN; riboflavin 5&#8242;-phosphate) and then to another coenzyme flavine adenine dinucleotide (FAD). About 60% of FMN and FAD are bound to plasma proteins. Riboflavin is excreted in urine, partly as metabolites. As the dose increases, larger amounts are excreted unchanged.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em> </p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rifabutin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction observed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Specific interaction studies have been conducted with rifabutin without evidence of interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>When the buffered formulation of ddI (167 or 250 mg twice daily for 12 days) was coadministered with rifabutin (300 or 600 mg once daily for 12 days) to 11 HIV-negative subjects, ddI AUC and Cmax increased 13% and 17% respectively. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>The effect of didanosine buffered tablets (167-375 mg twice daily according to body weight) on the pharmacokinetics of rifabutin (300 mg once daily) was studied in 12 HIV-infected subjects. No statistically significant differences were seen in rifabutin pharmacokinetics for Cmax (525&#177;255 vs. 511&#177;341 ng/ml) or AUC (5023&#177;2780 vs. 5650&#177;4420 ng.h/ml; mean&#177;sd, alone vs. +ddI). Metabolism of rifabutin (as indicated by ratio of parent drug to 25-acetyl metabolite) was also unaltered. <br /><em>Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. Li RC, et al. Antimicrob Agents Chemother, 1997, 41: 1566-1570. </em></p>
<p>The pharmacokinetics of didanosine (167-375 mg twice daily) when administered alone or with rifabutin (300 or 600 mg once daily) were determined in 12 HIV-infected subjects. When given with rifabutin there were no statistically significant changes in didanosine Cmax (17% increase) or AUC (13% increase). Based on safety and pharmacokinetic assessments, rifabutin did not appear to interact with didanosine. <br /><em>A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients. Sahai J, et al. J Acquir Immune Defic Syndr Hum Retrovirol, 1995, 9: 274-279. </em></p>
<p>Impaired absorption of rifabutin by concomitant administration of didanosine has been reported in a 45-year-old HIV-infected man treated with lopinavir/ritonavir, efavirenz, lamivudine and didanosine (400 mg daily). One month after starting levofloxacin and rifabutin (150 mg twice daily) for Mycobacterium xenopi spondylodiscitis, the patient had to be hospitalised because of microbiological failure. Rifabutin analysis showed undetectable concentrations. Drug history revealed that the patient had been taking didanosine only 30 min prior to the other drugs. Rifabutin analysis was repeated after administration of didanosine 3 h prior to rifabutin and showed quantifiable levels. <br /><em>Impaired absorption of rifabutin by concomitant administration of didanosine. Marzolini C, et al. AIDS, 2001, 15: 2203-2204. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rifampicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as rifampicin is deacetylated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rifapentine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as rifapentine is deacetylated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rifaximin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Rifaximin is mainly excreted in faeces, almost entirely as unchanged drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rilpivirine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of rilpivirine (150 mg once daily) and didanosine (Videx EC, administered 2 hours before rilpivirine) had no effect on rilpivirine Cmax, AUC or Cmin. Didanosine Cmax decreased by 4% and AUC increased by 12%. No dose adjustment is required, but didanosine is to be administered on an empty stomach at least 2 h before or 4 h after rilpivirine (which should be taken with food). [Note: this interaction study has been performed with a dose higher than the licensed dose for rilpivirine assessing the maximal effect on the co-administered drug. The dosing recommendation is applicable to the licensed dose of rilpivirine 25 mg once daily.] </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration of didanosine (400 mg once daily) and a higher than the recommended dose of rilpivirine increased didanosine AUC by 12%, but had no effect on didanosine Cmax, nor rilpivirine AUC, Cmax or Cmin. No dose adjustment is required. Didanosine should be administered at least two hours before or at least four hours after rilpivirine. </div>
<div><em>Edurant Summary of Product Characteristics, Janssen-Cilag Ltd, November 2011</em> 
<div>&nbsp;</div>Coadministration of rilpivirine (150 mg once daily) and didanosine enteric coated capsules (Videx EC) was studied in 21 subjects.&nbsp; Didanosine, administered 2 hours before rilpivirine had no effect on rilpivirine Cmax, AUC or Cmin. Didanosine Cmax decreased by 4% and AUC increased by 12%. No dose adjustment is required when rilpivirine is coadministered with didanosine. Didanosine is to be administered on an empty stomach and at least two hours before or at least four hours after rilpivirine (which should be administered with a meal).</div>
<div><em>Edurant Prescribing Information, Tibotec Inc, May 2011.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rilpivirine/FTC/TAF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Odefsey is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Odefsey is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products.<br><em>Odefsey Summary of Product Characteristics, Gilead Sciences Ltd, June 2016.</em></p>

</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rimantadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rimantadine is both hydroxylated and glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Risperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Risperidone is metabolized by CYP2D6 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ritonavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>As ritonavir is recommended to be taken with food and didanosine should be taken on an empty stomach, dosing should be separated by 2.5 h. Dose alterations should not be necessary. No significant interaction is expected with didanosine gastro-resistant capsules (ddI-EC). Coadministration of didanosine (200 mg twice daily) given 2 hours prior to ritonavir (600 mg twice daily) decreased didanosine AUC (13%) and Cmax (16%) and had no effect on Cmin. There was no effect on ritonavir pharmacokinetics. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><em><strong>LHPG Comment: </strong>Unlike the Videx chewable/dispersible tablets, the new formulation of ddI (Videx EC) does not contain antacids. Interactions with the old formulation that were due to the presence of antacid should not apply to the new formulation. Timing of administration of Videx EC with other medications will still be dependent on food requirements, but no longer on gastric pH requirements. </em></p>
<p>When the buffered formulation of ddI (200 mg twice daily for 4 days) was coadministered with ritonavir (600 mg twice daily for 4 days) to 12 HIV-negative subjects, ddI AUC and Cmax decreased by 13% and 16% respectively. There was no change in the AUC or Cmax of ritonavir. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>Coadministration of didanosine (200 mg twice daily) given 2 hours prior to ritonavir (600 mg twice daily) decreased didanosine AUC by 13% and had no effect on Cmin. As ritonavir is recommended to be taken with food and didanosine should be taken on an empty stomach, dosing should be separated by 2.5 h. Dose alterations should not be necessary. <br /><em>Norvir Summary of Product Characteristics, Abbott Laboratories Ltd, April 2012.</em></p>
<p>Coadministration of ritonavir (600 mg every 12 hours for 4 days) with didanosine (200 mg every 12 hours for 4 days), in 12 subjects, caused no alteration in ritonavir AUC, Cmax or Cmin but decreased didanosine AUC and Cmax by 13% and 16%, respectively with no change in didanosine Cmin. <br /><em>Norvir Prescribing Information, Abbott Laboratories, February 2012.</em></p>
<p>Coadministration of ritonavir (600 mg every 12 h) and didanosine (200 mg every 12 h) to 12 HIV+ individuals found that the AUC and Cmax of didanosine were both reduced by ~15%. The relative small magnitude of change in ddI pharmacokinetics is of doubtful clinical significance and probably does not warrant an alteration in ddI dosage. However, dosing of ritonavir and ddI should be separated by 2.5 h to avoid formulation incompatibilities. Didanosine has little, if any, effect on ritonavir pharmacokinetics. <br /><em>Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-positive patients. Cato A, Qian J, Hsu A, et al. J Acq Immune Def Syndr Hum Retrovirol, 1998, 18:466&#8211;72.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rituximab</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rituximab is a monoclonal IgG antibody. Elimination is similar to endogenous IgG and occurs primarily via proteolytic catabolism throughout the body.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rivaroxaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Rivaroxaban is partly metabolized in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine (by P-gp and BCRP).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rizatriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rizatriptan is metabolized by oxidative deamination by monoamine oxidase-A (MAO-A).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rocuronium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Rocuronium is mostly cleared in the bile although up to 30% may be excreted renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ropinirole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ropinirole is metabolised predominantly by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rosiglitazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Rosiglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Rosuvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as rosuvastatin is largely excreted unchanged via the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sacubitril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sacubitril is rapidly converted to LBQ657 (active metabolite) by carboxylesterases and the active metabolite is not further metabolized to a significant extent.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Salbutamol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolized to the inactive salbutamol-4-O-sulphate. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Salmeterol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Saquinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No data with the 500 mg formulation of saquinavir. Coadministration with saquinavir soft gel and ritonavir (1600/100 mg once daily) decreased saquinavir AUC and Cmax, but had no effect on Cmin (data from 8 HIV- subjects). Dose modification not recommended. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><em><strong>LHPG Comment:</strong> Unlike the Videx chewable/dispersible tablets, the new formulation of ddI (Videx EC) does not contain antacids. Interactions with the old formulation that were due to the presence of antacid should not apply to the new formulation. Timing of administration of Videx EC with other medications will still be dependent on food requirements, but no longer on gastric pH requirements. </em></p>
<p>The effects of a single dose of didanosine 400 mg on the pharmacokinetics of saquinavir/ritonavir (1600/100 mg once daily for 2 weeks) was investigated. Didanosine decreased saquinavir AUC and Cmax approximately 30% and 25%, respectively, and had no effect on saquinavir Cmin. No dose adjustment required. <br /><em>Invirase Summary of Product Characteristics, Roche Products Ltd, June 2012.</em></p>
<p>The soft gel formulation of saquinavir (1600 mg once daily) plus low dose ritonavir and a single dose of didanosine (400 mg) were given 1 h apart to eight healthy volunteers. There was a 12% decrease in saquinavir AUC and a 9% decrease in Cmax. <br /><em>Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Kilby JM, Sfakianos G, Gizzi N, et al. Antimicrob Agents Chemother, 2000, 44: 2672-8.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Saw palmetto (Serenoa repens)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Saxagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolized by CYP3A4/5 but does not inhibit or induce this enzyme.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Senna</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces and also in other secretions. No clinically significant drug interactions are known.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>There is some absorption of anthraquinone laxatives following administration by mouth. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces and also in other secretions including breast milk. No clinically significant drug interactions are known.<br /><em>Senna Laxative Tablets, UK Summary of Product Characteristics, The Boots Company PLC, updated February 2008</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sertraline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolized by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Seville orange juice</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sevoflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as sevoflurane is almost exclusively eliminated unchanged by the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sildenafil (Erectile Dysfunction)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sildenafil (Pulmonary Arterial Hypertension)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Simeprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but no clinically relevant drug-drug interaction is expected. No dose adjustment is required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied. No clinically relevant drug drug interaction is expected. No dose adjustment is required.</div><div><em>Olysio Summary of Product Characteristics, Janssen-Cilag, May 2014.</em></div><div>&nbsp;</div><div>No clinically relevant drug-drug interaction is expected when simeprevir is co-administered with abacavir.</div><div><em>Olysio US Prescribing Information, Janssen, December 2013.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Simvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sirolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sirolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sitagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, P-gp) and metabolism by CYP3A4 represents a minor elimination pathway. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sodium nitroprusside</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Sodium nitroprusside is rapidly metabolised, likely by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase. There is little potential for sodium nitroprusside to affect the disposition of antiretrovirals, or to be affected if co-administered with antiretrovirals.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Sodium nitroprusside is rapidly metabolized, probably by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase (rhodanase). This mitochondrial enzyme normally is present in excess quantities such that the rate-limiting step in the conversion of cyanogen to thiocyanate usually is the availability of sulfur donors (e.g., thiosulfate, cystine, cysteine). Sodium nitroprusside is excreted entirely as metabolites, principally thiocyanate. In animals, sodium nitroprusside metabolites are excreted mainly in urine, exhaled air, and probably in feces. The elimination half-life of thiocyanate is 2.7&#8211;7 days when renal function is normal but is longer in patients with impaired renal function or hyponatremia.<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, 01/2009</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sodium stibogluconate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for pharmacokinetic interaction. Pancreatitis has been described as a relatively common serious adverse effect of sodium stibogluconate therapy, and has also been associated with didanosine therapy (<1% of patients) and has been fatal in some cases. When treatment with other medicinal products known to cause pancreatic toxicity is required, didanosine should be suspended whenever possible. If concomitant therapy is unavoidable, close observation is warranted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Transient rises in serum lipase and amylase usually occur during treatment with sodium stibogluconate. Symptomatic pancreatitis has also been reported<br /><em>Pentostam&#174; (sodium stibogluconate) injection UK Summary of Product Characteristics, GlaxoSmithKline UK, updated August 2007</em></p>
<p>Various case studies and trials of efficacy/tolerability of sodium stibogluconate describe pancreatitis during treatment, particularly in immunosuppressed individuals. Several authors recommend monitoring of serum amylase and consideration of pancreatitis in patients experiencing abdominal pain.<br /><em>Donovan KL et al. J Infect. 1990 Jul;21(1):107-10; McCarthy AE et al. Clin Infect Dis. 1993 Nov;17(5):952-3; McBride MO et al. Clin Infect Dis. 1995 Sep;21(3):710; Aronson NE et al. Clin Infect Dis. 1998 Dec;27(6):1457-64; Aronson NE et al. PLoS Negl Trop Dis. 2010 Mar 9;4(3):e628.</em></p>
<p>Pancreatitis is a known serious complication among HIV infected patients. It has also been associated with didanosine therapy (&lt;1% of patients) and has been fatal in some cases. Didanosine should be used only with extreme caution in patients with a history of pancreatitis. Positive relationships have been found between the risk of pancreatitis and daily dose of didanosine. Whenever warranted by clinical conditions, didanosine should be suspended until the diagnosis of pancreatitis is excluded by appropriate laboratory and imaging techniques. Similarly, when treatment with other medicinal products known to cause pancreatic toxicity is required, didanosine should be suspended whenever possible. If concomitant therapy is unavoidable, close observation is warranted. Dose interruption should be considered when biochemical markers of pancreatitis have significantly increased, even in the absence of symptoms. Significant elevations of triglycerides are a known cause of pancreatitis and warrant close observation. <br /><em>Videx EC&#174; (didanosine) gastroresistant capsules, UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated&nbsp; February 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Didanosine is phosphorylated to an active triphosphate form and is excreted via the kidneys by tubular secretion. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Solifenacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Solifenacin is metabolized by CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sorafenib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Sorafenib is metabolized to a moderate extent by CYP3A4 and UGT1A9, UGT1A1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Spectinomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Spectinomycin is predominantly eliminated unchanged by the kidneys via glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Spironolactone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolized by the flavin containing monooxygenases.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Stanozolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Stavudine (d4T)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant PK interaction observed. However, coadministration not recommended due to increased risk of peripheral neuropathy, pancreatitis and lactic acidosis. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Coadministration is not recommended. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving didanosine and ribavirin with or without stavudine. Pancreatitis (fatal and nonfatal) and peripheral neuropathy (severe in some cases) have been reported in HIV infected patients receiving didanosine in association with hydroxyurea and stavudine. Specific interaction studies have been conducted with stavudine without evidence of interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Patients treated with didanosine in combination with stavudine may be at increased risk for pancreatitis. Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. The combination of didanosine and stavudine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk. Peripheral neuropathy has occurred more frequently in patients with advanced HIV disease, in patients with a history of neuropathy, or in patients being treated with neurotoxic drug therapy, including stavudine. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Patients treated with didanosine in combination with stavudine, with or without hydroxyurea, may be at increased risk for pancreatitis and hepatotoxicity, which may be fatal, and severe peripheral neuropathy. The combination of didanosine and hydroxyurea, with or without stavudine, should be avoided. When the buffered formulation of ddI (100 mg twice daily for 4 days) was coadministered with stavudine (40 mg twice daily for 4 days) to 10 HIV-negative subjects, there was no change in ddI AUC or Cmax. When the same doses were studied in 10 HIV-infected subjects, there was no change in stavudine AUC and a 17% increase in Cmax. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>Coadministration is not recommended. Pancreatitis (fatal and nonfatal) and peripheral neuropathy (severe in some cases) have been reported in HIV infected patients receiving stavudine in association with hydroxyurea and didanosine. Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV infected patients treated with antiretroviral agents and hydroxyurea; fatal hepatic events were reported most often in patients treated with stavudine, hydroxyurea and didanosine. In vitro studies indicate that the activation of stavudine is inhibited by doxorubicin and ribavirin but not by other medicinal products used in HIV infection which are similarly phosphorylated, e.g. didanosine, zalcitabine, ganciclovir and foscarnet. <em>Zerit Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, March 2011.</em></p>
<p>&nbsp;</p>
<p>Fatal and nonfatal pancreatitis have occurred during therapy when stavudine was part of a combination regimen that included didanosine in both treatment-naive and treatmentexperienced patients, regardless of degree of immunosuppression. The combination of stavudine and didanosine and any other agents that are toxic to the pancreas should be suspended in patients with suspected pancreatitis. Reinstitution of stavudine after a confirmed diagnosis of pancreatitis should be undertaken with particular caution and<br />close patient monitoring; avoid use in combination with didanosine. Patients treated with stavudine in combination with didanosine, with or without hydroxyurea, may be at increased risk for pancreatitis and hepatotoxicity, which may be fatal, and severe peripheral neuropathy. The combination of stavudine and hydroxyurea, with or without didanosine, should be avoided.. Coadministration of stavudine (40 mg twice daily for 4 days) and didanosine (100 mg twice daily for 4 days) was studied in 10 HIV-infected subjects. There was no change in stavudine AUC and a 17% increase in Cmax. Didanosine AUC and Cmax were unaltered. <br /><em>Zerit Prescribing Information, Bristol-Myers Squibb Company, January 2012.</em></p>
<p>The pharmacokinetics of single and coadministered doses of didanosine (100 mg) and stavudine (40 mg) were evaluated in 10 HIV-positive subjects. No significant changes in Cmax, AUC, elimination half life or renal clearance of didanosine and stavudine were observed when the drugs were administered simultaneously. Cmax and AUC values for didanosine (alone vs. combination) were 422&#177;184 vs. 419&#177;153 mg/ml and 615&#177;170 vs. 637&#177;155 ng/ml.h, respectively. Cmax and AUC values obtained for stavudine were 603&#177;160 vs. 726&#177;188 and 1246&#177;230 vs. 1326&#177;267 ng/ml.h, respectively. <br /><em>Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Seifert RD, et al. Br J Clin Pharmacol, 1994, 38: 405-410. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>St John&#39;s Wort</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. St Johns wort is unlikely to affect the exposure of NRTIs such as didanosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Streptokinase</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. Streptokinase is unlikely to affect the disposition of antiretrovirals, or to be affected if co-administered with antiretrovirals.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The elimination kinetics of streptokinase follows a biphasic course. A small proportion of the dose is bound to anti-streptokinase antibodies and metabolised with a half-life of 18 minutes, whilst most of it forms the streptokinase-plasminogen activator complex and is biotransformed with a half-life of about 80 minutes. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys.<br /><em>Streptokinase 750,000 iu UK Summary of Product Characteristics, Beacon Pharmaceuticals, updated August 2012</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Streptomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Streptomycin is excreted rapidly in the urine by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Strontium ranelate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as strontium ranelate is not metabolised and is excreted unchanged by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sufentanil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as sufentanil undergoes extensive CYP3A4 metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sulfadiazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. In vitro studies suggest that sulfadiazine is metabolized in part by CYP2C9. Adverse reactions to sulfadiazine are thought to be more common in patients with AIDS.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Sulfadiazine is readily absorbed from the gastrointestinal tract and peak blood concentrations occur 3 to 6 hours after a single dose; 20 to 55% has been reported to be bound to plasma proteins. It penetrates into the CSF within 4 hours of an oral dose to produce therapeutic concentrations, which may be more than half those in the blood. Up to 40% of sulfadiazine in the blood is present as the acetyl derivative. About 50% of a single dose of sulfadiazine given orally is excreted in the urine in 24 hours; 15 to 40% is excreted as the acetyl derivative. The urinary excretion of sulfadiazine and the acetyl derivative is dependent on pH. About 30% is excreted unchanged in both fast and slow acetylators when the urine is acidic whereas about 75% is excreted unchanged by slow acetylators when the urine is alkaline.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em></p>
<p>The sulfadiazine hydroxylamine metabolite has been linked to greatly increased rates of adverse reactions to sulfadiazine experienced by people with HIV infection. A study investigated the in vitro human cytochrome P450 (P450) and N-arylamine acetyltransferase (detoxification) metabolism of sulfadiazine. Formation of both the hydroxylamine and 4-hydroxy sulfadiazine was NADPH-dependent in human liver microsomes (HLM). Significant (p &lt; 0.05) inhibition by selective P450 isoform inhibitor sulfaphenazole (2.1 microM; CYP2C9) indicated a role for CYP2C9 in the formation of the hydroxylamine. Hydroxylamine formation correlated strongly with tolbutamide 4-hydroxylation (CYP2C8/9) in HLM (r = 0.76, p &lt; or = 0.004, n = 12). Fluconazole (CYP2C9/19 and CYP3A4 inhibitor at clinical concentrations) inhibited hydroxylamine formation, with one-enzyme model K(i) estimates ranging from 9 to 40 microM. Acetylation of sulfadiazine in human liver cytosol (HLC) correlated strongly with NAT2 activity as measured by sulfamethazine N-acetylation (r = 0.92, p &lt; 0.001, n = 12).&nbsp; The polymorphic acetylation of sulfadiazine may predispose slow acetylator patients to adverse reactions to sulfadiazine. On the basis of our K(i) estimates, clinical fluconazole concentrations of 25 microM would produce decreases of 40 to 70% in hepatic-mediated hydroxylamine production. Therefore, we predict that fluconazole may prove useful in the clinic as an in vivo inhibitor of sulfadiazine hydroxylamine formation to suppress adverse reactions to this drug.<br /><em>Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Winter HR, Unadkat JD. Drug Metab Dispos. 2005 Jul;33(7):969-76.</em></p>
<p>&nbsp;</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sulfadoxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Sulfadoxine is rarely used alone, but is usually given in combination with pyrimethamine. Coadministration has not been studied, but as pyrimethamine needs an acidic pH for absorption, administer sulfadoxine/pyrimethamine 2 hours before or 1 hour after didanosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sulfasalazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction. Multiple mechanisms are thought to be involved in sulfasalazine metabolism including acetylation, hydroxylation, and glucuronidation. There is therefore low potential for clinically significant interactions with didanosine via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Around 90% of a dose reaches the colon where bacteria split the drug into sulfapyridine (SP) and mesalazine (ME). These are also active, and the unsplit sulfasalazine (SASP) is also active on a variety of symptoms. Most SP is absorbed, hydroxylated or glucuronidated and a mix of unchanged and metabolised SP appears in the urine. Some ME is taken up and acetylated in the colon wall, such that renal excretion is mainly AC-ME. SASP is excreted unchanged in the bile and urine. Turning to mesalazine, in urine only AC-ME (not free ME) was demonstrable, the acetylation probably largely achieved in the colon mucosa. After a 3g SASP dose lag time was 6.1&#177;2.3 hours and plasma levels kept below 2&#181;g/ml total ME. Urinary excretion half life was 6.0&#177;3.1 hours and absorption half life based on these figures 3.0&#177;1.5 hours. Renal clearance constant was 125ml/min corresponding to the GFR.<br /><em>Salazopyrin En-Tabs&#174; (Sulfasalazine) UK Summary of Product Characteristics, Pfizer Limited, updated August 2010</em></p>
<p>Sulfasalazine is metabolised by intestinal bacteria to sulfapyridine (SP) and 5-ASA. Approximately 15% of a dose of sulfasalazine is absorbed as parent and is metabolised to some extent in the liver to the same two species. The observed plasma half life for IV sulfasalazine is 7.6 &#177;3.4 hrs. The primary route of metabolism of SP is via acetylation to form AcSP. The rate of metabolism of SP to AcSP is dependent upon acetylator phenotype. SP can also be metabolised to 5-hydroxy-sulfapyridine and N-acetyl-5-hydroxy-sulfapyridine. 5-ASA is primarily metabolised in both the liver and intestine to N-acetyl-5-aminosalicylic acid via a non-acetylation phenotype dependent route. Due to low plasma levels produced by 5-ASA after oral administration, reliable estimates of plasma half lives are not possible. Absorbed SP and 5-ASA and their metabolites are primarily eliminated in the urine either as free metabolites or glucuronide conjugates. The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl 5-ASA within the feces. The calculated clearance of sulfasalazine following IV administration was 1L/hr. Renal clearance was estimated to account for 37% of total clearance.<br /><em>Sulfasalazine tablets USP US Prescribing Information, Watson Laboratories Inc, updated May 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sulpiride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction is expected with Videx-EC (didanosine gastro-resistant capsules).  However, didanosine chewable/dispersible tablets and powder for oral solution contain an antacid. Administration antacids may reduce the bioavailability of sulpiride, which should be administered at least 2 hours before and not with or after antacids.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sumatriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sumatriptan is eliminated primarily by metabolism mediated by monoamine oxidase A.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Sunitinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Sunitinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Suramin sodium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Suramin appears to be eliminated predominantly unchanged via renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The clinical pharmacokinetics of suramin were studied in 4 patients with AIDS given 6.2 g intravenously over 5 weeks. Suramin accumulated during treatment and plasma concentrations exceeded 100 micrograms/mL for several weeks. After the last dose the terminal half-life of suramin ranged from 44 to 54 days. At least 99.7% was bound to plasma proteins. Renal clearance accounted for most (80%) of the elimination of suramin from the body. There appeared to be little or no metabolism of suramin.<br /><em>Collins JM, Klecker RW Jr, Yarchoan R, et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol. 1986 Jan;26(1):22-6.</em></p>
<p>Suramin was administered to 49 patients in a Phase I cancer trial with real-time pharmacokinetic monitoring and dose individualization to achieve targeted mean plasma concentrations of 210 and 155 mg/liter during the 7-day period between days 15 and 22. Pharmacokinetic sampling after doses on days 1, 3, 5, and 8 was used to modify weekly suramin doses, beginning on day 15, in an attempt to achieve specific averaged plasma concentrations of 210 and 155 mg/liter. A 200-mg test dose was not effective in prospectively determining individual pharmacokinetic parameters and dosage requirements. Prospective use of surrogate substrates for CYP1A2, CYP3A3/4, and CYP2D6 showed no consistent effect of suramin on these enzymes. Although a correlation between creatinine clearance and suramin renal clearance was found (r2 = 0.38; P &lt; 0.00005), there was no correlation between creatinine clearance and total suramin clearance (P = 0.21). As expected for a drug eliminated renally by filtration, the extrapolated intercept of suramin renal clearance approximates zero at a creatinine clearance of 0 ml/min<br /><em>Hutson PR, Tutsch KD, Rago R, Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. Clin Cancer Res. 1998 Jun;4(6):1429-36.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Suxamethonium (Succinylcholine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Suxamethonium is hydrolysed by plasma cholinesterase. There is therefore little potential for interaction with didanosine via modulation of or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Following intravenous administration, there is rapid hydrolysis by pseudocholinesterase with the initial metabolite being succinylmonocholine a weak neuro-muscular drug. This is metabolised to succinic acid with only a small amount excreted in the urine.<br /><em>Suxamethonium Chloride Injection BP UK Summary of Product Characteristics, Mercury Pharma Group, updated May 2012</em></p>
<p>Succinylcholine is rapidly hydrolyzed by plasma cholinesterase to succinylmonocholine (which possesses clinically insignificant depolarizing muscle relaxant properties) and then more slowly to succinic acid and choline. About 10% of the drug is excreted unchanged in the urine.<br /><em>Anectine&#174; (Succinylcholine Chloride Injection, USP) US Prescribing Information, Sandoz Inc, updated September 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tacrolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tacrolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tadalafil (Erectile Dysfunction)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tadalafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tadalafil (Pulmonary Arterial Hypertension)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tadalafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tamoxifen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Tamoxifen metabolism occurs mostly via two pathways: the formation of N-desmethyltamoxifen (via mainly CYP3A4 and CYP3A5) is the main route (92%) and the formation of 4-hydroxytamoxifen (via CYP2D6 > 2C9/19, CYP3A4 and CYP2B6) is a minor route (7%). Further metabolism of both metabolites results in the formation of endoxifen which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen. Endoxifen is formed from N-desmethyltamoxifen via CYP2D6 and from 4-hydroxytamoxifen via CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tamsulosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Telaprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as telaprevir is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Telbivudine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telbivudine is eliminated primarily by urinary excretion as unchanged drug. The renal clearance of telbivudine approaches normal glomerular filtration rate, suggesting that filtration is the main mechanism of excretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Telithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as telithromycin is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Telmisartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as telmisartan is mainly glucuronidated by UGT1A3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Temazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as temazepam is mainly glucuronidated. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Temsirolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Temsirolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tenofovir-DF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is not recommended due to increased didanosine concentrations and toxicity. If this combination is judged strictly necessary, patients should be carefully monitored for efficacy and didanosine related adverse events. The US Prescribing Informations for didanosine and tenofovir-DF recommend a reduced dose of didanosine (250 mg once daily for adults weighing 60 kg or greater with creatinine clearance 60 mL/min or greater; 200 mg once daily for adults weighing less than 60 kg with creatinine clearance 60 mL/min or greater). A decreased dosage of 250 mg didanosine with tenofovir-DF has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Co-administration of didanosine and tenofovir disoproxil fumarate results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse events. Rare cases of pancreatitis and lactic acidosis, sometimes fatal, have been reported. When didanosine gastro-resistant capsules were administered 2 hours prior to or concurrently with tenofovir disoproxil fumarate, the AUC for didanosine was on average increased by 48% and 60% respectively. The mean increase in the AUC of didanosine was 44% when the buffered tablets were administered 1 hour prior to tenofovir. In both cases the pharmacokinetic parameters for tenofovir administered with a light meal were unchanged. A reduced didanosine dose (250 mg) has been tested to avoid over-exposure to didanosine in case of co-administration with tenofovir disoproxil fumarate, but this has been associated with reports of high rate of virological failure and of emergence of resistance at early stage within several tested combinations. Co-administration of didanosine and tenofovir disoproxil fumarate is therefore not recommended, especially in patients with high viral load and low CD4 cell count. Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine. If this combination is judged strictly necessary, patients should be carefully monitored for efficacy and didanosine related adverse events. <br />Triple NRTI Therapy:<br />There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when didanosine was combined with tenofovir disoproxil fumarate and lamivudine as a once daily regimen. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate. Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy. Coadministration of tenofovir disoproxil fumarate with didanosine should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response. Didanosine should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop. Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily. A dose reduction of didanosine taken together with tenofovir disoproxil fumarate and a light meal (400 kcalories or less and 20% fat or less) or in the fasted state is recommended. Administer didanosine 250 mg once daily to adults weighing at least 60 kg with creatinine clearance of at least 60 mL/min and didanosine 200 mg once daily to adults weighing less than 60 kg with creatinine clearance of at least 60 mL/min. The appropriate dose of didanosine coadministered with tenofovir disoproxil fumarate in patients with creatinine clearance of less than 60 mL/min has not been established. Patients should be monitored for didanosine-associated toxicities and clinical response. <br />Coadministration of tenofovir (300 mg once daily with a light meal) and didanosine (400 mg single dose, 2 h before tenofovir) was studied in 26 HIV-negative subjects. AUC and Cmax of ddI both increased by 48%. Data from 25 subjects showed no change in the AUC and Cmax of tenofovir. <br />Coadministration of tenofovir (300 mg once daily) and didanosine (400 mg single dose) together and with a light meal was studied in 25 HIV-negative subjects. AUC and Cmax of ddI increased by 60% and 64% respectively. There was no change in the AUC and Cmax of tenofovir. <br />Coadministration of tenofovir (300 mg once daily) and didanosine (200 mg single dose) together and with a light meal was studied in 33 HIV-negative subjects. When compared to didanosine pharmacokinetics obtained with ddI 250 mg given alone under fasting conditions, AUC of ddI increased by 16% and Cmax decreased by 12%. <br />Coadministration of tenofovir (300 mg once daily) and didanosine (250 mg single dose) together and with a light meal was studied in 33 HIV-negative subjects. When compared to didanosine pharmacokinetics obtained with ddI 400 mg given alone under fasting conditions, there was no change in the AUC of ddI and a 20% decrease in Cmax. <br />Coadministration of tenofovir (300 mg once daily) and didanosine (325 mg single dose) together and with a light meal was studied in 33 HIV-negative subjects. When compared to didanosine pharmacokinetics obtained with ddI 400 mg given alone under fasting conditions, AUC of ddI increased by 13% and Cmax decreased by 11%.<br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended. Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse events. Rare cases of pancreatitis and lactic acidosis, sometimes fatal, have been reported. Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine. A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil fumarate therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection. <br />Triple NRTI Therapy: <br />There have been reports of a high rate of virological failure and of emergence of resistance at early stage when tenofovir disoproxil fumarate was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen. <br /><em>Viread Summary of Product Characteristics, Gilead Sciences Ltd, May 2015.</em></p>
<p><div>Coadministration of tenofovir-DF and didanosine should be undertaken with caution and patients receiving this combination should be monitored closely for didanosine-associated adverse reactions. Didanosine should be discontinued in patients who develop didanosine-associated adverse reactions. When administered with tenofovir-DF, Cmax and AUC of didanosine increased significantly. The mechanism of this interaction is unknown. Higher didanosine concentrations could potentiate didanosine-associated adverse reactions, including pancreatitis and neuropathy. Suppression of CD4+ cell counts has been observed in patients receiving tenofovir-DF with didanosine 400 mg daily. In patients weighing greater than 60 kg, the didanosine dose should be reduced to 250 mg once daily when it is coadministered with tenofovir-DF. In patients weighing less than 60 kg, the didanosine dose should be reduced to 200 mg once daily when it is coadministered with tenofovir-DF. When coadministered, tenofovir-DF and didanosine EC may be taken under fasted conditions or with a light meal (less than 400 kcal, 20% fat). For additional information on coadministration of tenofovir-DF and didanosine, please refer to the full prescribing information for didanosine. When didanosine 250 mg enteric-coated capsules were administered with tenofovir-DF, systemic exposures of didanosine were similar to those seen with the 400 mg enteric-coated capsules alone under fasted conditions. Coadministration of tenofovir-DF (300 mg once daily) and buffered didanosine (250 or 400 mg once daily for 7 days, n=14) had no effect on tenofovir AUC, Cmax or Cmin. Coadministration of tenofovir-DF (300 mg once daily) and enteric-coated didanosine (250 mg simultaneously with tenofovir-DF and a light meal) decreased didanosine Cmax by 20% and had no effect on AUC when compared to values obtained with didanosine (400 mg) given alone under fasting conditions.<br /><em>Viread Prescribing Information, Gilead Sciences International Inc May 2015.</em></div><em></em></p>
<p>Intracellular concentrations of active phosphate metabolites were determined in three groups of HIV-infected subjects receiving didanosine alone (400 mg once daily, n=16), tenofovir (300 mg once daily, n=8) or didanosine/tenofovir (250/300 mg once daily, n =14). There were no significant differences in ddA-TP or TDF-DP when didanosine or tenofovir were administered alone or in combination. This study does not support the existence of a strong intracellular interaction between didanosine and tenofovir, but can not conclude that there is absolutely no interaction due to small sample size. As ddA-TP concentrations were similar when didanosine given alone (400 mg) or at a reduced dose (250 mg) with tenofovir, the study supports the dose adaptation proposed for this combination. <br /><em>Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Pruvost A, et al. Antimicrob Agents Chemother, 2005, 49: 1907-1914. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Terazosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as terazosin is extensively metabolized in the liver possibly via CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Terbinafine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Terbinafine is metabolized by CYP1A2, 2C9, 3A4 and to a lesser extent CYP2C8 and 2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Terfenadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terfenadine undergoes extensive metabolism mainly by CYP3A4 to form azacyclonol and terfenadine alcohol.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Testosterone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely as testosterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tetracaine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Absorbed tetracaine is predominantly metabolised by pseudocholinesterases in the plasma.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Tetracaine undergoes rapid mucosal absorption and is heavily protein-bound in blood. Tetracaine is metabolised in the liver (and sometimes in the kidney) to para-aminobenzoic acid<br /><em>Eludril&#174; Spray (Tetracaine hydrochloride/Chlorhexidine digluconate) UK Summary of Product Characteristics, Pierre Fabre Limited, updated January 2011</em></p>
<p>Tetracaine is hydrolysed in the body to p-amino-benzoic acid and should not therefore be used in patients being treated with sulphonamides.&nbsp; The primary site of metabolism for tetracaine is the plasma. Pseudocholinesterases in the plasma hydrolyse tetracaine to 4-aminobenzoic acid. Unmetabolised drug is excreted in the urine<br /><em>Minims Tetracaine Hydrochloride 1.0% w/v eye drops UK Summary of Product Characteristics, Bausch &amp; Lomb U.K Limited, updated July 2008</em></p>
<p>Tetracaine is reported to be about 15% bioavailable after application of a 4% gel to intact skin, with a mean absorption and elimination half-life of about 75 minutes.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via medicines Complete), latest modification: 05-Dec-2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tetracyclines</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction is expected with Videx-EC (didanosine gastro-resistant capsules).  However, didanosine chewable/dispersible tablets and powder for oral solution contain an antacid and should not be taken with any tetracycline antibiotic.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>As with other products containing magnesium and/or aluminium antacid components, didanosine chewable/dispersible tablets should not be taken with any tetracycline antibiotic.<br /><em>Videx Chewable/Dispersible Tablet Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Thalidomide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as thalidomide is cleared by non-enzymatic hydrolysis. However, use with caution due to the risk of peripheral neuropathy associated with both drugs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Theophylline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolized by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Thiamine (Vitamin B1)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Thiamine is absorbed from the GI tract and is widely distributed to most body tissues. It is not stored to any appreciable extent in the body and amounts in excess of requirements are excreted in the urine as unchanged thiamine or metabolites.<br /><em>Vitamin B Compound Strong Tablets UK Summary of Product Characteristics, Actavis UK Ltd, updated July 2012</em></p>
<p>Small amounts of thiamine are well absorbed from the gastrointestinal tract after oral doses, but the absorption of doses larger than about 5 mg is limited. It is also rapidly absorbed on intramuscular injection. It is widely distributed to most body tissues. Within the cell, thiamine is mostly present as the diphosphate. Thiamine is not stored to any appreciable extent in the body and amounts in excess of the body's requirements are excreted in the urine unchanged or as metabolites.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Thiopental</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Thiopental is almost completely metabolised in the body with a very small percentage excreted unchanged in urine. Ring desulfuration to the corresponding oxibarbiturate, pentobarbital, retains pharmacological activity. This active metabolite represents 3.3 to 3.6% of an anaesthetic dose and 10% of the parent concentration in the blood of patients receiving high dose thiopental therapy. Both thiopental and pentobarbital undergo oxidation on the terminal carbon atom of the 1-methyl-butyl side chain in the course of metabolic transformation and leads to thiopental carboxylic acid and pentobarbital carboxylic acid, which are pharmacologically inactive. A second metabolic pathway leads to thiopental alcohol and pentobarbital alcohol (metabolites without activity) by hydroxylation in position 3 of the methyl-butyl side chain. Oxidation to the thiopental carboxilic acid is the major step of detoxification in humans, and the urinary excretion of this product accounted for about 10 to 25% of the administered doses. It seems that the main determining factor in the metabolism rate is not the activity of the microcomal enzyme systems but the slow thiopental release from fat deposits. <br /><em>Pharmacodynamics and pharmacokinetics of thiopental. Russo H, Bressolle F. Clin Pharmacokinet. 1998 Aug;35(2):95-134</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Thioridazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Thioridazine is metabolized by CYP2D6 and to a lesser extent by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tiapride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tiapride is excreted largely unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ticagrelor</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ticagrelor undergoes extensive CYP3A4 metabolism and is only a mild inhibitor of CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Timolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction when timolol is used either orally or as eye drops. Timolol is predominantly metabolised via CYP2D6, there is therefore little potential for interaction with didanosine via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Like other topically applied ophthalmic drugs, 'Timoptol' may be absorbed systemically and adverse reactions seen with oral beta-blockers may occur.<br /><em>Timoptol&#174; (Timolol) 0.25% and 0.5% w/v Eye Drops Solution UK Summary of Product Characteristics, Merck Sharp &amp; Dohme Limited, updated June 2008</em></p>
<p>An in vitro study identified four timolol metabolites, the most abundant being a hydroxy metabolite, M1. Metabolism of timolol with recombinant P450s and correlation analysis confirmed that the drug is metabolized principally by CYP2D6, CYP2C19 being only a minor contributor (&lt;10%) to the intrinsic microsomal clearance. The CYP2D6 inhibitor quinidine proved a potent competitive inhibitor of timolol metabolism, with an in vitro K(i) value of 0.08 microM. Fluvoxamine, an inhibitor of CYP2C19, inhibited timolol metabolism to a lesser extent, confirming its minor contribution. Timolol itself did not inhibit CYP2D6-catalyzed dextromethorphan O-demethylation. Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo. The inhibition of timolol metabolism by quinidine should be taken into account when patients are treated with timolol. However, when plasma timolol concentrations in patients remain low (&lt; or = 0.2 microg/l), it is suggested that such interaction is of minor clinical relevance.<br /><em>Volotinen M, Turpeinen M, Tolonen A et al. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos. 2007 Jul;35(7):1135-41</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tipranavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration with tipranavir/ritonavir 500/200 mg has not been studied. Coadministration of tipranavir/ritonavir 500/100 mg decreased didanosine AUC (10%) and Cmax (20%), but increased Cmin (17%). Tipranavir AUC and Cmax increased by 8% and 32%, respectively and Cmin decreased by 34%. The clinical relevance of the reduction in didanosine levels has not been established. When the enteric coated formulation of didanosine is used, administration should be at least 2 h apart from tipranavir/ritonavir. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>&nbsp;</p>
<div>Coadministration of didanosine (200 mg bd if 60 kg or above, 125 mg bd if &lt;60 kg) and tipranavir/ritonavir (250/200 mg bd) decreased didanosine Cmax and AUC by 43% and 33%. When the same weight related doses were administered with tipranavir/ritonavir (750/100 mg bd) didanosine Cmax decreased by 24% and there was no change in AUC. The clinical relevance of this reduction in didanosine concentrations has not been established. Dosing of enteric-coated didanosine and tipranavir soft capsules, co-administered with low dose ritonavir, should be separated by at least 2 hours to avoid formulation incompatibility. <br /><em>Aptivus Summary of Product Characteristics, Boehringer Ingelheim International GmbH, December 2011.</em></div>
<p>Coadministration of tipranavir/ritonavir (500/100 mg bd) with a single dose of didanosine (400 mg) to 5 subjects increased tipranavir Cmax and AUC by 32% and 8% respectively, but decreased Cmin by 34%. Didanosine Cmax and AUC were decreased by 20% and 10% respectively, and Cmin increased by 17%. Coadministration of didanosine (200 mg bd if 60 kg or above, 125 mg bd if &lt;60 kg) and tipranavir/ritonavir (250/200 mg bd) to 10 HIV+ subjects resulted in a 43% decrease in didanosine Cmax and a 33% decrease in AUC. When the same weight related doses were administered with tipranavir/ritonavir (750/100 mg bd) to 8 HIV+ subjects, didanosine Cmax decreased by 24% and AUC decreased by 3%. Clinical relevance of reduction in didanosine levels not established. For optimal absorption, didanosine should be separated from tipranavir/ritonavir dosing by at least 2 h.<br /><em>Aptivus Prescribing Information, Boehringer Ingelheim, April 2012.</em></p>
<p>When enteric coated ddI and tipranavir/ritonavir (500/100 mg or 750/200 mg bd) were coadministered to 23 HIV- subjects, no change in the pharmacokinetic profile of ddI was observed. Tipranavir AUC was unchanged, Cmax increased by 32%, and Cmin decreased by 34%. Administration of enteric ddI and tipranavir/ritonavir should be separated by 4 h.<br /><em>Standard doses of efavirenz, zidovudine, tenofovir and didanosine may be given with tipranavir/ritonavir. Roszko PJ, Curry K, Brazina B, et al. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 2003, abstract 865.</em></p>
<p>The addition of tipranavir/ritonavir (1250/100 mg, n=9; 750/100 mg, n=8; 250/100 mg, n=10) was studied in HIV+ subjects on stable HAART regimens containing didanosine. No clinically significant changes in didanosine AUC were observed.<br /><em>Pharmacokinetic drug interaction screen of three doses of tipranavir/ritonavir in HIV-infected patients on stable highly active antiretroviral therapy. Goebel FD, Sabo JP, MacGregor TR, et al. HIV DART, Naples (Florida), December 2002.</em></p>
<p>Coadministration of ddI (200 mg bd, n=4) and tipranavir (900, 1200 or 1500 mg, three times daily) resulted in a decrease in ddI AUC from 1280&#177;1000 to 692&#177;321 ng/ml.h. <br /><em>The pharmacokinetics of nucleoside reverse transcriptase inhibitors when coadministered with the HIV protease inhibitor tipranavir in HIV-1 infected patients. Phillips H, Borin MT, Hopkins NK, et al. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2000, abstract 81.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tizanidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as tizanidine is metabolised by CYP1A2.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tolbutamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tolbutamide is mainly metaboliized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tolterodine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 having a major role in CYP2D6 poor metabolisers.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Topiramate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Topiramate is mainly eliminated by renal elimination in unchanged form (up to 60% of the dose) and partly by oxidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Topotecan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration has not been studied. Topotecan undergoes both hepatic and renal elimination. Hepatic elimination involves mainly non-enzymatic hydrolysis and, to a minor extent, CYP mediated N-demethylation as well as glucuronidation. Renal elimination is by both active secretion (mainly via OAT3) and glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Torasemide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as torasemide is mainly metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Toremifene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Toremifene is mainly metabolized by CYP3A4 to N-demethyltoremifene.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tramadol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Trandolapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as trandolapril is hydrolysed to trandolaprilat.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tranexamic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranexamic acid is mainly cleared by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Tranylcypromine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranylcypromine is hydroxylated and acetylated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Trazodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as trazodone is primarily metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Triamcinolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as triamcinolone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Triazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as triazolam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Triclabendazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Triclabendazole appears to be metabolised in part by CYP450 enzymes, whereas didanosine is excreted via the same pathways responsible for elimination of endogenous purines.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In vivo, triclabendazole is rapidly oxidised into its sulfoxide metabolite, which is further oxidised to the sulfone metabolite. The sulfoxide form is predominant in plasma, with the parent compound and the sulfone metabolite having AUCs respectively of approximately 1% and 10% of that of the sulfoxide. The rapid biotransformation of triclabendazole in man and the previous findings in animals produced evidence of presystemic biotransformation including first-pass metabolism of triclabendazole. <br />In animals, the drug is largely excreted via the biliary tract in the faeces (90%), together with the sulfoxide and subsequently the sulfone metabolite. Less than 10% of an oral dose is excreted in the urine.<br /><em>Egaten&#174; Summary of product Charateristics, Novartis Pharma AG Basel, Switzerland, Produced July 2000</em></p>
<p>Ketoconazole, a CYP450 enzyme inhibitor was found to inhibit metabolism of triclabendazole in vitro<br /><em>Devine C, Brennan GP, Lanusse CE, et al. Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitol Res. 2011 Oct;109(4):981-95.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Trimethoprim/Sulfamethoxazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction observed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Specific interaction studies have been conducted with trimethoprim and sulfamethoxazole without evidence of interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>When the buffered formulation of ddI (200 mg single dose) was coadministered with trimethoprim (200 mg single dose) to 8 HIV-infected subjects, there was no change in ddI AUC and a 17% increase in Cmax. Trimethoprim AUC increased 10% and Cmax decreased by 22%. When the buffered formulation of ddI (200 mg single dose) was coadministered with sulfamethoxazole (1000 mg single dose) to 8 HIV-infected subjects, there was no change in ddI AUC or Cmax. Sulfamethoxazole AUC and Cmax decreased by 11% and 12% respectively. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>The pharmacokinetics of didanosine (200 mg, buffered tablets), trimethoprim (200 mg) and sulfamethoxazole (1000 mg) were evaluated in 10 HIV-infected subjects as single agents and upon coadministration of single doses. The addition of didanosine to trimethoprim/sulfamethoxazole resulted in a statistically significant decrease of 32% in renal clearance of trimethoprim and a statistically significant decrease of 8% in sulfamethoxazole AUC. There were no statistically significant effects of trimethoprim and/or sulfamethoxazole on the AUC or Cmax of didanosine. However, didanosine renal clearance decreased by 35% and percentage urinary recovery decreased by 16% when the three drugs were coadministered. These changes are no considered to be clinically relevant and dose modification is not required. <br /><em>A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. Srinivas NR, et al. Br J Clin Pharmacol, 1996, 41: 207-215. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Trimipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Trospium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trospium is minimally metabolized and is mainly eliminated unchanged renally, in part by OCT2.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Turmeric (Curcuma longa)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ulipristal</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Ulipristal is mainly metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Valaciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valaciclovir is converted to aciclovir which is eliminated renally via glomerular filtration and active renal secretion by OAT1. Didanosine is only partly eliminated via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Valerian</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Valproate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Valproate is mainly glucuronidated by UGTs 1A6, 1A9 and 2B7 and metabolized by CYP2C9 and CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Valsartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as valsartan is eliminated unchanged mostly through biliary excretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Vancomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Vancomycin is predominantly eliminated unchanged via renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Vancomycin is metabolized only to a low extent. After parenteral administration it is excreted almost completely as microbiologically active substance (approx. 75-90% within 24 hours) through glomerular filtration via the kidneys. Biliary excretion is insignificant (less than 5% of a dose). The clearance of vancomycin from plasma correlates nearly with the glomerular filtration rate. No vancomycin metabolites have been identified so far in humans<br /><em>Vancomycin, 500 mg, powder for solution for infusion Summary of Product Characteristics, Sandoz Limited, updated November 2011</em></p>
<p>In the first 24 hours, about 75% of an administered dose of vancomycin is excreted in urine by glomerular filtration. Mean plasma clearance is about 0.058 L/kg/hr, and mean renal clearance is about 0.048 L/kg/hr. Renal dysfunction slows excretion of vancomycin. In anephric patients, the average half-life of elimination is 7.5 days. The distribution coefficient is from 0.3 to 0.43 L/kg. There is no apparent metabolism of the drug.<br /><em>Sterile vancomycin hydrochloride, USP Fliptop Vial For Intravenous Use, US Prescribing Information, Hospira Inc, updated December 2007</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Vardenafil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vardenafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Varenicline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interactions due to cytochrome P450 metabolism or renal secretion expected. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Based on varenicline characteristics and clinical experience to date, varenicline has no clinically meaningful drug interactions. No dosage adjustment of varneicline or co-administered medicinal products listed below is recommended. In vitro studies indicate that varenicline is unlikely to alter the pharmacokinetics of compounds that are primarily metabolised by cytochrome P450 enzymes. Furthermore since metabolism of varenicline represents less than 10% of its clearance, active substances known to affect the cytochrome P450 system are unlikely to alter the pharmacokinetics of varenicline and therefore a dose adjustment of varenicline would not be required. In vitro studies demonstrate that varenicline does not inhibit human renal transport proteins at therapeutic concentrations. Therefore, active substances that are cleared by renal secretion are unlikely to be affected by varenicline. <br /><em>Champix Summary of Product Characteristics, Pfizer Ltd, August 2008.</em></p>
<p>No clinically meaningful pharmacokinetic drug-drug interactions have been identified. In vitro studies demonstrated that varenicline does not inhibit the following cytochrome P450 enzymes (IC50 &gt;6400 ng/mL): 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5. Also, in human hepatocytes in vitro, varenicline does not induce the cytochrome P450 enzymes 1A2 and 3A4. In vitro studies demonstrated the active renal secretion of varenicline is mediated by the human organic cation transporter, OCT2. Co-administration with inhibitors of OCT2 may not require a dose adjustment of varenicline as the increase in systemic exposure to varenicline is not expected to be clinically meaningful. Furthermore, since metabolism of varenicline represents less than 10% of its clearance, drugs known to affect the cytochrome P450 system are unlikely to alter the pharmacokinetics of varenicline and therefore a dose adjustment of varenicline would not be required. <br /><em>Chantix Prescribing Information, Pfizer Inc, May 2008.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Velpatasvir/Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Didanosine is phosphorylated to its active triphosphate form and is not a substrate of any CYP isoenzyme. It is renally excreted.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Venlafaxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Verapamil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as verapamil is metabolised mainly by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Vercuronium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning the metabolism/elimination and toxicity profile of vercuronium, there is little potential for interaction with didanosine via modulation of, or competition for metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In man, urine recovery of vecuronium varies from 3 to 35% within 24 hours. Data derived from patients requiring insertion of a T-tube in the common bile duct suggests that 25 to 50% of a total intravenous dose of vecuronium may be excreted in bile within 42 hours. Only unchanged vecuronium has been detected in human plasma following use during surgery. In addition, one metabolite, 3-desacetyl vecuronium, has been rarely detected in human plasma following prolonged clinical use in intensive care units. The 3-desacetyl vecuronium metabolite has been recovered in the urine of some patients in quantities that account for up to 10% of injected dose; 3-desacetyl vecuronium has also been recovered by T-tube in some patients, accounting for up to 25% of the injected dose.<br /><em>Vecuronium bromide for injection US Prescribing Information, Pfizer Inc, updated February 2011</em></p>
<p>The metabolic fate of vecuronium bromide in humans has not been fully characterized. In vitro, vecuronium undergoes spontaneous deacetylation to form the hydroxy derivatives. The neuromuscular blocking activity of the 3&#945;-hydroxy derivative appears to be at least 50% that of the unchanged drug. In vitro, the 3&#945;-hydroxy derivative undergoes rapid conversion to the 3&#945;,17&#946;-dihydroxy derivative. The 17&#946;-hydroxy and 3&#945;,17&#946;-dihydroxy derivatives appear to have about 5 and 2% of the neuromuscular blocking activity of the unchanged drug respectively. The extent of spontaneous deacetylation and/or metabolism of vecuronium in humans remains to be clearly determined. Vecuronium bromide and its metabolite(s) appear to be excreted principally in feces via biliary elimination; the drug and its metabolite(s) are also excreted in urine. Although only unchanged drug has been detected in plasma in patients receiving the drug as an adjunct to surgical anesthesia, up to 10% of a dose of vecuronium bromide has been excreted in urine and 5&#8211;25% in bile as the 3&#945;-hydroxy derivative in some patients. Another metabolite, 3-desacetyl vecuronium, has been detected rarely in plasma following prolonged clinical use of the drug in an intensive care setting. Approximately 20&#8211;30% (range: 3&#8211;36%) of an IV dose of vecuronium bromide is excreted in urine within 24 hours after administration in humans, principally as unchanged drug and to a lesser extent as the 3&#945;-hydroxy derivative. In patients with a T-tube in the common bile duct, 12&#8211;45% of an IV dose of vecuronium was reportedly excreted in bile within 18&#8211;42 hours after administration, almost completely as unchanged drug. <br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, January 2009</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Vigabatrin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as vigabatrin is cleared mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Vildagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vildagliptin is inactivated via non-CYP mediated hydrolysis. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Vinblastine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as vinblastine undergoes extensive metabolism and is excreted primarily by the biliary route. However, coadministration can increase the risk of peripheral neuropathy due to additive toxicity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Vincristine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as vincristine is excreted primarily by the biliary route. However, coadministration can increase the risk of peripheral neuropathy due to additive toxicity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Vitamin E</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Voriconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as voriconazole is metabolised by CYPs 2C19, 2C9 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Vorinostat</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Vorinostat is mainly metabolised by glucuronidation (UGT2B17) and hydrolysis followed by B oxidation (non CYP-mediated).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Warfarin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolized by different cytochromes. R-warfarin is primarily metabolized by CYPs 1A2 and 3A4 whereas S-warfarin (more potent) is metabolized by CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Xipamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (50%) and glucuronides (30%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Zaleplon</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as zaleplon is mainly metabolized by aldehyde oxidase and to a lesser extent CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Zanamivir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. A small amount of the orally inhaled zanamivir is systematically absorbed. Absorbed zanamivir is excreted unchanged in the urine whereas unabsorbed zanamivir is excreted in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Zidovudine (AZT/ZDV)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction observed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Specific interaction studies have been conducted with zidovudine without evidence of interaction.There is no evidence that didanosine potentiates the myelosuppressive effects of zidovudine. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>When the buffered formulation of ddI (200 mg twice daily for 3 days) was coadministered with zidovudine (200 mg three times daily for 3 days) to 6 HIV-infected subjects, there was no change in ddI AUC or Cmax. Zidovudine AUC and Cmax decreased by 10% and 17% respectively. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>The pharmacokinetic interaction between zidovudine (200 mg three times daily) and didanosine (200 mg twice daily) was investigated in 6 HIV-infected subjects. Coadministration of zidovudine had no significant effect on didanosine pharmacokinetic parameters (&lt;12% difference in treatment means, p&gt;0.1). Coadministration of didanosine did not significantly alter zidovudine pharmacokinetic parameters, but did cause statistically significant increases in renal (18.5%) and apparent formation (30.5%) clearances of zidovudine glucuronide. These changes are unlikely to be clinically significant. <br /><em>Pharmacokinetics of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients. Sahai J, et al. J Acquir Immune Defic Syndr Hum Retrovirol, 1995, 10: 54-60. </em></p>
<p>The influence of didanosine on the pharmacokinetics of zidovudine was investigated in 5 HIV-infected subjects. Addition of didanosine resulted in lower zidovudine levels in 4/5 subjects with an average decrease in zidovudine AUC of 14%. Didanosine pharmacokinetics were similar to historical data. The decrease in zidovudine exposure was not statistically significant and probably not clinically relevant. <br /><em>Pharmacokinetic interaction study of zidovudine and didanosine. Burger DM, et al. J Drug Dev, 1994, 6: 187-194. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Ziprasidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Zoledronic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Zoledronic acid is eliminated unchanged renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Zolpidem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C9 and CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Zonisamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zonisamide is metabolized partly by CYP3A4 and also by N-acetyl-transferases and conjugation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Zopiclone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Zotepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent CYP1A2 and CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Didanosine (ddI)</p>
              <p>Zuclopenthixol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zuclopenthixol is metabolized by sulphoxidation, N-dealkylation (by CYP2D6 and CYP3A4) and glucuronidation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


    </div>

  </div>

</div>

    <div class='commercial sponsors' id='sponsors'>
<div class='inner-wrapper'>
<div class='sponsors-title'>
SPONSORS
</div>
<a target="_blank" href="http://www.janssen.com/emea/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/001/tiny/sponsor-logo-janssen.png?1451996945" alt="Sponsor logo janssen" />
</a><a target="_blank" href="http://www.gilead.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/002/tiny/sponsor-logo-gilead.png?1451996988" alt="Sponsor logo gilead" />
</a><a target="_blank" href="http://www.msd-uk.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/003/tiny/sponsor-logo-msd.png?1451997044" alt="Sponsor logo msd" />
</a><a target="_blank" href="https://www.viivhealthcare.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/004/tiny/sponsor-logo-viiv.png?1451997075" alt="Sponsor logo viiv" />
</a><a target="_blank" href="http://www.abbvie.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/006/tiny/sponsor-logo-abbvie.png?1451997117" alt="Sponsor logo abbvie" />
</a><a target="_blank" href="http://www.bms.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/005/tiny/sponsor-logo-bristol-myers-squibb.png?1451997097" alt="Sponsor logo bristol myers squibb" />
</a></div>
</div>

<div class='editorial sponsors' id='sponsors'>
<div class='inner-wrapper'>
<div class='sponsors-title'>
EDITORIAL SPONSORS
</div>
<a target="_blank" href="http://www.bhiva.org/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/008/tiny/bhiva.jpg?1453297795" alt="Bhiva" />
</a><a target="_blank" href="http://www.hiv11.com/ContentPageView.aspx?ContentPageId=79"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/010/tiny/Glasgow.png?1453297904" alt="Glasgow" />
</a><a target="_blank" href="http://www.eacsociety.org/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/009/tiny/EACS_logo_2014.jpg?1453297878" alt="Eacs logo 2014" />
</a></div>
</div>


    <div class="footer">
  <div class="inner-wrapper">
    <div class="footer-left-column">
      <div class="footer-links">
        <a href="http://www.hiv-druginteractions.org/cookie-policy">Cookie Policy</a>
        <a href="http://www.hiv-druginteractions.org/privacy">Privacy Statement</a>
        <a href="http://www.hiv-druginteractions.org/terms">Terms &amp; Conditions</a>
      </div>
        <p>Last Review: January 25, 2017</p>

      <p>Copyright  2017 The University of Liverpool. All rights reserved.</p>
      <p>Designed and developed by the team at <a target="_blank" href="http://podmedics.org">Podmedics</a></p>
    </div>

    <div class="footer-right-column">

      <a href="https://www.liverpool.ac.uk/" target="_blank" class="footer-liverpool-logo"></a>

    </div>
  </div>
</div>

  </body>
  
</html>
